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Cardiovascular disease remains the leading cause of death, being responsible for almost one third of 
all deaths worldwide and close to half of all deaths in Europe. However, in some parts of Europe 
including Belgium, cancer is now for the first time the cause of more deaths than cardiovascular 
disease among men. This may be partly explained by a decrease in mortality in coronary artery 
disease (CAD) due to a better prevention and treatment policy.1  
 
Together with the ageing of the population, this success in secondary prevention and prolonging 
survival in patients suffering from coronary events, may contribute to the increasing overall 
prevalence of heart failure (HF). HF affects about 1-2% of the population with a sharp rise to more 
than 10% above the age of 70 years.2 CAD is by far the most common cause of HF, but also 
hypertension, tachyarrhythmia, cardiomyopathies and valvular heart disease (VHD) may eventually 
lead to HF.3 VHD is usually less regarded as a major public-health problem, however a substantial 
burden of this disease exists and will probably further increase, due to increasing life expectancy and 
its link with degenerative valve disease.4, 5  
 
Exercise intolerance is a hallmark feature of HF with symptoms of breathlessness and fatigue and 
indicates a poor prognosis. Likewise, an impaired exercise capacity is also seen in CAD and VHD 
patients6-9 with a similar prognostic value.6, 10 Cardiac rehabilitation (CR) has been recommended in 
both CAD and HF to reduce risk factors and to improve exercise tolerance, health-related quality of 
life and prognosis.2, 11, 12 Nevertheless, more than half of eligible cardiac patients do not attend CR or 
drop out prematurely.13, 14 
 
To date, the mechanisms underlying exercise intolerance in patients both with and without HF are 
not entirely clear, suggesting further investigation. In addition, the outcome in hospitalized HF 
patients  has not been investigated in Belgium thus far and needs to be further explored as well as 
the value of exercise training as a treatment modality in a broader spectrum of cardiac patients. 
Finally, the implementation of CR in the ‘real-life setting’ encounters several barriers, which should 
be adequately addressed to further increase participation in CR.  
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1 Exercise intolerance in heart failure 
 
HF can be defined as an abnormality of cardiac structure or function leading to failure of the heart to 
deliver oxygen at a rate corresponding with the requirements of the metabolizing tissues.2 While 
traditionally associated with a pump failure or reduced ejection fraction (HFREF), it has become 
widely recognized that HF can occur even when left ventricular ejection fraction (LVEF) is preserved 
(HFPEF).15 Unlike HFREF, which is diagnosed when signs and symptoms of HF are present together 
with a reduced LVEF, patients with HFPEF have similar signs and symptoms but evidence of a normal 
systolic LV function and diastolic LV dysfunction.2, 16 HFPEF is currently observed in 50% of HF 
patients and outcomes are similar to those in HFREF.17  
 
1.1  Pathophysiology 
 
In HFREF, left ventricular remodeling is driven by a progressive loss of cardiomyocytes, because of 
oxidative stress usually resulting from ischemia, infection or toxicity. This results in a shift in the 
balance between collagen deposition and degradation, contributing to LV dilatation and eccentric LV 
remodeling. In advanced HFREF , endothelial dysfunction is also present and contributes to the raised 
plasma levels of inflammatory parameters such as tumor necrosis factor alpha and interleukin 6 
which affects diastolic function. A novel paradigm has been proposed in HFPEF with comorbidities 
contributing to a systemic inflammatory state. This inflammatory state induces oxidative stress in the 
coronary microvascular endothelium, which reduces myocardial nitric oxide bioavailability and leads 
to a reduced protein kinase G activity in cardiomyocytes which therefore become stiff and 
hypertrophied, resulting in impaired left ventricular filling.18 
 
1.2 From ‘pump failure’ to a systemic disease 
 
HF is marked by an interplay between the underlying myocardial dysfunction and the compensatory 
neurohormonal mechanisms, including the sympathetic nervous system, the renin-angiotensin-
aldosteron system (RAAS) and several cytokines. Although the activation of these systems can 
initially compensate for the depressed myocardial function, their long-term activation results in a 
further impairment of cardiac function and cardiac remodelling leading to progression of heart 
failure and cardiac decompensation. 19-21 One of the key stones of this neurohormonal activation, the 
autonomic nervous system (ANS), is described in Part 1 of this thesis, but is also summarized in the 
following section. The majority of research has focused on the impact of autonomic imbalance in 
HFREF, limited information exists in HFPEF.22, 23  
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The ANS enables the body to adjust its circulation and respiration to maintain an appropriate oxygen 
delivery to tissues. The balance between the sympathetic (SNS) and parasympathetic nerve system 
(PNS) is mediated by the interaction between the central command originating from the central 
motor areas and peripheral feedback afferents, including the baroreflex, chemoreflex and 
ergoreflex.24, 25 The nucleus tractus solitarius (NTS) is the integrating centre located in the medulla 
oblongata.25-27 SNS activation is mediated via the release of norepinephrine and epinephrine, 
whereas the PNS acts through the release of acetylcholine. 21, 28   
 
The SNS exerts a wide variety of cardiovascular effects, including heart rate acceleration, increase in 
cardiac contractility, accelerated cardiac relaxation and decrease in venous capacitance in order to 
increase cardiac performance as part of the so called fight – or flight response. Conversely, the PNS 
slows the heart rate but has no effect on cardiac contractility.21 Baroreceptors are together with 
ergoreceptors and peripheral chemoreceptors responsible for these hemodynamic changes with 
baroreceptors having an inhibitory function whereas the other receptors rather stimulate the SNS.24, 
29 In HF, an increase in chemoreflex and ergoreflex responsiveness is seen with a reduction in 
baroreflex activity, resulting in an increase in adrenergic outflow.20, 24, 29, 30 This results in an enhanced 
peripheral vasoconstriction during exercise in order to preserve an adequate blood pressure level, 
thereby unfortunately limiting blood flow in the exercising muscle which further exacerbates 
muscular abnormalities typically seen in HF.  
 
Ergoreceptors and chemoreceptors also take part in the regulation of ventilation by influencing the 
respiratory neurons in the pons and medulla.31 Very recently, a synaptic interaction between 
respiratory and sympathetic neurons has been proposed with the NTS as a coordinating centre.27 
Overactivity of these receptors is related to the inappropriate increase in the ventilatory drive in HF 
with a detrimental impact on prognosis.32-35  
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Figure 1. Mechanisms of autonomic control. Under normal conditions, the inhibitory input of the baroreceptors 
is the major controlling mechanism. As heart failure progresses, baroreceptor activity is blunted and the 
excitatory input of the chemoreceptors and ergoreceptors predominates with an increase in sympathetic 
activity and ventilation. 
 
RAAS is a second neurohormonal mechanism that is activated in response to a decrease in blood 
pressure with the conversion of angiotensinogen to angiotensin I via the secretion of renin. 
Angiotensin I is cleaved further by angiotensin converting enzyme (ACE) to generate the active 
angiotensin II. This latter peptide helps to maintain the extracellular fluid volume and arterial blood 
pressure 1) by its stimulation of aldosterone secretion which promotes renal salt and water 
retention, 2) by a generalized vasoconstriction through direct action and also through boosting of 
sympathetic activity and finally 3) by stimulating the sensation of thirst and hence fluid intake. In HF, 
this cascade ultimately results in an excessive vasoconstriction and fluid retention.19, 36 
 
Neurohormonal activation is also characterized by an increase in several biomarkers, including 
natriuretic peptides of which brain natriuretic peptides (BNP) are most commonly used for 
evaluation. The main stimulus is stretch of cardiac myocytes, but also certain hormones (such as 
catecholamines and angiotensin II) and hypoxia in the setting of acute coronary syndrome (ACS) may 
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activate these peptides. On secretion, the propeptide is split into the biologically active BNP and the 
remaining part of the prohormone N-terminal proBNP (NT-proBNP). Activation of natriuretic 
peptides causes diuresis, vasodilatation and a decrease in renin and aldosterone secretion in order to 
oppose the acute increase in ventricular volume.37-39  
 
1.3 Markers of exercise intolerance 
 
Exercise intolerance is a hallmark feature of HF and indicates a poor prognosis. In general, exercise 
capacity is slightly more impaired in HFREF as in HFPEF.40 Since the landmark study of Mancini, peak 
oxygen consumption (peak VO2) has become widely accepted as a prognosticator.
41 However, several 
drawbacks have led to a search for novel prognostic exercise parameters. The VE/VCO2 slope, which 
describes the increase in ventilation in response to a rising CO2 production,
42 has been proven to be 
prognostically superior, not only in predicting mortality but also in providing additional information 
regarding hospitalization,43both in HFREF as in HFPEF.44 Instead of the traditional cut-off values of 
peak VO2 <14 ml.min
-1.kg-1 and a VE/VCO2 slope >34 to indicate a poor prognosis, a 4-level 
classification has recently been introduced. Under current medical management strategies, a 
VE/VCO2 slope ≥45 and a peak VO2 <10 ml.min
-1.kg-1 are indicative of a particularly poor prognosis.45, 
46 Likewise, an impaired peak VO2 and a steep ventilatory slope are seen in a substantial part of CAD 
patients with a similar prognostic value.6, 47-51  
 
Different pathophysiological mechanisms are thought to underlie these parameters. The peak VO2 is 
dependent on the cardiac output (CO) and the arterio-venous O2 difference, whereas the VE/VCO2 
slope is rather attributable to a combination of an elevated dead space and a reduced arterial CO2 
tension with the latter being partly driven by the ergoreflex. These mechanisms are further described 
in detail in Part 1 of this thesis.  
 
Besides peak VO2 and VE/VCO2 slope, also other cardiopulmonary exercise test (CPET) parameters 
have been proven to be prognostically important. An irregular breathing pattern that persists during 
exercise with cyclic fluctuations in minute ventilation and gas exchange kinetics, also known as 
exercise oscillatory ventilation (EOV) and the partial pressure of end-tidal CO2 (PET)CO2 are further 
described in part 1 of this thesis. In addition, chronotropic incompetence which is an inadequate 
heart rate response to exercise, is also a marker of poor prognosis even in the setting of β 
blockade.52-54  
 
General introduction 
18 
 
A frequently used submaximal exercise test is the six-minute walking test (6MWT), which 
approximates the capacity to perform activities of daily living but does not allow for a thorough 
investigation into the pathogenetic mechanisms involved in fatigue and dyspnoea sensation.55 
Although the distance walked in six minutes (6MWD) is described as a prognostic marker of cardiac 
death and cardiovascular events,56, 57 there is currently no supportive evidence for its use as an 
alternative to CPET derived variables.55 
 
1.4 Treatment 
 
The introduction of medication influencing neurohormonal activation, was a milestone in the 
treatment and outcome of HFREF. Beta (β) blockers, angiotensin converting enzyme inhibitors (ACE-
I), angiotensin receptor blockers (ARB) and aldosterone receptor antagonists are known to reduce 
neurohormonal activation with a positive influence on prognosis.2 In addition, β blocker therapy has 
also been shown to reduce the VE/VCO2 slope without significantly altering peak VO2,
43, 58 whereas 
ACE-I may influence both peak VO2 and VE/VCO2 slope although this is not supported in all studies.
59-
63 
 
Recently, Cha et al.64 reported that cardiac resynchronization therapy (CRT) may also modulate the 
sympathetic function. Furthermore, CRT may increase peak VO2 with a concomitant decrease in the 
VE/VCO2 slope.
65 The role of exercise training in the treatment of HF is discussed in the next section.  
 
1.5 Exercise training  
 
Cardiac rehabilitation (CR) has been recommended in both CAD and HF to reduce risk factors and to 
improve exercise tolerance, health-related quality of life and prognosis.2, 11, 12, 66, 67 A recent meta-
analysis demonstrates that CR has no effect on short-term mortality in HF but a trend towards a 
decrease in long-term mortality is present. A small body of evidence suggests that CR may also 
benefit HFPEF patients, but further studies are needed.68 
 
An improvement in exercise intolerance after exercise training has been widely recognized with an 
increase in peak VO2 and a concomitant decrease in ventilatory abnormalities. Peripheral rather than 
central adaptations are thought to be responsible, with changes in skeletal muscle mass, muscle 
metabolism, endothelial function, inflammatory state and changes occurring at the lung level.69-73 
These changes in the periphery may result in a decrease in ergoreflex and chemoreflex activation 
with a concomitant decrease in hyperventilation and sympathetic outflow.74-79 Likewise, a decrease 
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in natriuretic peptides after exercise training suggests neurohormonal improvement.80, 81 Although 
far less described, also central adaptations are reported with an increase in CO due to changes in 
heart rate and stroke volume.82 
 
Because of its proven efficacy and safety, aerobic training is widely recommended.2 To affect the 
muscle alterations typically seen in HF patients, strength training should also be considered.83 In 
order to further improve the effects of exercise training, novel training modalities are currently being 
tested such as high-intensity aerobic interval training84, 85 and inspiratory muscle training.86  
 
1.6 Research questions 
 
According to the aforementioned literature, ergoreflex activity may play a major role in exercise 
intolerance in HF. Nevertheless, the presence of ergoreflex activity in the current situation is less 
clear because of changes in pharmacological treatment. In addition, an increased ventilatory drive 
has been demonstrated not only in HF, but also in CAD with a similar prognostic value.50, 51 However, 
information on the ergoreflex is currently lacking in this population. Therefore, the first part of this 
thesis will focus on exercise intolerance and the relevance of the ergoreflex.  
 
2 Outcome and the key role of exercise training in heart failure 
 
2.1 Outcome of HF 
 
Despite improvements in medical treatment, mortality and readmission rates remain high in HF, with 
an increase in patients with HFPEF.87 In the latter group, the use of similar drugs  as in HFREF did not 
result in an improvement in prognosis,16 indicating the urgent need for novel treatment strategies.  
 
Data from hospitalized HF patients may be useful to better understand the clinical characteristics, 
patient management and outcomes and may ultimately help to improve patient outcomes.88, 89 
Research has shown that important geographic variations exist, both in patient characteristics and 
treatment.89-91 Therefore, country specific data are important but for Belgium, no such data have 
been published so far. 
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2.2 The role of natriuretic peptides in exercise capacity and exercise training 
 
Natriuretic peptides have become increasingly important for the diagnosis and prognosis of HF 
patients, both with reduced and preserved ejection fraction.38, 92 Despite significantly higher baseline 
levels of natriuretic peptides in HFREF, the prognosis in patients with HFPEF is as poor as in those 
with HFREF for a given BNP level. This may indicate that neurohormonal activation is the primary 
driver of outcome instead of LVEF. 92, 93 In addition, natriuretic peptides have also been 
demonstrated to be predictive for cardiac events and mortality in other clinical settings such as acute 
coronary syndrome, coronary artery bypass graft (CABG), VHD and even in patients without CAD at 
baseline. 38, 94-98  
 
The link between natriuretic peptides and an impaired exercise capacity or increased ventilatory 
drive has already been demonstrated in HF.99-103 Furthermore, exercise training may improve both 
exercise intolerance and neurohormonal activation.75, 80, 81, 104-108 However, it is not clear whether 
exercise capacity and the improvement after exercise training are primarily affected by left 
ventricular function or natriuretic peptides.  
 
2.3 Research questions 
 
Because of the lack of data on the clinical characteristics and outcome of HF patients in Belgium, the 
second part of this dissertation will provide data on this subject. In addition, since natriuretic 
peptides seem to have a major impact on outcome, its influence on exercise capacity and the training 
response will be further explored, both in cardiac patients with reduced and preserved LVEF.  
 
3 Barriers in the implementation of cardiac rehabilitation 
 
3.1 Participation and drop-out in cardiac rehabilitation 
 
Despite the clear benefits of CR as described in the previous section, figures on participation in CR 
are disappointing with less than 50% attendance of the eligible patients.13 In addition, a considerable 
number of those patients who actually attend CR, drop out prematurely varying from 22% to 65%.14, 
109 Patients after myocardial infarction and CABG are most commonly provided by CR. Despite 
evidence on the benefits of CR for the increasing population of HF patients, this is not reflected in the 
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sobering number of less than 20% participating in CR.13, 110 Specific data on participation in CR are 
lacking for Belgium.  
 
Adherence to application of exercise recommendations is dependent on both the adherence of 
health-care providers to clinical guidelines (guideline adherence) as well as to adherence of the 
patient to clinician’s advice (patient adherence).  
 
Barriers for guideline adherence are related to the physician’s knowledge about the effects of 
exercise training as well as to organizational and political issues such as availability of exercise 
training sites and reimbursement for enrolment in CR.83 Referral is a prerequisite to have access to 
CR, but remains suboptimal particularly among women.111  
 
Patient adherence is a multidimensional phenomenon, determined by the interplay of a set of five 
dimensions: social and economic factors, factors related to the health-care system, factors related to 
the patient’s condition, the therapy and the patients themselves. Literature has shown that 
adherence is particularly determined by age, female gender, a low socio-economic status, a lack of 
motivation, psychological characteristics, and financial and medical concerns. 83 Also the perception 
of self-control of the problem and illness cognition may play a key role.112 Several of these barriers 
are potentially modifiable and should therefore be adequately addressed in order to increase 
participation in CR. 
 
3.2 Valvular heart disease  
 
Although VHD is less common in industrialized countries than CAD, HF, or hypertension, VHD is 
frequent and often requires intervention.4, 5 In industrialized countries, the prevalence of VHD is 
estimated at 2.5%. Because of the predominance of degenerative aetiologies, the prevalence of VHD 
increases markedly after the age of 65 years, in particular with regard to aortic stenosis and mitral 
regurgitation which accounts for 3 in 4 cases of VHD.4, 113 
 
Decision-making for intervention is complex, since VHD is often seen at an older age and, as a 
consequence, there is a higher frequency of comorbidity, contributing to increased risk of 
intervention.4, 5 Several registries worldwide have consistently shown that, in current practice, 
therapeutic intervention for VHD is underused in high-risk patients with symptoms, for reasons 
which are often unjustified. This stresses the importance of the widespread use of careful risk 
stratification.114 The two most widely used scores are the European System for Cardiac Operative 
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Risk Evaluation (EuroSCORE) and the Society of Thoracic Surgeons score, the latter having the 
advantage of being specific to VHD but less user-friendly than the EuroSCORE.115  
 
In the past two decades, progress has been made regarding minimal invasive surgery to reduce the 
surgical trauma. Minimal invasive surgery, such as ministernotomy for aortic valve and port access 
procedures for mitral valve disease, has been considered to have several advantages besides the 
cosmetic aspect, including a reduced ventilation time, less bleeding and a reduced hospital stay. Few 
of these aspects however, have been objectively established.116-120  
 
Although exercise capacity is an important parameter of prognosis and quality of life, there is limited 
information regarding the effect of valvular surgery on exercise capacity. Current literature suggests 
that despite improvements in symptomatic status, exercise capacity does not recover spontaneously 
after aortic (AVS) or mitral valve surgery (MVS).7-9 This argues in favour of the need for cardiac 
rehabilitation, although this is currently not mentioned in the management guidelines on VHD. 
 
3.3 Research questions 
 
Attendance and adherence in CR seem to be disappointing but specific data on the Belgian situation 
are scarce. Therefore, the third part of this work will assess participation and drop-out and will try to 
gain insight in the current barriers in the implementation of CR. Another type of barrier is the lack of 
knowledge on exercise capacity and exercise training in an important subgroup of the cardiac patient 
population, i.e. VHD patients. This will therefore, be the focus of the final chapter.   
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The general aim of this thesis is to obtain knowledge on the mechanisms of exercise intolerance in 
cardiac patients both with and without heart failure, to evaluate outcome in heart failure and the 
effects of exercise training in a broader cardiac patient population. In addition, the implementation 
of cardiac rehabilitation in ‘the real life setting’ encounters several barriers regarding participation 
and drop-out, which are further explored in this work.  
 
Part 1 
 
It is remarkable that a reflex arising from the exercising muscle, i.e. the ergoreflex, may influence 
both fatigue and dyspnoea, being the major characteristics of exercise intolerance in HF. Ergoreflex 
activity has been related to exercise intolerance and in particular to the increased ventilatory drive 
typically seen in HF. Moreover, overactivity of the ergoreflex has been proven to be an ominous sign 
for a poor prognosis.1-4 However, numerous issues regarding this mechanism remain unanswered. 
Since pharmacological treatment has changed over the past decades with the introduction of 
neurohormonal agents with an impact on survival and exercise intolerance, ergoreflex activity in HF 
patients at present is unknown. In addition, an increased ventilatory drive is not exclusively seen in 
HF patients but also in cardiac patients without signs of HF,5, 6 a population whose ergoreflex activity 
has not been investigated thus far. Even in healthy subjects, the contribution of the ergoreflex to 
ventilation remains unclear.1, 3, 4, 7 Therefore, the first part of this thesis handles about exercise 
intolerance and its mechanisms. Because of the extensive amount of literature on this topic and its 
complexity, available literature has been reviewed and the current knowledge about this topic has 
been described in the first two chapters of this work. Chapter 1 provides an overview on the role of 
the autonomic nervous system of the heart in the development of HF, with a special focus on its role 
during exercise. In chapter 2, an update is given on prognostically important cardiopulmonary 
exercise variables and their determinants in HF. Chapter 3 reports on the activity of the ergoreflex 
and its current relationship to exercise intolerance and subsequent prognosis in a broad spectrum of 
subjects, ranging from healthy subjects and patients with coronary artery disease to HF patients. 
  
Part 2 
 
Despite improvements in the treatment of HF, mortality and readmission rates remain high with an 
increase in HF patients with preserved ejection fraction. 8 In the latter group, the use of similar drugs 
does not result in an improvement in prognosis,9 indicating the urgent need for novel treatment 
strategies. Data from hospitalized HF patients are useful to better understand the clinical 
characteristics, patient management and outcomes and may help to improve patient outcomes,10, 11 
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however, such data are currently lacking for Belgium. In addition, the similarities in outcome 
between HF patients with reduced and preserved LVEF for a given BNP level,12 led us to investigate 
whether exercise capacity is predominantly affected by neurohormonal activation or LVEF and how 
exercise training may provide an answer for exercise intolerance, (in)dependent of the 
aforementioned factors. Hence, the second part of this dissertation focuses on outcome in HF in the 
Belgian situation but also on the role of neurohormonal activation in exercise capacity and the 
possibilities of exercise training as an effective treatment modality. In chapter 4, the first results of 
the Belgian BIO-HF registry are presented regarding patient characteristics and short-term outcome 
of patients hospitalized for HF. Chapter 5 evaluates the impact of NT-proBNP on exercise capacity in 
CAD patients with a wide range of left ventricular function and neurohormonal activation as well as 
whether the improvement after exercise training depends on one of these factors.  
 
Part 3 
 
Despite the clear benefits of CR, figures on participation in CR are disappointing with more than half 
of eligible patients who do not attend CR.13 In addition a considerable number of those patients who 
actually attend CR, drop out prematurely.14 In Belgium, specific data on participation among the 
different patient groups and in HF in particular, are lacking. A variety of reasons for drop-out have 
been described in literature but may be different among countries because of different legislation 
and environmental conditions. Therefore, the third part of this work assesses the current barriers in 
the implementation of CR. Chapter 6 reports on participation in CR among different patient groups 
with a focus on HF. In addition, potential predisposing clinical characteristics for (non-) participation 
are evaluated in HF as well as the benefit of exercise training in comparison with other patient 
groups. In chapter 7, drop-out is evaluated in a broad spectrum of cardiac patients with a focus on 
potential predisposing clinical characteristics, exercise parameters and psychosocial factors which 
could lead to drop-out. Despite the recommendation for CR in several cardiac patient groups, the 
effects of CR are not fully acknowledged in VHD thus far. Moreover, the influence of the preoperative 
state and the type of valvular surgery on exercise capacity are not known. Therefore, chapter 8 
focuses on exercise capacity and the effects of exercise training after valvular surgery according to 
the preoperative state, as assessed by the EuroSCORE, and to the type of surgery.   
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The analyses of this work are based on different datasets which are further explained in this section.  
 
To gain insight in the working mechanism of the ergoreflex (chapter 3), a broad spectrum of patients 
was tested ranging from healthy subjects to CAD patients and HF patients in different stages of 
disease severity. These patients were recruited between April 2011 and March 2013 in two 
participating hospitals: AZ Maria Middelares Ghent and Onze-Lieve-Vrouw Hospital Aalst.  
 
The BIO - Heart Failure (BIO-HF) registry was used to evaluate clinical characteristics and short-term 
outcome in hospitalized HF patients (chapter 4) as well as to analyze the participation rate in cardiac 
rehabilitation among HF patients (chapter 6). This Belgian ongoing prospective HF registry is the 
result of a cooperation since 2008 between the departments of cardiology of two hospitals (AZ Maria 
Middelares Ghent and University Hospital Brussels). The objective of this registry is to prospectively 
collect data regarding baseline characteristics, in-hospital treatments, medication at discharge and 
outcome for consecutive patients admitted with acute HF (NYHA III or IV). For the analysis 
concerning outcome, data from both hospitals were used. Data from AZ Maria Middelares Ghent 
were also used to evaluate the participation rate in CR among HF patients, by using both the BIO-HF 
registry and the Cardiac Rehabilitation database. 
 
The Cardiac Rehabilitation database is a multidisciplinary registry, which was started in October 2007 
in AZ Maria Middelares Ghent and since April 2011 simultaneously recorded in AZ Maria Middelares 
Ghent en Onze-Lieve-Vrouw Hospital Aalst. These data are prospectively collected at start and end of 
the rehabilitation program by the different disciplines (cardiologist, physiotherapist, social nurse, 
dietician and psychologist) and include medical background, medication use, laboratory results, 
exercise parameters, anthropometric measures, social and psychological characteristics of all 
patients entering CR, irrespective of the diagnosis. The aim of this project is to gain insight in the 
characteristics and pathologies of the diverse population that participates in CR, to study the effects 
of CR on different aspects of the patient’s condition and to evaluate outcome regarding 
hospitalization and mortality. Data from AZ Maria Middelares Ghent were used for the analysis of the 
impact of neurohormonal activation on exercise capacity and training effects (chapter 5) . Data from 
both hospitals were analyzed to evaluate drop-out (chapter 7) and to study the effects of exercise 
training in VHD patients (chapter 8) . 
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Figure 2. Overview of the two datasets used in this thesis. The timeline at the left side shows the period of data 
collection. The horizontal lines represent the time at which the cooperation with a participating hospital was 
started or ended. Studies based on the BIO-HF registry are indicated in red and studies based on the Cardiac 
Rehabilitation Database are indicated in green. The study in the middle of the figure is based on both datasets. 
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1 Introduction 
 
Heart failure is a clinical syndrome that develops in response of a cardiac insult, resulting in a decline 
of cardiac performance. Several neurohormonal mechanisms are activated in response to the 
underlying myocardial dysfunction, including the sympathetic nervous system (SNS) and the renin-
angiotensin-aldosteron axis (RAAS axis). Although the activation of these systems can initially 
compensate for the depressed myocardial function, their long-term activation results in a further 
impairment of cardiac function leading to progression of heart failure and cardiac decompensation.1, 
2 
As pointed out by Parati and Esler,3 sympathetic activation occurs subsequently to the development 
of heart failure and then impacts adversely on clinical outcome. This is in contrast to essential 
hypertension where SNS activation is already important in the initiation and the maintenance of 
hypertension.  Also, there is now clear evidence that besides sympathetic activation, also reduced 
vagal function plays a role in the development of heart failure.4 In this chapter we will briefly review 
the normal cardiovascular actions of the autonomic nervous system (ANS) and then discuss the 
pathophysiology and potential therapeutic implications of sympathetic hyperactivity and reduced 
vagal function in heart failure. 
 
2 The ANS and normal cardiac function 
 
In the normal heart, the SNS has different cardiovascular actions, including acceleration of the heart 
rate, increase in cardiac contractility, reduction of venous capacitance and constriction of resistance 
vessels. The cardiac sympathetic nerve fibers are located subepicardially and travel along the major 
coronary arteries.2, 5 The sympathetic outflow to the heart and peripheral circulation is regulated by 
cardiovascular reflexes. Afferent fibers are carried toward the central nervous system (CNS) by 
autonomic nerves, whereas efferent impulses travel from the CNS toward different organs.  The main 
reflex responses originate from the aortic arch and carotid baroreceptors (SNS inhibition), 
cardiopulmonary baroreceptors (including the Bezold-Jarish reflex, SNS inhibition), cardiovascular 
low-threshold polymodal receptors (SNS activation) and peripheral chemoreceptors (SNS 
activation).6 As already summarized by Van Stee,7 the effect of SNS activation on the periphery is 
mediated by 4 pathways: (1) norepinephrine releasing neurons through the right stellate ganglion 
reaching the sinus and atrioventricular nodes (resulting in an increase in heart rate and shortening of 
atrioventricular conduction) and through the left stellate ganglion reaching the left ventricle 
(resulting in an increase in contractile strength), (2) epinephrine released in circulation by the adrenal 
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cortex affecting both the myocardium and peripheral vessels, (3) direct effect on peripheral vessels 
through local release of epinephrine and norepinephrine, (4) circulating norepinephrine which can 
act on multiple locations (e.g. increase in heart rate during exercise in heart transplant recipients). 
Norepinephrine and epinephrine bind to specific adrenergic receptors, of which there are at least 9 
subtypes (3 alpha1-receptor subtypes, 3 alpha2-receptor subtypes and 3 beta-receptor subtypes).  In 
the human heart, activation of beta1 and beta2 adrenergic receptors is the most powerful 
physiologic mechanism to acutely increase cardiac performance and the beta adrenergic receptor 
density is greatest at the apical myocardium.8 Approximately 80% of norepinephrine released by the 
sympathetic nerve terminals is recycled by the norepinephrine transporter 1, whereas the remainder 
clears into the circulation.9  
 
The parasympathetic nervous system affects the cardiovascular system by slowing heart rate through 
vagal impulses. The parasympathetic fibers run with the vagus nerve subendocardially, and are 
mainly present in the atrial myocardium and less abundantly in the ventricular myocardium.2, 5 
Acetylcholine released from post-ganglionic cardiac parasympathetic nerves reduces heart rate by 
binding to muscarinic cholinergic receptors (primarily M2 subtype) on sinoatrial nodal cells.10, 11 
Parasympathetic-mediated changes in heart rate are initiated primarily in the CNS or originate from 
activation or inhibition of sensory nerves. Stimulation of arterial baroreceptors, trigeminal receptors 
and subsets of cardiopulmonary receptors with vagal afferents, reflexively increase cardiovagal 
activity and decrease heart rate. In contrast, stimulation of pulmonary stretch receptors with vagal 
afferents and subsets of visceral and somatic receptors with spinal afferents reflexively decrease 
cardiovagal activity and increase heart rate.12 Importantly, the parasympathetic nervous system and 
the SNS are often working interactively with opposing resulting effects.   
 
3 Heart failure and sympathetic hyperactivity 
 
3.1 Pathophysiology 
 
Patients with heart failure are characterized by an abnormally activated sympathetic and altered 
parasympathetic tone, with also attenuated cardiovascular reflexes and a maladaptive 
downregulation of adrenergic nerve terminals.13, 14  In the early changes of heart failure there is a 
selective cardiac change in the autonomic regulation with a decrease in heart rate variability and a 
selective increase in cardiac norepinephrine spillover in order to preserve cardiac output (CO). 
Chronic persistent myocardial dysfunction is associated with a more generalized sympathetic 
Research Part 1 – Chapter 1  
48 
 
hyperactivity. Evidence for this increased sympathetic activity in patients with heart failure includes 
increased central sympathetic outflow and increased norepinephrine spillover to plasma from 
activated sympathetic nerve fibers, and consequently increased plasma norepinephrine levels.  
Besides the increased muscle sympathetic nerve activity and norepinephrine spillover, patients with 
heart failure and reduced ejection fraction may also have a decreased neuronal density and a 
decreased neuronal function resulting in decreased norepinephrine concentration within the 
cardiomyocytes. Compared with myocardium of healthy individuals, the myocardium of patients with 
chronic left ventricular dysfunction is also characterized by a significant reduction of presynaptic 
norepinephrine uptake and postsynaptic beta1 adrenergic receptor density.15, 16 This latter 
phenomenon has been documented in patients after acute myocardial infarction where it 
contributes to adverse left ventricular remodeling, in patients with heart failure due to dilated 
cardiomyopathy as well as in patients with hypertrophic cardiomyopathy who develop left 
ventricular dilatation and heart failure.17-19 The increase in norepinephrine levels apparently results in 
a decrease in beta1 adrenergic receptor density and a beta1 adrenergic receptor desensitization 
which appears to be a predominantly protective adaptation. The role of cardiac beta2 and beta3 
adrenergic receptors as well as cardiac alpha1 adrenergic receptors in heart failure has not been fully 
elucidated yet.2 
 
3.2 Effects during exercise 
 
Hemodynamic effects 
 
During exercise, cardiovascular and respiratory responses are regulated by the ANS in order to 
provide a sufficient oxygen supply to the working muscles.20 The balance between parasympathetic 
and sympathetic nerve activity is mediated by the interaction between the central command, 
originating from the central motor areas, and peripheral feedback afferents, including the baroreflex, 
chemoreflex, and ergoreflex.20, 21 Sensory input from these cardiovascular afferents is projected to 
the nucleus tractus solitarius in the medulla oblongata, which plays a pivotal role in integrating and 
referring this information to other regions of the CNS with an impact on the sympathetic-
parasympathetic outflow.22 
 
Activation of the SNS during exercise normally induces a rise in heart rate and contractility resulting 
in an increased CO.2 Together with local metabolic vasodilatation, increased CO amplifies the blood 
flow to the working muscles. Local vasodilatation is, however, partially restrained by a SNS mediated 
vasoconstriction in order to maintain an adequate level of blood pressure.23  
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Baroreceptors, located in the aortic arch and carotid sinuses,24 are together with ergoreceptors, 
group III and IV skeletal muscle afferents,25 responsible for these hemodynamic changes. Once 
activated, the main function of these baroreceptors is to maintain the arterial blood pressure at an 
adequate level (set point) by increasing or decreasing peripheral vasoconstriction.24 During exercise, 
a rapid resetting of this set point occurs (towards a higher level) in order to allow a higher arterial 
pressure and increased blood flow to adjust to the increased metabolic demands.22 Importantly, in a 
significant number of conditions, including coexisting sleep apnoea, myocardial ischemia, obesity and 
inflammation, additional nonbaroreflex mediated excitatory stimuli may elevate the set point for 
central sympathetic outflow or neurotransmitter release at rest and during exercise. 
 
As metabolites accumulate during exercise and signal insufficient oxygen supply to the exercising 
muscles, ergoreceptors become activated and provide a rise in arterial pressure and blood flow 
primarily via an increased ventricular contractility and stroke volume with a resultant increase in 
CO.21, 26, 27 The effect of the ergoreflex on heart rate has been a matter of debate. Some authors 
suggested that the ergoreflex has only a minor influence on HR.28 However, when the mean arterial 
pressure is elevated, arterial baroreflex should decrease heart rate to lower mean arterial pressure.29 
As heart rate remains unchanged, the influence of the ergoreflex on heart rate regulation is thought 
to be masked by counterregulation of the arterial baroreflex.30 During severe exercise the ability of 
the ergoreflex to elicit further increases in CO becomes limited. Pressor responses are then mediated 
via peripheral vasoconstriction, but are smaller in comparison with the contribution of CO.31 In 
normal healthy subjects, ergoreflex activity is buffered by the arterial baroreflex. If this reflex is left 
unbuffered, than instead of a rise in CO, peripheral vasoconstriction in the active skeletal muscle is 
induced as a response to ergoreflex activation.32  
 
Due to a chronic left ventricular dysfunction, a catabolic state is seen in heart failure with metabolic 
changes and chronic underperfusion of the skeletal muscle. A shift from type I to type IIb muscular 
fibers has been reported with a decrease in oxidative enzyme capacity and a concomitant rise in 
lactate and lactate dehydrogenase activity.33, 34 Skeletal muscle apoptosis has also been described in 
heart failure and is thought to be triggered by pro inflammatory cytokines.35, 36 
 
This altered muscle metabolism may elicit an accumulation of metabolic byproducts which results in 
a chronic activation of the ergoreceptors and subsequently sympathetic hyperactivity. Whereas in 
normal conditions  the ergoreflex increases CO, a shift towards peripheral vasoconstriction is seen in 
heart failure, further limiting blood flow and exacerbating skeletal muscle abnormalities and fatigue 
complaints.37, 38 The loss of the CO response likely reflects the impaired ability to increase ventricular 
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function21, 31, 38 and the shift towards a peripheral vasoconstriction indicates a reduced baroreflex 
buffering in pathologic situations.39 
 
Ventilatory effects 
 
Apart from hemodynamic changes, ergoreceptors are also thought to take part in ventilatory 
responses during exercise. However, the role of these receptors in modulating ventilation in healthy 
subjects has been questioned due to conflicting results in the literature.28, 40, 41 On the other hand, in 
patients with heart failure, an overactive ergoreflex mechanism has been demonstrated resulting in 
an excessive increase in ventilation and symptoms of breathlessness. A disruption of this reflex has 
been shown to correlate with several prognostic exercise parameters, including the peak VO2  and 
the ventilatory slope.40, 42, 43  
 
Chemoreceptors may also play a critical role in the increased ventilatory response in heart failure.44, 
45 According to their location, they are subdivided into central medullary and peripheral carotid 
afferents with the former being particularly sensitive to changes in CO2 while the latter are activated 
in hypoxic conditions.22 In patients with heart failure, enhanced hypoxic and central hypercapnic 
chemosensitivity has been described.44-46 This hypersensitivity is associated with a higher incidence 
of arrhythmias, Cheyne-Stokes respiration and indicates a poor prognosis.45 When the chemoreflex 
and ergoreflex are combined, the response to ventilation is greater than the sum of the two 
responses separately, suggesting that their interaction has an additional stimulatory effect on 
ventilation.47 
 
In conclusion, in a generalized sympathetic state which is seen in patients with heart failure, an 
enhanced peripheral vasoconstriction occurs during exercise in order to preserve an adequate blood 
pressure level. Consequently, this limits blood flow in the exercising muscle and thereby further 
exacerbates muscular abnormalities. Concerning the ventilatory aspect, an inappropriate rise in 
ventilation is seen which is related to the complaints of breathlessness and indicates a poor 
prognosis. As such, sympathetic hyperactivity contributes to the downward vicious cycle 
characteristic for heart failure, with fatigue and dyspnoea being the major barriers for exercise 
tolerance. 
  
Research Part 1 – Chapter 1 
51 
 
3.3 Therapeutic implications 
 
Medication 
 
Several classes of medication can interact with the SNS and inhibit its activity in patients with heart 
failure. Chronic β blocker therapy has been extensively evaluated in patients with heart failure.  
Several large scale clinical trials have shown that bisoprolol, carvedilol, metoprolol succinate and 
nebivolol reverse left ventricular remodeling, reduce the risk of hospitalization and improve survival 
in patients with chronic heart failure.48 This protective effect of β blockers is multifactorial and 
related to several factors, including the inhibition of catecholamine cardiotoxic effects, beta1 
adrenergic receptor up regulation, attenuation of the RAAS-axis, subendocardial coronary flow 
enhancement and restoration of the reflex control on the heart and circulation.2, 49 A meta-analysis in 
almost 20.000 patients demonstrated that the risk reduction with β blockers in patients with systolic 
heart failure was predominantly due to heart rate reduction achieved by β blockade rather than the 
type of β blockade, the dose of the β blockade, the underlying course of heart failure and many other 
potential confounders.50  
 
The RAAS-axis is up regulated in heart failure and the resulting angiotensin-II and aldosterone 
production enhances the release and inhibits the uptake of norepinephrine at nerve endings.  
Because of this interaction with the SNS, a part of the beneficial effect of angiotensin-converting 
enzyme inhibitors and aldosterone antagonists in heart failure can probably be attributed to their 
effect on norepinephrine.49 However not all medications that interact with the SNS have shown 
beneficial effects in patients with heart failure.  Prazosin for example inhibits the alpha1 receptor but 
causes an increase in cathecholamine levels which probably explains a worse outcome in clinical 
trials.51 Also, moxonidine that acts through both alpha2 and imidazolidine receptors and causes a 
marked dose-related reduction in plasma norepinephrine, was associated with an increased 
mortality in clinical trials.52 
 
Device therapy 
 
Cardiac resynchronization therapy (CRT) is an effective therapy in patients with advanced heart 
failure and electrical/mechanical dyssynchrony. Several large outcome studies have shown that this 
device therapy is associated with an improvement of symptoms, quality of life and survival.48 Cha et 
al.53 recently reported that CRT modulates sympathetic function by up regulating presynaptic 
receptor function as evidenced by increased iodine-123 metaiodobenzylguanidine ([123I]-MIBG) 
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imaging. Importantly, the reversal of neuronal remodeling in response to CRT appeared to be beyond 
that achieved by medical therapy. Also, patients with a less impaired presynaptic adrenergic 
preservation (or a better sympathetic reserve) showed a better response to CRT. 
 
Exercise training 
 
Exercise training has been demonstrated to improve exercise tolerance and quality of life, and 
reduce hospitalisations in heart failure.54, 55 There is also limited evidence that exercise training 
reduces mortality. One of the responsible mechanisms for these beneficial effects is the 
counteraction of the sympathetic hyperactivity. Heart rate variability, beat to beat variations in time 
of consecutive heartbeats expressed in a normal sinus rhythm, is frequently used to evaluate the 
ANS.56 Training has been shown to improve heart rate variability, indicating that the ANS and the 
sinoatrial node respond dynamically to environmental changes.56-60  
 
Regular exercise reverses sympathetic hyperactivity in favor of exercise tolerance, through its 
influence on the different receptors which mediate the sympathico-vagal balance. Training effects 
have traditionally been attributed to peripheral rather than central adaptations. A (partial) reversal 
of structural abnormalities in skeletal muscle such as a decreased oxidative capacity, an impaired leg 
muscle blood flow with endothelial dysfunction and a glycolytic fiber type distribution, has been 
demonstrated after exercise training.61-64 This reshift towards an aerobic metabolism may result in a 
decreased ergoreflex activity with a concomitant reduced activation of the sympathetic outflow.42, 65, 
66 Another effect of exercise training is the restoration of the blunted baroreflex sensitivity.67, 68 The 
baroreflex is known to buffer the ergoreflex mediated vasoconstriction.32 This buffering mechanism 
together with a reduced triggering of the ergoreceptors, results in an improved skeletal muscle blood 
flow which has a positive effect on fatigue complaints.  
 
As ergoreflex activity is also known to influence ventilation, a decrease in its activation through 
exercise training, has a positive impact on the prognostic important ventilatory inefficiency, typically 
seen in patients with heart failure.42 Exercise training also reduces chemoreceptor activity, another 
mediator of the ventilatory drive.69  
 
Through its impact on the periphery, exercise training is able to influence the ANS thereby dealing 
with the two main reasons for exercise intolerance, dyspnoea and fatigue. 
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4 Heart failure and reduced vagal function 
 
4.1 Pathophysiology 
 
Dysfunction of the parasympathetic nervous system has been documented extensively in heart 
failure in both animal studies and humans. Already in 1971, Eckberg et al.70 showed that arterial 
baroreflex control of heart rate was reduced in patients with left ventricular dysfunction.  Moreover, 
altered vagal control of heart rate appears to be present early in the development of left ventricular 
dysfunction71 and is associated with a poor prognosis in patients post myocardial infarction and heart 
failure.72, 73 Despite the recognition of a reduced vagal control in heart failure and its association with 
worse outcomes, the precise anatomical sites and mechanisms of abnormal vagal control are not 
very clear.4 The overall (limited) evidence suggests that the anatomical level of dysfunction seems to 
lie at the level of the ganglion since postganglionic mechanisms are up regulated and functional.4 
Different non-invasive techniques can be used to measure vagal nerve activity including resting heart 
rate, heart rate variability, baroreflex sensitivity and heart rate turbulence (for an extensive review, 
see12). 
 
4.2 Effects during exercise 
 
In normal subjects, vagal control results in a reduction in resting heart rate through its inhibitory 
effect on the SNS and hyperpolarization of the sinus nodal cells. Via a NO pathway, parasympathetic 
activation can cause vasorelaxation, but vasoconstriction through its action on vascular smooth 
muscle has also been described.74 Apart from the bradycardic effect, a negative inotropic effect 
resulting in a decreased myocardial contractility has been demonstrated after vagal nerve 
stimulation.75 As such, parasympathetic activity decreases the cardiac work and myocardial oxygen 
demand.76   
 
Vagal function is blunted in heart failure71, 77, 78 and is thought to originate from a withdrawal of 
baroreflex activity. As blood pressure falls in heart failure, baroreflex activity is reduced resulting in a 
decrease in the inhibitory input to adrenergic control.79 Whereas in normal conditions, baroreceptor 
activity modulates chemoreceptor80, 81 and ergoreflex activation,32 this inhibition is impaired in heart 
failure, with a resultant increase in ergoreflex-mediated vasoconstriction39 and a hyperventilatory 
response during exercise.42-44 
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4.3 Therapeutic implications 
 
While β blockade has found its place as a corner stone therapy for heart failure that impacts the SNS, 
far less is known about medication and interventions that augment parasympathetic function. 
 
Medication  
 
Since there is a close interaction between the sympathetic and vagal nervous system, medical 
therapy that influences the SNS may also have an effect on the vagal nervous system. This has been 
shown both experimentally and clinically for β blockers in heart failure. They can augment the vagal 
nerve control of heart rate by blocking the cardiac sympathetic pre-junctional beta2 adrenoreceptor 
that facilitates norepinephrine release.82 Also, they can increase the density of M2 receptors 
especially in the endocardial tissues of the left ventricle free wall, and change heart rate variability 
measurements, suggesting increased parasympathetic function.83, 84 Accordingly, studies with ACE-
inhibitors and angiotensin receptor blockers suggest an additional protective role by their reduction 
of angiotensine II, which potentiates sympathetic activity and blunts vagal inhibitory action. Also, 
spironolactone might have sympatholytic effects. In contrast, loop diuretics inducing transient 
disturbances in fluid balances, may cause a greater suppression of parasympathetic tone (for an in 
depth review of this issue see85). 
 
Device therapy 
 
The association between impaired vagal reflexes and increased cardiac mortality raised the 
possibility that increasing vagal activity could have a protective effect. This has been shown in 
different animal models by direct electrical stimulation of the right cervical vagus.86-88 The first 
human experience of chronic vagal stimulation in patients with heart failure suggests that this 
treatment is feasible, safe and tolerable and leads to a subjective clinical improvement.89 Potential 
mechanisms of a favorable effect include a heart rate mediated effect, anti-adrenergic effects (that 
may occur at the central level and at the peripheral level), anti-apoptotic effects, increase in NO and 
anti-inflammatory effects.74, 90 Larger clinical trials are currently ongoing to further evaluate the 
safety and efficacy of vagus nerve stimulation in patients with heart failure.91 
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Exercise training 
 
Numerous studies have demonstrated that exercise training increases heart rate variability and 
baroreflex sensitivity, indicating a restoration of the baroreflex function and the concomitant vagal 
activity.59, 68, 92-95  
 
These training effects are thought to be related to the mediation of different neuromodulators of the 
parasympathetic nerve activity. A decrease in neuronal nitric oxide synthase (nNOS) has been shown 
in heart failure and may be involved in the parasympathetic withdrawal.96 Another modulator is 
angiotensin II, which is known to inhibit vagal function through its action on the baroreflex function 
and to facilitate sympathetic activity.97, 98 Exercise training increases NO bioavailability and 
endothelial function, and suppresses angiotensin II, thereby improving vagal function.97, 99, 100 By 
restoring baroreflex function, exercise training limits the detrimental effects of ergoreflex and 
chemoreflex activity which results in improvements of exercise tolerance in patients suffering from 
heart failure. 
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Abstract 
 
Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor 
prognosis. This review provides an update on cardiopulmonary exercise variables, proven to be 
prognostically important in heart failure. Besides the widely accepted peak oxygen consumption 
(peak VO2) and VE/VCO2 slope, other exercise variables – exercise oscillatory ventilation (EOV) and 
partial pressure of end-tidal CO2 (PETCO2) – should gain attention in the interpretation of 
cardiopulmonary exercise testing. In addition to prognosis, the pathophysiological origin is also 
discussed. Different mechanisms underlie these exercise variables with an important contribution of 
hemodynamic, pulmonary and peripheral abnormalities. Given the different pathophysiological 
origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be 
encouraged, not only for diagnostic and prognostic  purposes but also for evaluating the effect of 
interventions.  
 
Keywords: heart failure, cardiopulmonary exercise testing, exercise intolerance, prognosis, diagnosis, 
intervention  
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1 Introduction 
 
Heart failure is a syndrome, initiated by a reduction in cardiac function and mainly characterized by 
symptoms and signs which are the result of compensatory hemodynamic, autonomic and 
neurohormonal mechanisms.1 Exercise intolerance is a hallmark feature of chronic heart failure and 
indicates a poor prognosis. This review provides an update on cardiopulmonary exercise variables 
which have proven to be prognostically important in heart failure. 
 
2 Cardiopulmonary exercise parameters 
 
2.1 Aerobic capacity: peak oxygen consumption 
 
Originally, the heart was thought to be the major determinant of exercise intolerance. This 
presumption is partially true as exercise capacity, expressed by the peak oxygen consumption, is 
determined by cardiac output and the arterio-venous O2 difference according to the Fick’s principle. 
Since Stringer and his colleagues2 demonstrated that the (A-V) O2 difference was similar between 
normal subjects and heart failure patients, exercise intolerance in heart failure was assumed to be 
the result of an impaired cardiac function. This has, however, been questioned by others as there is 
only a weak correlation between resting measures of left ventricular function and exercise capacity.3  
 
Since Mancini et al.4 demonstrated its prognostic value in heart transplant candidates, peak oxygen 
consumption has become a widely accepted prognosticator. In contrast to healthy subjects who have 
a plateau in oxygen uptake in line with increasing workload (maximum oxygen uptake or VO2 max), 
heart failure patients often do not achieve a plateau phase due to early occurrence of intolerable 
symptoms limiting exercise. Therefore, the term peak oxygen consumption (peak VO2) has been 
used, calculated as the average oxygen consumption of the last 30 seconds of peak exercise (Figure 
1A).5 
 
During the last decade, this parameter appeared to have its drawbacks. Its predictive information is 
affected by the subject’s effort and is limited in heart failure patients with an intermediate exercise 
tolerance, i.e. a peak VO2 between 10 and 18ml.min
-1.kg-1.6 Moreover, the traditional cut point of 
14ml.min-1.kg-1  to indicate a heightened risk for mortality, did not seem to provide the same 
predictive information in female patients.7 As β blockade has become a standard pharmacological 
intervention in recent years, the prognostic power of peak VO2 in patients receiving β blockers, has 
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been questioned. Recent research in large study populations demonstrated that peak oxygen 
consumption is a determinant of survival, even in the setting of β blockade.8, 9 Whether the threshold 
needs to be adjusted to the use of β  blockers, is still a matter of debate. While some authors advise 
a downward adjustment of the traditional cut-off for an appropriate estimation of the risk,8 others 
have found that the optimal prognostic threshold value (14 ml.min-1.kg-1) is similar between patients 
treated with or without β blockers.9 Current guidelines recommend the use of the 4-level Weber 
classification of peak VO2 for risk stratification in heart failure , with a peak VO2 less than 10 ml.min
-
1.kg-1 reflecting the worst prognosis (Table 1).10 
 
Figure 1. (A) Example of the peak oxygen consumption during exercise. Peak oxygen consumption is calculated 
as the average of the last 30 seconds of peak exercise. VO2, oxygen consumption, peak VO2, peak oxygen 
consumption. (B) Schematic representation of the linear increase in ventilation in response to a rising CO2 
production. The ventilatory slope is represented in the equation y=0.05046x+0.9159 as the slope = 50.46. 
VE/VCO2 slope, ventilatory slope; VE, ventilation; VCO2, carbon dioxide production. (C) Illustration of an 
oscillatory ventilation pattern during exercise. VE, ventilation. (D) Example of the partial pressure of end-tidal 
CO2. The line at the bottom of the graph represents the PETCO2. In this case, PETCO2 is below the cut-off value of 
33mmHg. PETCO2, partial pressure of end-tidal carbon dioxide. 
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Table 1. Risk stratification and prognosis in chronic heart failure patients 
 
EOV, exercise oscillatory ventilation; peak VO2, peak oxygen consumption; PETCO2, partial pressure end-tidal 
carbon dioxide; VE/VCO2 slope, ventilatory slope; VC I, ventilatory class I; VC II, ventilatory class II; VC III, 
ventilatory class III; VC IV, ventilatory class IV.  
 
2.2 Ventilatory inefficiency: the ventilatory slope 
 
The limitations in the prognostic value of peak VO2 have led to a search for novel prognostic 
parameters. As exercise ventilation inefficiency is a key characteristic in the complaints of heart 
failure patients, this phenomenon has gained attention.  
 
The VE/VCO2 slope describes the linear increase in ventilation in response to a rising CO2 production 
(Figure 1B). Nevertheless, this relation is not linear during the whole exercise test. Beyond the 
respiratory compensation point, VE increases disproportionately to VCO2 because it is driven both by 
CO2 output and by a decrease in plasma pH when the buffering action of bicarbonates is exceeded.
11 
Whether the calculation of the VE/VCO2 slope from data of the early part of exercise provides equally 
prognostic power as data from the whole exercise test to peak exercise, has been an interesting 
point of discussion. Currently, there is important evidence in favour of the inclusion of the last part to 
peak exercise in the calculation of the VE/VCO2 slope to optimize its prognostic sensitivity. The 
submaximal slope computed from the first 50% of the data points or below the respiratory 
compensation point, could provide a prognostic surrogate in those patients who are unable to 
perform a maximal test.12 
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Even though the peak oxygen consumption and the VE/VCO2 slope seem to be related, there is no 
clear linear relation between these parameters (Figure 2). Different pathophysiological mechanisms 
have been proposed for elucidating the increased ventilatory demand. Using the modified alveolar 
equation VE/VCO2 = 863/[PaCO2 * (1-VD/VT)], the VE/VCO2 slope can be explained by two main 
factors: the physiological dead space/tidal volume ratio (VD/VT) and the arterial CO2 tension (PaCO2). 
Early lactic acidosis has been proposed as an additional factor explaining the rise in ventilation.13 
However, this should rather be seen as being part of the change in arterial CO2 tension, which will be 
discussed later in this review. 
 
Increased dead space ventilation is a common finding in heart failure patients and is the result of 
injury to the lungs due to the backward hemodynamic effects of heart failure with a pressure and 
volume overload.14 One of the disturbances occurring at the lung level is the development of a 
restrictive lung pattern with reductions in vital capacity and forced expiratory volume.15 Also, 
disturbances in lung diffusion capacity are seen with a reduced alveolar-capillary membrane 
conductance.16 A third plausible cause of an increased VD/VT is  a ventilation-perfusion mismatch with 
the blood flow distributed more to the upper part of the lungs in patients with a steep slope.17  
 
Recent research has demonstrated an increased ventilatory drive with subsequent reductions in 
PaCO2.
18
 This hyperventilation is the second mechanism to explain ventilatory inefficiency in heart 
failure and is thought to originate from disturbances in the chemoreflex and the ergoreflex.  
According to their location, chemoreceptors are subdivided into central medullary and peripheral 
carotid afferents with the former being particularly sensitive to changes in CO2 while the latter are 
activated in hypoxic conditions.19 In heart failure patients, enhanced hypoxic and central hypercapnic 
chemosensitivity has been described.20 This hypersensitivity may play a critical role in the increased 
ventilatory response20 and reflects a worse clinical status with a higher incidence of arrhythmias and 
Cheyne-Stokes respiration.21 Moreover, it was found to be an independent predictor of death.21  
Similar to the chemoreflex, overactivation of the ergoreflex has been proposed in chronic heart 
failure. Ergoreceptors are myelinated group-III and unmyelinated group-IV skeletal muscle afferents 
which are sensitive to mechanical deformations and metabolic products of the exercising muscles, 
respectively.22 Several metabolites have been postulated as potential triggers, prostaglandins, 
bradykinins and a decrease in pH being the most important determinants.23, 24 Endothelium 
impairment with a concomitant decreased muscle perfusion has also been linked to ergoreflex 
activation.25 A disruption of this reflex has been shown to correlate with the ventilatory slope and is 
inversely related to the peak VO2.
26 A link between the ergoreflex and the chemoreflex has been 
demonstrated, indicating a common mechanism of activation.26 When these two reflexes are 
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combined, the response to ventilation is greater than the sum of the two responses separately, 
suggesting that their interaction has an additional stimulatory effect on ventilation.27 
 
Besides the dead space ventilation and the arterial CO2 tension, some authors have suggested that 
muscle deconditioning with concomitant early lactate acidosis is a third possible mechanism to 
explain the increased ventilatory demand.13 However, it should rather be seen as a part of the so-
called ‘muscle hypothesis’ with the ergoreflex playing a pivoting role. Due to a chronic left ventricular 
dysfunction, a catabolic state is seen in heart failure with metabolic changes and chronic 
underperfusion of the skeletal muscle. A shift from type-I to type-IIb muscular fibres has been 
reported with a decrease in oxidative enzyme capacity and a concomitant rise in lactate and lactate 
dehydrogenase activity.28 This altered muscle metabolism may elicit an accumulation of metabolic 
byproducts which results in a chronic activation of the ergoreceptors. This enhanced activity causes 
an increase in the VE/VCO2 slope with symptoms of breathlessness and sympathetic activation with 
an increased vascular resistance further exacerbating the skeletal muscle abnormalities and the 
fatigue complaints.29  
 
Whether the hyperventilation or the increase in dead space ventilation is the most important 
determinant of ventilatory efficiency, has been discussed by several authors. While some of them 
argue there is an equal contribution of the two mechanisms,30 Guazzi and his colleagues18 
demonstrated that a decrease in PaCO2 at peak exercise retained a greater prognostic significance. 
Wensel et al. 30 described that the VE/VCO2 ratio is predominantly related to the VD/VT ratio at rest 
and during aerobic exercise but as anaerobic metabolism ensues, the hyperventilatory response 
affects the VE/VCO2 ratio. As such, hyperventilation leads to an increase in overall VE/VCO2 slope. 
Since research has shown that the overall VE/VCO2 slope is prognostically superior,
11 regulatory 
mechanisms involved in the tight control of ventilatory command and blood gas tension, rather than 
lung function abnormalities may play a critical pathophysiological role in the exercise ventilation 
inefficiency of CHF patients.18 As literature shows that the overactive ergoreflex is more closely 
related to exercise tolerance than other autonomic indexes or reflexes, this mechanism arising from 
the periphery can be seen as the keystone in symptom generation and disease progression.26 
 
Numerous studies have compared the VE/VCO2 slope with the peak VO2 to assess their value for 
predicting the risk for mortality and cardiovascular events. Arena et al.31 recently analysed this 
extensive literature and resumed that the majority of these investigations indicated that the 
ventilatory response to exercise was superior to peak VO2, not only in predicting mortality but also in 
providing additional information regarding hospitalisation. One study revealed that the VE/VCO2 
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slope retained its prognostic significance up to 36 months whereas the peak VO2 was related to 
adverse events for only 18 months.32 Another strength of the slope is its potential to stratify the 
mortality risk in patients with intermediate exercise tolerance.33 It should be noticed that the greater 
part of the current investigations concerned heart failure patients with a reduced ejection fraction. 
However, those who have focused on patients with preserved ejection fraction obtained similar 
findings.34 
An abnormal slope is commonly identified as a value of more than 34. This threshold was originally 
introduced by Chua et al.35 whose follow-up survey of 18 months demonstrated a survival rate of 
95% in patients with a normal VE/VCO2 slope compared with 69% in those with a high slope. 
Whether the use of β blockers affects the prognostic power of the ventilatory slope, has scarcely 
been studied. According to a study with 417 heart failure patients, it can be assumed that this 
parameter retains its prognostic significance, independently from the prescribed medication.9 
Recently, the EACPR and AHA working group used the 4-level ventilatory classification to provide an 
appropriate risk stratification in heart failure, whereby a VE/VCO2 slope higher than 45 is indicative of 
a particularly poor prognosis (Table 1).10, 32  
 
Figure 2. Illustration of the relationship between the peak oxygen consumption and the ventilatory slope. R² 
linear=0.108 represents a weak correlation between the two parameters. Peak VO2, peak oxygen consumption; 
VE/VCO2 slope, ventilatory slope. 
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2.3 A new marker of ventilatory inefficiency: exercise oscillatory ventilation (EOV) 
 
A third parameter that recently gained more attention, is an irregular breathing pattern at rest that 
persists during exercise with cyclic fluctuations in minute ventilation and gas exchange kinetics, 
known as exercise oscillatory ventilation (Figure 1C).10 This phenomenon is seen in 12 to 35% of heart 
failure patients.36 The wide variation in prevalence may be due to the lack of unambiguous diagnostic 
criteria. The most commonly used definitions are those proposed by Corra37 and Leite38. Both authors 
use the range and the amplitude of the ventilatory oscillations to describe this phenomenon but 
apply different practical cut-off values. Ingle et al.36 evaluated the impact of the use of different 
criteria on the prevalence and prognostic significance of EOV and established that the prevalence 
varied between 25 and 31%, according to the Corra or the Leite criteria respectively. In addition, EOV 
using the Corra criteria, was a more powerful predictor of adverse outcome indicating the 
importance of the use of uniform criteria in future studies. The EACPR and AHA working group 
currently uses the definition of Corra to describe EOV as an oscillatory pattern at rest that persists for 
≥60% of the exercise test at an amplitude of ≥15% of the average resting value (Table 1).10, 37  
 
In contrast to the ventilatory slope, the origin of the oscillatory breathing pattern during exercise has 
been less explored. A recent study of Murphy et al.39 demonstrated that the presence of EOV signals 
hemodynamic impairment during exercise as indicated by an impaired cardiac index and elevated 
filling pressures. While some authors suggest that a prolonged circulatory time between lung and 
chemoreceptors resulting in an imprecise control of respiration, is an important determinant of 
periodic breathing,40 others have refuted this hypothesis.41 A third potential mechanism is an 
increased chemoreceptor sensitivity,42 although there is currently no consensus in literature.39, 41 As 
the ergoreflex is linked to chemoreceptor sensitivity and periodic breathing is common in patients 
with disturbances in the muscle reflex, this peripheral feedback mechanism could also be a possible 
link to instability in exercise ventilation.26 In conclusion, the presence of exercise oscillatory 
ventilation suggests a combination of an impaired hemodynamic function with disturbed autonomic 
reflex mechanisms. 
 
The presence of EOV is always an abnormal ventilatory response to exercise and is associated with 
poor outcome. Although the majority of the studies focused on heart failure patients with a reduced 
ejection fraction, one study demonstrated a similar prevalence and prognostic value of oscillatory 
breathing in heart failure patients with a preserved ejection fraction.43  
Both short-term follow-up of 6 months44 as well as long-term investigations of 2 to 3 years45-47 
established that EOV is a strong predictor of poor prognosis and mortality. The presence of this 
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oscillatory breathing pattern might even have more predictive value than other prognosticators such 
as the peak VO2 or the ventilatory slope.
45, 47 A recently published study by Guazzi et al.45 assessed 
whether any additional prognostic indication may be obtained by combining an established cardiac 
biomarker such as N-terminal pro brain natriuretic peptide (NT-proBNP) and exercise ventilatory 
abnormalities assessed by cardiopulmonary exercise testing (CPET). Their conclusion was that  NT-
proBNP combined with EOV provided the highest level of risk prediction for cardiac outcome. The 
survival rate among patients with mild levels of neurohormonal activation but EOV was even worse 
than that observed in patients with the most unfavorable NT-proBNP but no EOV.  
Although the pathogenetic bases for an increased ventilatory slope are in part similar to those 
proposed for the oscillatory gas kinetics,  the presence of EOV does not necessarily imply an elevated 
ventilatory slope but when both are present, the burden of risk for cardiac death is considerably 
elevated.47 Both ventilatory markers might also be different in predicting the mode of death. 
Whereas VE/VCO2 slope was the strongest independent marker of cardiac pump failure events, 
exercise oscillatory breathing was the only exercise parameter providing predictive information on 
sudden cardiac death.46  
 
2.4 Partial pressure of end-tidal CO2 (PETCO2) 
 
Assessment of the partial pressure of end-tidal CO2 (PETCO2) as a prognostic exercise parameter has 
been strongly recommended by the current guidelines (Table 1).10  
 
PETCO2 is the CO2 pressure which is non-invasively measured at the end of the expiration (Figure 1D). 
It reflects the elimination of carbon dioxide at rest and during exercise and represents, therefore, 
cardiac function and the matching of ventilation and perfusion within the pulmonary system.10 If 
cardiac output (CO) is impaired, blood flow to the lungs is reduced resulting in a diminished carbon 
dioxide elimination, as expressed by a decreased PETCO2. This presumption has been confirmed by 
several studies with a significant correlation between PETCO2 and indicators of cardiac function.
48 A 
significant negative correlation with VD/VT ,a non-invasive indicator of ventilation-perfusion 
matching, was also found.49 In the case of a ventilation-perfusion mismatch, which is not uncommon 
in heart failure, a steep line rather than a plateau phase is seen in PETCO2, making the estimation of 
the absolute CO2 pressure difficult. However, relative changes, e.g. after an intervention, are still 
interpretable. Besides cardiac function and ventilation-perfusion matching, a link with a decrease in 
the arterial CO2 pressure has also been suggested.
50 Therefore, a reduced PETCO2 is likely to be 
multifactorial with cardiac output, the enlarged physiologic dead space and the arterial CO2 pressure 
being important mechanisms. 
Research Part 1 – Chapter 2 
73 
 
Under normal circumstances, resting values of 36-42 mmHg have been observed, with an increase 
between 3 and 8 mmHg at the ventilatory threshold.10 A low resting PETCO2, i.e. less than 33 mmHg, 
as well as a limited increase of PETCO2 during exercise, particularly at the ventilatory threshold, is a 
marker of poor prognosis and predicts cardiac-related events and mortality independently from 
other exercise variables. Significant correlations with other prognostic parameters such as the peak 
VO2 and the VE/VCO2 slope have been demonstrated.
49 
 
3 Therapeutic possibilities: targets for the future 
 
3.1 Pharmacological therapy 
 
In the last two decades, pharmacological treatment has changed as β blocker therapy has become a 
standard of care in heart failure. The most remarkable effect of β blockade is seen in the decrease of 
the ventilatory slope,51 which is in part the result of a reduction in peripheral chemosensitivity and 
ergoreflex activity. 52 51 On the other hand, the positive effect on diffusion capacity may also result in 
an improvement in ventilatory efficiency.53 
 
Angiotensin converting enzyme (ACE) inhibitors may positively influence exercise capacity due to 
their vasodilatory characteristics. Early studies demonstrated that the use of ACE inhibitors improved 
the peak oxygen consumption.54 This finding, however, was not supported by other authors who only 
saw a decrease in the ventilatory slope whereas the peak VO2 remained unchanged.
55 The positive 
effects of the administration of ACE inhibitors and angiotensin receptor blockers were not seen in 
heart failure with a preserved ejection fraction.56 
 
A greater availability of nitric oxide (NO) due to phosphodiesterase 5 inhibition with sildenafil, is a 
relatively novel treatment strategy in chronic heart failure. Sildenafil has been shown to improve 
cardiac output (CO), to reduce the pulmonary vasomotor  tone and to improve the diffusion capacity, 
resulting in an increase in peak VO2 with a concomitant decrease of the ventilatory inefficiency and a 
reversal of the oscillatory breathing pattern.57, 58 Whether sildenafil influences the ventilatory reflex 
mechanisms, has not been fully  investigated. However, one author  revealed that an improvement in 
endothelial activity and muscle perfusion through phosphodiesterase 5 inhibition, resulted in a 
decrease in ergoreflex activity which was related to an improvement in aerobic capacity and 
ventilatory efficiency.59, 60 These improvements in exercise capacity, however, have not been 
confirmed in heart failure patients with preserved ejection fraction.61 
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3.2 Exercise training 
 
Physical training has become an important part of heart failure management since it has been 
demonstrated to improve exercise tolerance and quality of life, and to reduce hospitalisation in heart 
failure. There is also limited evidence that exercise training reduces mortality.62 An increase in peak 
oxygen consumption and a consonant decrease in the VE/VCO2 slope has been widely recognized.
63  
A recently published study has provided evidence that exercise training may also decrease or even 
reverse exercise oscillatory ventilation.64 Literature concerning the influence of exercise training on 
PETCO2 in heart failure is lacking. A study in patients following physical training after acute myocardial 
infarction, however, suggests that improvement in PETCO2 with a concomitant increase in cardiac 
index is possible.65 Despite some improvements in left ventricular function, peripheral adaptations 
are thought  to be primarily responsible for the enhanced exercise tolerance in heart failure after 
exercise training.  
 
A reduction in both muscle mass and muscle quality has been observed in heart failure patients, 
commonly referred as ‘heart failure myopathy’ and is related to an impaired exercise capacity. This 
myopathy is characterized by apoptosis, a shift towards glycolytic type-II fibres with a concomitant 
rise in lactate and lactate dehydrogenase activity, a depressed oxidative enzyme capacity and a lower 
mitochondrial volume.28, 66 In addition, insulin resistance and a pro-inflammatory state which are 
typically seen in heart failure, contribute to the anabolic/catabolic imbalance.67 Physical training has 
been shown to counteract several features of this myopathy with a shift towards type-I fibre 
distribution, an increase in oxidative enzyme capacity and mitochondrial density.68 A reduction in 
local expression of inflammatory cytokines has also been demonstrated after exercise training.69 The 
shift towards an aerobic metabolism may result in a decreased ergoreflex and chemoreflex activity, 
with a concomitant decrease in hyperventilation, exercise oscillatory ventilation and sympathetic 
outflow.64, 70 
 
Endothelial dysfunction, due to a decreased nitric oxide (NO) bioavailability, is another key feature in 
chronic heart failure. Exercise training improves the endothelium mediated vasodilation with a 
concomitant increase in leg blood flow and exercise capacity. In addition, by decreasing peripheral 
vascular resistance and ventricular afterload, small but significant improvements in stroke volume 
and a reduction in cardiomegaly has been demonstrated.71 
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Besides these peripheral changes, training also induces alterations that occur at the lung level with 
an increase in alveolar-capillary membrane diffusion capacity which may contribute to an improved 
ventilatory efficiency.72 
 
3.3 Devices  
 
Cardiac resynchronization therapy (CRT) was introduced in order to restore the abnormal electrical 
activation which is frequently seen in patients with advanced heart failure. Conduction 
abnormalities, such as a left bundle-branch block, are known to be responsible for mechanical 
dyssychrony with an impaired ejection fraction and mitral regurgitation as a result. Besides these 
haemodynamic consequences, conduction disturbances also take part in the ventricular remodelling 
process.73 Implantation of a CRT device has been demonstrated to improve ventricular function, 
symptoms, exercise tolerance and quality of life and to substantially reduce the risk for mortality and 
hospitalisation.74  
 
Although several studies reported an improvement of peak oxygen consumption and the distance 
walked in six minutes, fewer studies evaluated the ventilatory slope. However, trials which also 
included the VE/VCO2 slope consistently reported an improvement in both aerobic capacity and 
ventilatory efficiency.75 According to Piepoli and his colleagues, improvement in exercise capacity 
occurs 12 months after implantation whereas cardiac indices restore already after 6 months, 
indicating the importance of peripheral changes.76 These peripheral changes include the restoration 
of the neurohormonal reflex control with a particular emphasis on the ergoreflex.76, 77 An additional 
beneficial effect on exercise tolerance is seen when CRT implantation is followed by exercise 
training.78 This finding further emphasizes the importance of the peripheral adaptations. 
 
4 Conclusions 
 
Cardiopulmonary exercise testing is a well recognised instrument for the evaluation of exercise 
intolerance in CHF. Besides the peak VO2 and the VE/VCO2  slope, other exercise variables – EOV and 
PETCO2 - should gain attention in the interpretation of CPET. As mentioned in this review, VE/VCO2 
slope and EOV have been demonstrated to be superior in providing prognostic information. Although 
less known in literature, PETCO2 seems to be also a promising variable. Given the different 
physiological origin of these 4 exercise variables, a multivariate assessment with the inclusion of all 
the aforementioned parameters should be encouraged , not only for diagnostic and prognostic  
purposes but also for evaluating the effect of interventions.   
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Abstract 
 
Background: The presence of ergoreflex activity and its current relation to hyperventilation and 
prognosis in cardiac patients is unclear. Therefore, we evaluated ergoreflex activity in cardiac 
patients with and without heart failure (CHF) as well as in healthy subjects, and we examined how 
strong ergoreceptor activity was related to a mortality risk score in CHF (MAGGIC).  
Methods and results: Twenty-five healthy subjects and 76 patients were included, among whom 
were 25 with ischemic heart disease (IHD), 24 with stable CHF, and 27 with unstable CHF. Ergoreflex 
activity was measured with a dynamic handgrip exercise, followed by post-handgrip regional 
circulatory occlusion (PH-RCO). Ergoreflex activity contributed significantly to ventilation (median 
[interquartile range] %V) in unstable CHF (81 [73 – 91] %V without PH-RCO, 92 [82 – 107] %V with 
PH-RCO, and 11 [6 – 20] difference in %V, p < 0.001) and was positively correlated with the MAGGIC 
risk score (Spearman ρ = 0.431, p=0.002). No ergoreflex activity was observed in healthy subjects (-4 
[-10 to 5] difference in %V), IHD (0 [-8 to 3] difference in %V) and stable CHF (-3 [-11 to 6] difference 
in %V). 
Conclusions: Ergoreflex activity contributes to hyperventilation, but only in CHF patients with 
persistent symptoms and is closely related to the MAGGIC risk score. Ergoreflex activity was not 
present in patients with IHD or stable CHF, suggesting other reasons for the increased ventilatory 
drive in those patients. 
 
Keywords: ergoreflex, ventilation, MAGGIC risk score, heart failure, ischemic heart disease, healthy 
subjects 
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1 Introduction 
 
Chronic heart failure (CHF) has been mainly characterized by exercise intolerance with symptoms of 
fatigue and breathlessness,1 with the latter being expressed by ventilatory inefficiency during 
exercise. A steep ventilatory slope has not only been demonstrated with CHF, but also with ischemic 
heart disease (IHD) 2 with a similar prognostic value.3  
 
Overactivity of the ergoreceptors, i.e. skeletal muscle afferents, has been shown to contribute to the 
excessive ventilatory response in CHF, with a detrimental impact on prognosis.4-8 Pharmacological 
treatment has changed over the last decades, with neurohormonal agents being recommended in 
CHF with reduced left ventricular ejection fraction (LVEF) because of their beneficial effect on 
hospitalization and premature death.9 Despite their obvious effect on survival, their influence on 
exercise intolerance and its determinants is less clear. 
Notwithstanding the presence of an increased ventilatory slope in a substantial number of patients 
with IHD, information on the ergoreflex is currently lacking. Also in healthy subjects, the role of the 
ergoreflex in ventilatory control remains rather unclear, with some studies reporting a contribution 
of the ergoreflex to ventilation and others stating there is no involvement.4, 5, 7, 10 
 
Therefore, the primary aim of this study was to evaluate the presence of ergoreflex activity and its 
current relation to the ventilatory response to exercise and exercise intolerance in a broad spectrum 
of subjects, ranging from healthy subjects and patients with IHD to stable and unstable CHF patients. 
In addition, we examined how activity of the ergoreceptors was related to a recently validated 
prognostic risk score in CHF patients, developed by the Meta-Analysis Global Group in Chronic Heart 
Failure (MAGGIC).11 
 
2 Methods 
 
2.1 Study population 
 
Twenty-nine healthy subjects and 76 patients were prospectively included from April 2011 to March 
2013. Healthy subjects were free from clinical signs or history of heart disease, diabetes, or 
pulmonary disease. A 1st patient group consisted of patients who had an ischemic event without 
signs of heart failure >1 month preceding the study (IHD, n=25), a 2nd group were stable heart failure 
patients with reduced LVEF (≤45%) who had an episode of decompensation >1 month preceding the 
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study and had no signs of fluid retention on the moment of testing (stable CHF, n=24). A third group 
consisted of heart failure patients with reduced LVEF (≤45%) who were recently decompensated (<1 
mo) and were still symptomatic despite optimal medical treatment (unstable CHF, n=27). Heart 
failure patients with ischemic or nonischemic heart disease and who were treated according to the 
recommendations of the European Society of Cardiology (ESC) regarding medication -β-blocker, 
angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and 
mineralocorticoid receptor antagonist (MRA)- and devices9 were included. Seriously limiting 
musculoskeletal or neurologic disorders such as recent orthopedic surgery (<6 mo), rheumatoid 
arthritis or a cerebrovascular accident (CVA) with potential influence of the performance of the tests, 
were considered to be exclusion criteria. 
 
2.2 Ethics 
 
This study protocol was approved by the local ethical committees of the two participating hospitals 
(AZ Maria Middelares, Ghent, and Onze-Lieve-Vrouw Hospital, Aalst) and each of the participants 
gave informed consent. The clinical investigations were conducted according to the principles of the 
Declaration of Helsinki. 
 
2.3 Risk score calculation  
 
An integer risk score for predicting mortality was calculated in CHF patients (n=51), with the use of 
the online calculator from the MAGGIC group.11 The following predictors were included in the risk 
calculation: age, sex, diabetes, chronic obstructive pulmonary disease (COPD), time since diagnosis, 
current smoker, New York Heart Association (NYHA) class, the use of β blockers and ACE inhibitors or 
ARB, body mass index (BMI), systolic blood pressure at rest, serum creatinine, and LVEF. A 
progressively higher risk score identified an increased risk for mortality within 1 and 3 years, 
expressed as the median [interquartile range]. According to the cumulative mortality risk over 3 
years, patients were categorized into 6 risk groups in the original study.11 Because of the small 
sample in the present study, CHF patients were classified into 3 risk groups: 24 patients were 
classified as having a low risk with a score ≤20 (1-y risk 6% [4% - 9%], 3-y risk 15% [11% - 22%]), 14 
patients had a medium risk with a score 21 – 28 (1-y risk 15% [12% - 18%], 3-y risk 36% [29% - 40%]) 
and 13 patients had a high risk with a score >28 (1-y risk 32% [25% - 46%], 3-y risk 63% [52% - 79%]). 
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2.4 Ergoreflex activity 
 
Before the test, maximal handgrip force was measured with the nondominant arm as the greatest of 
the peak forces produced by 3 brief maximal handgrip contractions with a Baseline pneumatic 
squeeze dynamometer. Ergoreflex activity was evaluated with the post-handgrip regional circulatory 
occlusion (PH-RCO) method, consisting of 2 parts which were performed in random order. 
Ventilatory parameters were measured (Cortex Metalyzer 3B breath-by-breath analysis) during 3 
minutes of resting, followed by a rhythmic handgrip exercise at 50% of the predetermined maximal 
capacity until exhaustion (30 squeezes/min) and a recovery period of 3 minutes. After a pause of 30 
minutes, the same exercise protocol was used, but followed by 3 minutes of blood flow stasis in the 
exercising arm by inflation of a forearm tourniquet 30mmHg above systolic pressure (PH-RCO). After 
the cuff was inflated, the subject was instructed to relax. Four of the 29 healthy subjects complained 
of pain or serious discomfort and were excluded from further analysis. This protocol has been shown 
to isolate the metabolic state of the muscle and to prolong the activation of the ergoreceptors.10, 12 
Because the performance was not equal during the 2 parts of the tests with a difference in peak 
exercise, ergoreflex activity was expressed as the percentage exercise response that was maintained 
during PH-RCO (2nd and 3rd minutes) compared with the percentage exercise response maintained 
during normal recovery (2nd and 3rd minutes).4 The difference between these 2 percentages 
represents the contribution of the ergoreflex activity to the ventilatory parameters (Fig 1).  
 
Figure 1. Measurement of ergoreflex activity. Ergoreflex activity is expressed as the percentage exercise 
response that is maintained during recovery with occlusion (12.9/11.0 = 117%) compared with the percentage 
exercise response maintained during recovery without occlusion (10.7/10.4 = 103%). The difference between 
these 2 percentages represents the contribution of the ergoreflex activity to ventilation (difference in %V = 
14%) 
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2.5 Exercise testing 
 
Cardiopulmonary exercise testing was performed on a cyclo-ergometer with the use of a protocol 
adapted to the subjects’ physical status. Ventilatory and respiratory gas measurements were 
obtained on a breath-by-breath basis with the use of an Oxycon Pro spirometer (Jaeger – Viasys 
Healthcare, Germany). Heart rate (HR) was continuously registered with the use of a 12-lead 
electrocardiography, and blood pressure was noninvasively measured, with the use of a manual 
sphygmanometer every 2 minutes during the exercise test. Patients and healthy subjects exercised to 
the limits of their functional capacities or until the physician stopped the test because of adverse 
events, such as chest pain, dizziness, potentially life-threatening arrhythmias, ST segment deviations, 
and marked systolic hypotension or hypertension. The maximal achieved load during incremental 
exercise was recorded. Peak oxygen consumption (peak VO2) was defined as the mean of the last 30 
seconds of peak exercise and was expressed as ml.min-1.kg-1. The slope of the linear relation between 
VE (y-axis) and VCO2 (x-axis), the VE/VCO2 slope, was calculated by including all data points to the 
end of exercise. A classification according to tertiles of peak VO2 (<14 – 14-17 – ≥18 ml.min
-1.kg-1) and 
to ventilatory classes of VE/VCO2 slope 
13 (<30 – 30-35 – 36-44 – ≥45) was made for evaluating 
ergoreflex activity by measures of exercise tolerance. 
 
2.6 Statistical methods 
 
Statistical analysis was performed with the use of IBM SPSS Statistics for Windows, Version 21.0 
(IBM, Armonk, New York). Overall differences in clinical characteristics and exercise capacity 
between the three patient groups were assessed with the χ² test or Fisher exact test for proportions 
and Kruskal Wallis test for continuous variables. A level of alpha of 0.05 was used to indicate 
statistical significance. The Mann-Whitney U test was used to further evaluate differences in 
continuous variables between the individual patient groups. In the latter analyses, the inflation of 
type I error due to multiple comparisons was taken into account by considering an alpha level of 0.01 
to indicate statistical significance. Ergoreflex activity within healthy subjects and in each patient 
group separately was evaluated with the use of the Wilcoxon matched-pairs signed-ranks test. 
Differences in ergoreflex activity between the patient groups were compared with the use of the 
Kruskal-Wallis test and Mann-Whitney U test. No comparison with healthy subjects was made, 
because this was not a matched control group. Because age was significantly different between the 
individual patient groups, ergoreflex activity was further evaluated in patient groups stratified by the 
median age (64 y). A similar analysis was performed to assess the influence of COPD on ergoreflex 
activity in unstable CHF patients. The Kruskal-Wallis test and the Mann-Whitney U test were also 
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used to evaluate ergoreflex activity according to groups of MAGGIC score, peak VO2 and VE/VCO2 
slope. The relationship between ergoreflex activity and prognostic parameters was assessed with 
Spearman bivariate correlations.  
 
3 Results 
 
3.1  Clinical characteristics 
 
 Clinical characteristics of the patient groups are presented in Table 1; 85% of the total patient 
population were men and their median age was 64 [interquartile range 53 – 72] years. Unstable CHF 
patients were older than stable CHF and IHD patients (overall p<0.001)  and had a lower BMI (p<0.01) 
than patients with IHD. LVEF was significantly different among the 3 groups (overall p<0.001), with 
the lowest values in the group with unstable CHF. The group with unstable CHF was also more 
symptomatic, with 45% of the patients in NYHA functional class III or IV (p<0.01). Calculation of the 
MAGGIC risk score in heart failure patients resulted in a significantly higher risk score (median 
[interquartile range]) in unstable CHF (26 [22 – 33] vs 15 [11 – 20], p<0.001). Worse exercise capacity 
was also seen in unstable CHF, as expressed by a progressively lower load and peak VO2 and a higher 
VE/VCO2 slope (overall p<0.001). Of the healthy subjects, 56% were men and their median age was 
45 years. Only a small number of them had cardiovascular risk factors; 4% had hypertension, 17% 
had hyperlipidemia and 1 (4%) was an active smoker on the moment of testing. None of the healthy 
subjects took heart disease-related medication, except for 1 who took aspirin. Exercise capacity was 
found to be normal with a median peak VO2 of 33 ml.min
-1.kg-1 and a VE/VCO2 slope of 28. 
 
3.2 Ergoreflex activity in healthy subjects and patients  
 
As presented in Table 2, ergoreflex activity was present only in unstable CHF, with a significant 
contribution of the ergoreflex to ventilation (p<0.001). Ventilation during recovery with PH-RCO was 
11% higher than during normal recovery and this was likely the result of the higher breathing 
frequency (p=0.001). Healthy subjects and IHD and stable CHF patients showed no sign of ergoreflex 
contribution to their ventilatory pattern. Similar results were obtained when patients were first 
stratified according to their age. Ergoreflex activity was present only in unstable CHF, both in patients 
younger and older than 64 years (Supplement 1). Supplementary analyses in unstable CHF according 
to the presence of COPD showed ergoreflex activation in both patient groups regardless of COPD 
(Supplement 2).  
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Table 1. Clinical characteristics 
 Healthy 
subjects 
n=25 
IHD 
n=25 
Stable CHF 
n=24 
Unstable 
CHF 
n=27 
Diff between  
patient 
groups: P 
value 
Age (years) 45 [35,57] 62 [55,68] 55 [48,64] 71 [65,79]
a,d 
<0.001 
Men (%) 56 84 91 85 0.761 
BMI (kg/m²) 24 [23,26] 28 [26,30] 27 [25,30] 25 [24,28]
a 
0.010 
CAD (%)  100 71
e 
67
a 
0.007 
Etiology CHF (%)     0.813 
Ischemic   62 59  
Non ischemic   38 41  
LVEF (%)  67 [62,73] 30 [24,37]
f 
25 [17,30]
b,c  
<0.001 
NYHA class (%)     <0.001 
I  92 25
f 
0
b,d 
 
II  8 75 55  
III  0 0 41  
IV  0 0 4  
Risk factors & comorbidities (%)      
Hypertension 4 76 50 56 0.142 
Hyperlipidemia 17 96 75 78 0.092 
Diabetes 0 28 29 37 0.746 
Smoking 4 16 29 7 0.026 
COPD 0 0 8 30
a 
0.003 
AF during hospitalisation  20 42 41 0.188 
Systolic BP at rest (mmHg) 130 
[120,140] 
125 
[120,130] 
110 
[110,124]
e 
110 
[105,120]
a 
0.005 
Creatinine (mg/dl)  0.99 
[0.89,1.13] 
1  
[0.90,1.43] 
1.33 
[1.02,1.67]
a 
0.007 
HF diagnosed last 18 months (%)   54 37 <0.001 
Medication (%)      
Aspirin 4 100 38
f 
52
b 
<0.001 
Β blockers 0 88 88 70 0.194 
ACE-inhibitors/ ARB 0 60 83 82 0.106 
Diuretics 0 12 67
f 
89
b 
<0.001 
Spironolacton 0 0 88
f 
93
b 
<0.001 
Antiarrhythmic drugs  0 4 17 11 0.374 
Digoxin 0 0 17 22
 
0.035 
Exercise capacity      
Maximal load (Watt) 168 
[147,250] 
125 
[108,153] 
110  
[88,143] 
74  
[51,80]
b,d 
<0.001 
Peak VO2 (ml.min
-1
.kg
-1
) 33 [26,38] 19 [17,22] 17 [12,20] 12 [10,14]
b,c 
<0.001 
VE/VCO2 slope 28 [25,30] 33 [28,36] 35 [32,39] 44 [36,50]
a,c 
0.001 
Continuous variables are presented as median [interquartile range], categorical variables are presented as 
percentage.  
IHD, ischemic heart disease; CHF, chronic heart failure; Diff, difference; BMI, body mass index; CAD, coronary 
artery disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; COPD, chronic 
obstructive pulmonary disease; AF, atrial fibrillation; BP, blood pressure; HF, heart failure; ACE-inhibitors, 
Angiotensin Converting Enzyme inhibitors; ARB, Angiotensin Receptor Blockers; peak VO2, peak oxygen 
consumption 
a
p<0.01 
b
p<0.001, unstable CHF vs IHD patients 
c
p<0.01 
d
p<0.001, unstable CHF vs stable CHF patients 
e
p<0.01 
f
p<0.001, stable CHF vs IHD patients 
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Table 2. Ergoreflex activity in healthy subjects and patients 
 Healthy 
subjects 
n=25 
IHD 
n=25 
Stable CHF 
n=24 
 
Unstable CHF 
n=27 
Diff in % exercise 
response  
between the 
patient groups: 
 P value 
Ventilation (V)      
% without PH-RCO 84 [79,95] 85 [76,88] 86 [81,91] 81 [73,91]  
% with PH-RCO 83 [78,90] 81 [76,86] 85 [75,93] 92 [82,107]  
P value 0.174 0.326 0.458 <0.001  
Diff in %V -4 [-10,5] 0 [-8,3] -3 [-11,6] 11 [6,20]
a,c
 <0.001 
      
Breathing frequency 
(BF) 
     
% without PH-RCO 90 [72,96] 84 [74,100] 90 [81,100] 85 [76,83]  
% with PH-RCO 81 [68,92] 88 [79,95] 85 [79,93] 95 [83,117]  
P value 0.069 0.427 0.376 0.001  
Diff in %BF -5 [-12,1] 5 [-9,15] -5[-9,6] 8 [0,18]
b 
0.013 
      
Tidal volume (VT)      
% without PH-RCO 97 [88,118] 97 [86,104] 95 [89,104] 96 [84-103]  
% with PH-RCO 100 [91,123] 94 [84,100] 97 [83,106] 96 [83-109]  
P value 0.397 0.122 0.932 0.719  
Diff in %VT 4 [-8,13] -1 [-19,5] 2 [-12,14] 5 [-12,10] 0.235 
Variables are presented as median [interquartile range]. IHD, ischemic heart disease; CHF, chronic heart 
failure; Diff, difference; PH-RCO, post-handgrip regional circulatory occlusion; V, ventilation; Diff in %V, 
difference in percentage ventilation; BF, breathing frequency; Diff in %BF, difference in percentage breathing 
frequency;  VT, tidal volume; Diff in %VT, difference in percentage tidal volume. 
a
 p<0.001 unstable CHF vs. IHD 
b
p<0.01 unstable CHF vs. stable CHF 
c
p<0.001 unstable CHF vs. stable CHF  
 
When patients were subdivided according to their peak VO2, a difference in ergoreflex activity was 
found between patients who had a peakVO2 ≥14 ml.min
-1.kg-1 and patients with a peak VO2 <14 
ml.min-1.kg-1 (overall p<0.05). A classification according to the ventilatory classes of the VE/VCO2 
slope, revealed a difference in the activity of the ergoreceptors between patients who had a 
ventilatory slope ≥45 and those with a VE/VCO2 slope below this value (overall p<0.05). Ergoreflex 
activity according to diagnosis, peak VO2, and VE/VCO2 slope is represented in Figure 2. 
 
In the total patient group, ergoreflex contribution to ventilation was negatively correlated with LVEF 
(Spearman ρ=-0.298, p=0.018) and peak VO2 (Spearman ρ=-0.276, p=0.028). No correlation was 
found with the VE/VCO2 slope. When the patient population was subdivided according to the 
VE/VCO2 slope (≤34 and >34), correlations were more pronounced in patients with an elevated 
VE/VCO2 slope compared with the total patient group (LVEF, Spearman ρ=-0.353; p=0.030, peak VO2, 
Spearman ρ=-0.588, p<0.001; VE/VCO2 slope, Spearman ρ=0.455, p=0.004). In contrast, in patients 
with a VE/VCO2 slope <34, no significant correlations with LVEF, peak VO2, or VE/VCO2 slope were 
demonstrated. These findings are shown in Figure 3. 
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Figure 2. Ergoreflex activity according to (A) diagnosis, (B) MAGGIC mortality risk score, (C) peak oxygen 
consumption (peak VO2) and (D) VE/VCO2 slope and expressed as the median value with the interquartile range 
[Q1, Q3] on top of each bar. *Significant difference. 
 
3.3 Ergoreflex activity and the MAGGIC risk score  
 
The overall MAGGIC score (median [interquartile range]) in CHF patients was 21 [14 – 29] with 
estimated 1-year and 3-year all-cause mortality risk of 11% [6% - 23%] and 27% [15% - 49%] 
respectively. Unstable CHF patients had a considerably higher MAGGIC score and associated 
mortality risk (26 [22 – 33], 1-y risk 18% [12% - 32%], 3-y risk 40% [29% - 63%]) than stable CHF 
patients (15 [11 – 20], 1-y risk 6% [4% - 10%], 3-y risk 16% [11% - 24%]) (all p<0.001). 
 
Ergoreflex was evaluated in 3 risk groups with a clear activation in patients with a score >20 (overall 
p<0.05; Fig 2). A positive correlation was found between ergoreflex activity and the MAGGIC risk 
score (Spearman ρ=0.431, p=0.002). 
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Figure 3. Relationship between ergoreflex activity and (A) left ventricular ejection fraction (LVEF), (B) peak 
oxygen consumption (peak VO2), and (C) VE/VCO2 slope, represented in scatterplots according to the 
ventilatory slope (≤34 and >34). Patients with a VE/VCO2 slope ≤34 are indicated with squares and the 
relationship with a dashed line. Patients with a VE/VCO2 slope >34 are indicated with circles and the 
relationship with a solid line. 
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4 Discussion 
 
The major finding of this study is that in a broad spectrum of subjects including healthy subjects and 
patients with IHD and heart failure, ergoreflex activation contributes to hyperventilation and exercise 
intolerance, but only in those heart failure patients with persistent symptoms. In contrast, activation 
of the ergoreceptors is not present in healthy subjects nor in patients with IHD or stable CHF. In 
addition, ergoreflex activity is clearly associated with the recently developed MAGGIC mortality risk 
score, thereby emphasizing the link with the severity of heart failure.  
 
No ergoreflex activity was found in patients with IHD or stable CHF nor in healthy subjects. 
Conflicting results have been reported regarding ergoreflex activity in healthy subjects.4, 5, 7 Our 
findings are in agreement with those reports stating there is no ergoreflex activity in healthy 
subjects, suggesting that in physiologic conditions mechanisms other than ergoreflex activity may 
play a major role in ventilatory control.7 The ventilatory response to exercise was elevated in IHD, 
which supports earlier studies demonstrating that an increased VE/VCO2 slope is not exclusively seen 
in the state of heart failure.2 Several mechanisms are thought to underlie this phenomenon with an 
enhanced chemoreceptor activity being the most plausible determinant.2 To date, the role of the 
ergoreceptors in the ventilatory control has not been investigated yet in IHD, although overactivation 
has been suggested owing to physical deconditioning.2 Our results demonstrate for the first time that 
activation of the ergoreflex is not involved in the increased ventilatory drive that is seen in a 
substantial proportion of patients with IHD. Nor could ergoreflex activity be demonstrated in stable 
CHF patients despite a similar level of exercise intolerance as in earlier studies.5, 7, 14, 15 Similar to IHD, 
their aberrant VE/VCO2 slope may indicate that other systems than ergoreflex activity are responsible 
for the increased ventilatory drive, including chemoreceptor activity or pulmonary dysfunction.2, 16  
 
Only recently decompensated CHF patients who were still symptomatic showed signs of ergoreflex 
activation, but to a lesser extent than was formerly assumed. A plausible explanation could be found 
in the introduction of ACE inhibitors and β-blockers as a standard of care. ACE inhibitors may 
positively influence exercise capacity and ventilatory efficiency owing to their vasodilatory 
characteristics driven by prostaglandins and their impact on diffusion capacity.17-19 However, 
prostaglandins may also stimulate ergoreflex overactivity and subsequent hyperventilation,20, 21 
which could in turn be counteracted by aspirin.22 Nevertheless, prostaglandin inhibition alone is 
unlikely to have a clinically significant influence on the ventilatory abnormalities seen in CHF.23 In this 
study, a high percentage of patients was on ACE inhibitors. Activation of the ergoreflex, however, 
was lower than in earlier investigations with a similar proportion of patients on this treatment.5, 6, 21, 
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22 A decrease in the ventilatory slope has already been demonstrated after β blocker therapy, 24, 25 
but the influence of β blockers on ergoreflex activity has not been investigated yet. In contrast to 
earlier studies with a low percentage of patients on β blockers, i.e. 20% - 30% on average, 5, 7, 15, 22 
88% of stable CHF and 70% of unstable CHF patients had β blocker therapy in the present study. 
Bisoprolol was mainly prescribed in stable CHF (73%) with an average daily dose of 4mg, whereas 
carvedilol was primarily used  in unstable CHF patients (36%) with an average daily dose of 12.5mg. 
The dosages reached in our study population extended the starting doses recommended by the ESC,9 
although the suggested target doses were rarely reached. β blocker therapy may have decreased 
ergoreflex activation, 24 but these findings should be interpreted with caution because this study was 
not aimed to investigate the impact of these medications on ergoreflex activity.  
 
Regardless of the diagnosis, ergoreflex activity was also evaluated according to measures of exercise 
tolerance. With a decrease in  peak VO2 to < 14 ml.min
-1.kg-1 and a rise in the VE/VCO2 slope to > 45, 
a progressive increase in ergoreflex contribution to the ventilatory response was observed. In earlier 
investigations, ergoreflex activity has also been demonstrated in patients who had a preserved 
exercise capacity and a normal VE/VCO2 slope,
5, 6 but this could not be confirmed by our results.  
Similarly, correlations were significant only in those patients with an abnormally elevated VE/VCO2 
slope (>34), suggesting a later onset of ergoreflex activation under current medical management 
strategies. 4-6, 14 Although our findings of a reduced ergoreflex activity might be encouraging, this 
reflex mechanism still contributes to hyperventilation and subsequent prognosis in an important 
subset of heart failure patients with persistent symptoms despite the current medical approach. 
 
In this study, ergoreflex activity was most pronounced in those patients with a VE/VCO2 slope > 45, a 
value that is indicative of a particularly high risk for adverse events within 2 years.13 In the past, 
activation of the ergoreceptors had already been related to a deterioration in clinical status, 
suggesting a link with prognosis.5, 6 Our study provides evidence for this hypothesis by demonstrating 
a clear relation with the MAGGIC mortality risk score, a risk calculator integrating 13 clinical factors 
and comorbidities to quantify individual patients’ prognosis in CHF.11 This link suggests that 
ergoreflex activity is a marker of the severity of heart failure and further emphasizes the importance 
of peripheral reflex mechanisms in the progression of heart failure disease. 
 
 
 
 
 
Research Part 1 – Chapter 3  
94 
 
4.1 Study limitations  
 
The activity of the ergoreceptors has already been widely studied, but mainly focused on CHF. In 
addition, pharmacological treatment has changed over the past decades with a beneficial effect on 
survival but a less clear impact on exercise intolerance and its determinants. Therefore, novel studies 
are necessary to provide new clinical insights on this topic and to evaluate its current prognostic 
value. The present study was not aimed to investigate the effect of the pharmacological treatment 
itself, but rather to provide a clinical update on the presence of ergoreflex activity and its current 
relationship to prognosis. The sample size in this study did not allow us to assess outcome; therefore, 
the MAGGIC risk score was used.  Nevertheless, this should be subject of larger studies. Because 
unstable CHF patients were older than IHD and stable CHF patients, age may have had a potential 
confounding effect on these results. Additional analyses according to age, however, revealed similar 
results in both younger and older patient groups. Similarly, COPD a comorbidity whose influence on 
ergoreflex activity is not entirely clear,26, 27 seemed not to influence the presence of ergoreflex 
activity in unstable CHF. A small number of patients in some subgroups may have led to 
underpowered results, in particular in the analyses according to age. Therefore, these results should 
be interpreted with caution. 
 
5 Conclusions 
 
In a broad spectrum of subjects including healthy subjects and patients with IHD and heart failure, 
ergoreflex activation contributes to hyperventilation,  but only in those heart failure patients with 
persistent symptoms, and is closely related to the MAGGIC mortality risk score. In contrast, no signs 
of ergoreflex activation were found in patients with IHD or stable CHF which may suggest that other 
mechanisms are involved in the increased ventilatory drive in these patients.    
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Supplement 1. Ergoreflex activity in patients according to age 
 ≤64 years P value 
Diff in % exercise 
response between the 
patient groups 
>64 years P value 
Diff in % exercise 
response between the 
patient groups 
 IHD Stable CHF Unstable CHF  IHD Stable CHF Unstable CHF  
 N=15 N=19 N=5  N=10 N=5 N=22  
Ventilation (V)         
% without PH-RCO 85 [77,86] 87 [84,94] 70 [61,92]  88 [75,92] 83 [69,86] 82 [74,91]  
% with PH-RCO 77 [72,85] 84 [77,94] 107 [68,118]  85 [79,88] 86 [71,91] 92 [83,105]  
P value 0.125 0.136 0.043  0.878 0.500 <0.001  
Diff in %V -1 [-8,1] -4 [-13,2] 11 [1,45]
a,b 
0.034 1 [-6,6] 6 [-4,11] 10[6,18]
a 
0.014 
         
Breathing frequency (BF)         
% without PH-RCO 84 [83,94] 93 [85,102] 79 [63,103]  86 [67,101] 80 [69,93] 85 [78,94]  
% with PH-RCO 88 [71,94] 86 [79,101] 104 [83,118]  89 [79,100] 82 [77,89] 94 [83,110]  
P value 0.776 0.314 0.080  0.386 0.686 0.006  
Diff in %BF 5 [-11,11] -5 [-9,4] 18 [2,36] 0.087 4 [-8,20] -5 [-5,13] 7 [0,17] 0.481 
         
Tidal volume (VT)         
% without PH-RCO 95 [86,101] 97 [89,104] 97 [78,113]  99 [85,116] 90 [83,116] 96 [85,100]  
% with PH-RCO 90 [82,99] 97 [85,104] 94 [83,103]  94 [87,101] 105 [81,115] 97 [82,111]  
P value 0.281 0.968 0.893  0.285 0.893 0.390  
Diff in %VT -1 [-19,3] 1 [-13,14] -11 [-21,20] 0.680 -10 [-29,8] 6 [-13,15] 6 [-8,8] 0.294 
Variables are presented as median [interquartile range]. IHD, ischemic heart disease; CHF, chronic heart failure; Diff, difference; PH-RCO, post-handgrip regional circulatory occlusion; 
V, ventilation; Diff in %V, difference in percentage ventilation; BF, breathing frequency; Diff in %BF, difference in percentage breathing frequency;  VT, tidal volume; Diff in %VT, 
difference in percentage tidal volume. 
a
p<0.01, unstable CHF vs IHD patients 
b
p<0.01 , unstable CHF vs stable CHF patients 
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Supplement 2. Ergoreflex activity in unstable CHF according to the presence of COPD  
COPD No 
N=19 
Yes 
N=8 
P value 
Diff in % exercise response 
between the patient groups 
Ventilation (V)    
% without PH-RCO 81 [73,91] 79 [67,90]  
% with PH-RCO 95 [81,106] 89 [85,108]  
P value <0.001 0.025  
Diff in %V 9 [6,20] 11 [3,23] 0.791 
    
Breathing frequency (BF)    
% without PH-RCO 86 [78,95] 80 [70,86]  
% with PH-RCO 96 [85,118] 91 [79,104]  
P value 0.002 0.161  
Diff in %BF 7 [0,17] 17 [-2,22] 0.396 
    
Tidal volume (VT)    
% without PH-RCO 96 [77,99] 96 [87,114]  
% with PH-RCO 94 [79,105] 103 [93,114]  
P value 0.748 0.779  
Diff in %VT 5 [-12,7] 5 [-20,20] 0.559 
Variables are presented as median [interquartile range]. CHF, chronic heart failure; Diff, 
difference; PH-RCO, post-handgrip regional circulatory occlusion; V, ventilation; Diff in %V, 
difference in percentage ventilation; BF, breathing frequency; Diff in %BF, difference in 
percentage breathing frequency;  VT, tidal volume; Diff in %VT, difference in percentage tidal 
volume. 
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Abstract 
 
Objective: Hospitalization for acute heart failure (HF) is associated with poor outcome. As specific 
data for Belgium are not available, the aim of the Belgian BIO-HF registry is to evaluate the clinical 
characteristics, in-hospital mortality and outcomes after discharge of patients hospitalized for acute 
HF.  
Methods and results: This is a prospective observational cohort study in 2 Belgian hospitals. For the 
current analysis, the first 904 patients enrolled between 2008 and 2012 were analyzed to evaluate 
clinical characteristics and short-term outcome (all-cause mortality and all-cause mortality + 
rehospitalization 3 months after discharge). Mean age of patients was 77 years, 44% were women 
and 64% had an eGFR <60 ml/min/1.73m². Mean LVEF was 42% with only 40% with LVEF≤35%. In-
hospital mortality was 7.1% with a mortality of 22% in the subgroup of patients with a creatinine ≥ 
2mg/dl and systolic blood pressure ≤110 mmHg on admission. Three months after discharge, the all-
cause mortality rate was 7.6% and the all-cause mortality or hospitalization for HF 18.3%. 
Multivariate Cox regression analysis revealed eGFR, COPD, absence of β blockers and atrial 
fibrillation at discharge (all p<0.05) as independent predictors of all-cause mortality. 
Conclusions: In this Belgian registry of mainly elderly patients admitted with acute HF, a relatively 
preserved LVEF and a reduced kidney function were present in the majority of patients. In-hospital 
and short-term mortality after discharge remain high and are mainly related to the presence of 
comorbidities such as renal failure and COPD. Comorbidities should be the focus for future efforts to 
improve the dire outcome of these patients. 
 
Keywords: acute heart failure, mortality, hospitalization, comorbidities 
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1 Introduction 
 
Heart failure (HF) is a global world-wide public health problem with an estimated prevalence of 15 
million patients alone in the countries represented by the European Society of Cardiology (ESC).1-3 
Hospitalizations for acute HF represent currently 1% to 2% of all hospitalizations in the Western 
world and remain associated with a high early post-discharge mortality and readmission rate.4-7 Data 
from hospitalized HF registries are useful to better understand the clinical characteristics, patient 
management and outcomes after discharge. Also, data from the “real-world” may help to develop 
quality improvement initiatives and ultimately improve patient outcomes.3, 8 Several international 
registries have shown that important geographic variations in patient characteristics and treatment 
exist.3, 9 Even for Europe, data from the ESC-HF Pilot survey indicate that differences across countries 
exist and may be due to different local medical practice as well to differences in healthcare 
systems.10 Thus, country specific data remain important to monitor and guide public policy at all 
levels. For Belgium, no specific clinical and outcome data on acute HF admissions have been 
published thus far and Belgium was also not part of the ESC-HF Pilot survey or ESC-HF Long-Term 
registry.10, 11  
 
Therefore, the current analysis of the BIO-Heart Failure (BIO-HF) registry aims to report the specific 
clinical characteristics as well as the in-hospital course and 3 months outcome after discharge for 
acute decompensated HF in 2 Belgian hospitals. Also a comparison is made with other recent 
European and international HF registries that have reported on clinical characteristics and short-term 
outcomes after hospitalization for HF.10, 12-14 
 
2 Methods 
 
2.1 Study population 
 
The BIO-HF registry is an ongoing prospective HF registry evaluating all patients admitted with NYHA 
class III-IV HF in 2 hospitals in Belgium (AZ Maria Middelares Hospital Ghent and University Hospital 
Brussels).15 The departments of cardiology of both hospitals provide on-site interventional cardiology 
and electrophysiology/device implantation as well as cardiac surgery but do not perform heart 
transplantation. The objective of the registry is to prospectively collect data regarding baseline 
characteristics, in-hospital treatments, medication at discharge and outcome for consecutive patients 
admitted with acute HF. For the present analysis, we included all patients that entered the database 
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between 2008 and May 2012 at the AZ Maria Middelares Hospital Ghent and the patients that 
entered the database in 2008 at the University Hospital Brussels. Clinical data as well as data on risk 
factors and comorbidities (including the presence of ischemic heart disease, atrial fibrillation, 
hypertension, diabetes, smoking, COPD, peripheral artery disease, stroke and malignancy) were 
collected. Also laboratory results on admission (including creatinine and sodium levels and estimated 
glomerular filtration rate, eGFR) as well as medication on admission and discharge were 
documented. Echocardiography was performed with a measurement of left ventricular ejection 
fraction (LVEF, Simpson’s method) within the first two days of admission. QRS duration was 
measured from the surface electrocardiogram on admission. NT-proBNP levels on admission were 
also collected but were not available in all patients (54% of the total population). 
 
In total 960 patients admitted with acute HF were included (838 at the AZ Maria Middelares Hospital 
Ghent and 122 at the University Hospital Brussels). Echocardiography and LVEF measurements were 
lacking in 56 patients (6%) and they were excluded for further analysis. Thus, in total 904 patients 
formed the study population. During the index hospitalisation 64 patients (7%) died, leaving 840 
patients who were discharged alive. These patients were followed for the endpoints of all-cause 
mortality and the combined endpoint of all-cause mortality or hospitalisation for HF at 3 months (91 
days) after discharge. Of these 840 patients, 46 patients (5%) were lost to follow-up, leaving 794 
patients for the outcome analysis.  
 
2.2 Outcome data 
 
In hospital mortality was recorded in all patients as well as in-hospital length of stay. In-hospital 
mortality was further evaluated according to the results of the ADHERE registry7 with 2 predictors : 
admission creatinine <2 mg/dl versus ≥2 mg/dl and admission systolic blood pressure ≤110 mmHg 
versus >110 mmHg. The primary outcome measure for the 3 months follow-up post discharge was 
all-cause mortality. The secondary endpoint was the combination of all-cause mortality and 
hospitalisation for HF. 
 
2.3 Statistical analysis 
 
Data are expressed as mean ± SD or median (interquartile range) for continuous variables and as 
percentage (%) for categorical variables. Student’s t-test, ANOVA or Wilcoxon-rank sum test for 
continuous variables and X2 test for categorical variables were used to examine the difference 
between groups. For the comparison of medication on admission versus discharge, the non-
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parametric McNemar test for comparison of related samples was used. Kaplan-Meier analysis with 
Cox proportional hazards regression was used for time-to-event analysis, for both the evaluation of 
the primary and secondary endpoints after 3 months follow-up. Multivariate Cox proportional 
hazards regression was based on the variables that were associated with the endpoint in univariate 
analysis (p<0.1). The variables evaluated included age, LVEF, ischemic heart disease, acute coronary 
syndrome on admission, left bundle branch block, atrial fibrillation at discharge, comorbidities 
including renal function, hypertension, diabetes, COPD, active smoking, stroke and malignancy, as 
well as medication at discharge (β blockers, angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers (ACE-I/ARB), mineralocorticoid receptor antagonist (MRA)). Odds ratios (ORs) with 
95% confidence intervals (CIs) are reported. Survival was also evaluated using the Kaplan-Meier 
method and compared among groups using the log-rank test. Statistical significance was defined as 
p<0.05 or 95% CI for OR not including 1.0. All statistical analyses were performed with the use of 
SPSS Version 19.0 for Windows (SPSS Inc., Chicago, IL, USA). 
 
2.4 Ethics 
 
The study complied with the Declaration of Helsinki. The BIO-HF registry was approved by the Central 
Ethical Committee of the University Hospital Brussels and the AZ Maria Middelares Hospital Ghent 
(2010/262). Written informed consent was obtained from all patients or their legal representatives. 
 
3 Results 
 
3.1 General characteristics 
 
The clinical characteristics of the total study population are shown in table 1. Average age was high 
(77 years) and 51% of all patients were 80 years or older. A preserved LVEF ≥50% was noted in 40% 
of patients while another 40% had a LVEF ≤35%. Importantly, 20% of patients had an intermediate 
LVEF of 36-49%. Patients with preserved LVEF were older, more frequently women and had more 
frequently a history of hypertension. On admission, they presented with higher blood pressures, 
more frequently with atrial fibrillation and less frequently with an acute coronary syndrome. 
Creatinine levels were significantly higher in patients with reduced LVEF, but overall eGFR was 
comparable in the 3 groups. Mean QRS duration on the surface ECG as well as the presence of LBBB 
were significantly higher in patients with reduced LVEF. NT-proBNP values on admission (available in 
54% of all patients) were high in the 3 groups. Although patients with preserved LVEF presented with 
significantly lower NT-proBNP values, their admission values were still high (median NT-proBNP 5210 
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pg/ml). In contrast, sodium levels on admission were remarkably comparable between the 3 groups. 
The prevalence of implanted pacemakers was comparable between the 3 groups. The overall 
prevalence of implanted devices (ICD and/or CRT) was however low (1%-2% of all patients) and, as 
expected, almost completely restricted to patients with reduced LVEF.  
 
 
Table 1. Clinical characteristics on admission 
 Total group 
N=904 
LVEF ≤ 35% 
N=361  
(40%) 
LVEF 36-49% 
N=182  
(20%) 
LVEF ≥ 50% 
N=361  
(40%) 
Overall  
p-value 
Age (years) 77±11 74±12 78±10 79±10 <0.001 
Age ≥ 80 years (%) 51 41 51 60 <0.001 
Women (%) 44 31 42 57 <0.001 
LVEF (%) 42±17 25±6 42±3 60±7 <0.001 
AF on admission (%) 48 41 51 52 0.008 
AF at discharge (%) 21 18 21 25 0.100 
Ischemic heart disease (%) 45 52 57 33 <0.001 
ACS on admission  (%) 17 22 19 11 0.001 
Comorbidities (%)      
Hypertension 62 52 67 70 <0.001 
Diabetes 27 27 34 24 0.077 
Current smoking 12 16 12 9 0.009 
COPD 19 18 19 19 0.875 
PAOD 17 14 21 17 0.064 
Stroke 11 11 12 11 0.985 
Malignancy 12 9 14 14 0.098 
Devices (%)      
Pacemaker 9 9 10 8 0.797 
ICD 2 4 3 0.3 0.004 
CRT 1 3 0.5 0.3 0.016 
CRTD 0.3 0.8 0 0 0.104 
Lab-values       
Sodium (mmol/l) 138±4 138±4 138±4 138±4 0.779 
Creatinine (mg/dl) 1.4±0.9 1.4±1.1 1.4±0.8 1.3±0.6 0.017 
eGFR (ml/min/1.73m²) 54±21 54±20 54±21 54±21 0.954 
NT-proBNP(pg/ml) (n=487) 6500 
(3216,11800) 
8919 
(4150,17398) 
6563 
(2987,13147) 
5210 
(2907,9105) 
<0.001 
Clinical parameters 
Heart rate (beats/min) 93±28 97±28 93±28 89±28 0.002 
SBP (mmHg) 141±30 134±27 142±30 147±30 <0.001 
DBP (mmHg) 81±19 81±15 81±20 81±18 0.944 
ECG parameters      
QRS duration (ms)  115±34 123±35 114±34 107±31 <0.001 
Typical LBBB (%) 17 24 17 11 <0.001 
Data are presented as mean±SD, median ( interquartile range) or %.  
P-value: overall significance between the 3 groups of left ventricular ejection fraction (LVEF). AF, atrial fibrillation; 
ACS, acute coronary syndrome; COPD, chronic obstructive pulmonary disease; PAOD,  peripheral arterial occlusive 
disease; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; eGFR, estimated 
glomerular filtration rate; NT-proBNP, N-terminal pro brain natriuretic peptide; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; LBBB, left bundle branch block. 
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3.2 In-hospital mortality and in-hospital length of stay 
 
Of the 904 patients, 64 died during the hospitalization (overall in hospital mortality 7.1%). Patients 
who died were older (80±10 vs. 77±11 years, p=0.02), had a lower blood pressure on admission 
(systolic blood pressure 134±31 vs. 141±29 mmHg, p=0.04) and higher creatinine levels on admission 
(1.7±0.8 vs. 1.3±0.9 mg/dl, p<0.001). Admission heart rate was comparable (95±26 vs. 93±28 
beats/min, p=0.48) as well as sodium levels (137±5 vs. 138± 4 mmol/l, p=0.44). There was a trend 
towards higher in-hospital mortality in patients with LVEF ≤35% (9% mortality) and LVEF 36-49% 
(8.8% mortality) as compared to patients with LVEF ≥50% (4.7% mortality) (overall p-value = 0.076). 
The average LVEF of patients who died versus those who were discharged alive was also significantly 
lower (37±15% vs. 43±17%, p=0.01).  
 
Figure 1 shows the in-hospital mortality according to admission creatinine levels and systolic blood 
pressure. Patients with a creatinine <2 mg/dl and a systolic blood pressure >110 mmHg had the 
lowest in-hospital mortality (30/670, 4.5%), followed by patients with a creatinine <2mg/dl and 
systolic blood pressure ≤110 mmHg (10/108, 9.3%) and patients with a creatinine ≥2 mg/dl and 
systolic blood pressure >110 mmHg (18/99, 18.2%). The highest in-hospital mortality was noted in 
patients with a creatinine ≥2 mg/dl and systolic blood pressure ≤110 mmHg (6/27, 22.2%) (overall p-
value <0.01).  
 
Median in-hospital length of stay was 9 days (IQR 5,14) and this was comparable in patients with 
LVEF ≤35% (median 9 days, IQR 5,15), LVEF 36-49% (median 8 days, IQR 6,13) and LVEF ≥50% 
(median 8 days, IQR 5,15) (overall p-value = 0.44). Patients who died during hospitalization had a 
significantly higher median in-hospital length of stay of 15 days (IQR 9,31) (p<0.01 as compared to 
patients discharged alive). 
 
3.3 Medication on admission and discharge 
 
Table 2 shows the medical treatment of the patients who were discharged alive (n=794). Both their 
medication on admission and at discharge are shown according to LVEF. As compared with 
medication on admission, a significant increase in the prescription of β blockers, ACE-I/ARB and MRA 
at discharge can be noted in all groups, except for the use of ACE-I/ARB in patients with LVEF≥50% . 
Also at discharge, patients with a preserved ejection fraction were significantly less treated with β 
blockers, ACE-I/ARB and MRA. 
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Figure 1. In-hospital mortality according to renal function (creatinine < 2 mg/dl versus  ≥ 2 mg/dl) and systolic 
blood pressure (≤ 110 mmHg versus > 110 mmHg) on admission. 
 
Table 2. Medication on admission and discharge according to LVEF in the patients who were discharged alive 
 Total group 
N=794 
LVEF ≤ 35% 
N=310  
(39%) 
LVEF 36-49% 
N=152  
(19%) 
LVEF ≥ 50% 
N=332  
(42%) 
Overall p-
value 
Admission (%)      
 β blockers 52 46 61 53 0.005 
ACE-I/ARB 53 54 53 52 0.930 
MRA 15 15 19 14 0.291 
Discharge (%)      
 β blockers 77* 82* 84* 70* <0.001 
ACE-I/ARB 66* 76* 68* 55 <0.001 
MRA 33* 38* 38* 25* 0.001 
Data are expressed as %. P-value indicates overall significance between the 3 groups of LVEF, * indicates p-
value < 0.01 for the comparison between admission and discharge. ACE-I, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist. 
 
3.4 Follow-up 
 
After a follow-up of 3 months, 60 patients had died (7.6%) and 145 had died or were rehospitalized 
for heart failure (18.3%). Univariate predictors of all-cause mortality at 3 months after discharge are 
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presented in the supplementary table 1. Parameters associated with p-values <0.1 are used for the 
multivariate Cox regression analysis that is shown in table 3. As age, creatinine and eGFR were 
significantly related, only eGFR was used for multivariate regression analysis. The absence of β 
blockers at discharge, the presence of atrial fibrillation at discharge, a history of COPD as well as 
eGFR remained as independent predictors of short-term all-cause mortality after discharge. Figure 2 
(A-D) shows the Kaplan-Meier plots for all-cause mortality during follow-up according to LVEF (A: 
Log-Rank 0.059, p=0.808), use of β blockers at discharge (B: Log-Rank 7.33, p=0.007), history of COPD 
(C: Log-Rank 7.82, p=0.005) and eGFR (>60, 60-30 and <30 ml/min/1.73m²)(D: Log-Rank 21.8, 
p<0.001). As can be noted from panel A, there was no difference in short-term mortality at 3 months 
between patients with preserved (≥ 50%) and reduced (<50%) LVEF and patients with eGFR<30 
ml/min/1.73m² had a very high death rate of 18% at 3 months. 
 
Similar results were found for the combined end-point of all-cause mortality or rehospitalization for 
heart failure at 3 months after discharge (see supplementary tables 2 and 3). For this endpoint, a 
history of COPD as well as eGFR and a history of stroke remained as independent predictors. 
 
Table 3. Multivariate Cox regression analysis of all-cause mortality at 3 months after discharge 
 OR 95% CI p-value 
eGFR 0.97 0.96-0.99 <0.001 
COPD 2.35 1.27-4.36 0.006 
β Blocker at discharge 0.50 0.26-0.94 0.032 
ACE-I/ARB at discharge 0.67 0.35-1.27 0.219 
Stroke 1.51 0.70-3.26 0.298 
AF at discharge 2.06 1.08-3.91 0.028 
OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ACE-I, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation. 
 
 
 
Research Part 2 – Chapter 4  
110 
 
 
Figure 2. Kaplan-Meier plots for all-cause mortality during 3 months follow-up according to LVEF (A), use of 
beta-blockers at discharge (B), history of COPD (C) and eGFR (>60, 60-30 and <30 ml/min/1.73m²)(D). 
 
4 Discussion 
 
In this larger contemporary hospital registry, we describe in detail the clinical characteristics and 
short-term outcome of patients admitted with HF in 2 Belgian hospitals. A comparison with other 
recent registries that reported outcome after hospital discharge for acute decompensated HF is 
presented in table 4. Overall, our patients were older (mean age 77 years) and presented less 
frequently with a reduced LVEF. The difference in age might be explained by many factors including 
differences in the prevalence of underlying risk factors, life expectancy and standard of living and 
probably also reflects the continuous aging of the heart failure patients.3  
 
One of the strengths of this registry is that LVEF was measured in all patients with echocardiography 
during index admission. This allowed us to describe in detail the prevalence of HF according to LVEF. 
Strikingly, not only 40% of patients presented with a preserved LVEF (HFPEF patients with LVEF 
≥50%), but also another 20% showed only a moderately reduced LVEF between 35 and 50%. As a 
result, 60% of patients presented with a LVEF >35%, a population of patients for who scientific 
evidence regarding optimal treatment is limited. As expected, patients with a more preserved LVEF 
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were in general older, were more frequently women and presented more frequently with 
hypertension or atrial fibrillation and less frequently with ischemic heart disease. Similar as in several 
previous reports,10, 14, 16 LVEF did not predict outcome after discharge with a similar event rate for 
both all-cause mortality and all-cause mortality or HF rehospitalization. Despite the fact that average 
LVEF was somewhat higher than in previous registries, admission NT-proBNP values were higher than 
reported in e.g. the IN-HF and ESC-HF Pilot registries.10, 14 This might be explained by the older age 
and more advanced renal dysfunction in the present registry. Although patients with preserved LVEF 
presented with significantly lower NT-proBNP values, their admission values were still high (median 
NT-proBNP 5210 pg/ml). 
 
4.1 In-hospital mortality and length of in hospital stay 
 
The median length of stay in our registry was 9 days and this was comparable across the range of 
LVEF. As recently reviewed by Ambrosy et al,3 global heart failure hospitalization registries show that 
the median length of stay ranges from 4 to 20 days. Geographical differences (with shorter length of 
stay in US registries) can be largely explained by differences in clinical practice and reimbursement 
issues. We report an in-hospital mortality of 7.1% which is comparable to the in-hospital mortality of 
the IN-HF and KorAF registries12, 14 but somewhat higher than the ESC-HF Pilot or OPTIMIZE-HF 
results.10, 13 Differences in clinical characteristics including the higher age of our patients might partly 
explain these differences. Importantly, in line with the findings of the ADHERE registry,7 a set of 
simple parameters including systolic blood pressure and renal function on admission can help to 
discriminate hospital survivors and non-survivors (figure 1). However, even patients with a creatinine 
<2 mg/dl and a systolic blood pressure >110 mmHg on admission still had an in-hospital mortality of 
4.5%. 
 
4.2 Medication at discharge 
 
Overall we noted a significant increase in the prescription of β blockers, ACE-I/ARB and MRA at 
discharge as compared to admission. This was documented in all groups of LVEF, except for the use 
of ACE-I/ARB in patients with LVEF≥50%. The global use of β blockers was comparable to other 
registries (see table 4), but the use of ACE-I/ARB and MRA tended to be somewhat lower for the 
overall population as well as for the patients with a reduced LVEF. This might be partly explained by 
the more advanced age and renal dysfunction in our patients (eGFR<60 ml/min/1.73m² in 64%) but 
will also be explored in future studies within the BIO-HF study framework. Of note, even in patients 
Research Part 2 – Chapter 4  
112 
 
with preserved LVEF, β blockers were described in 70%, ACE-I/ARB in 55% and MRA in 25% although 
current evidence for using these medications in HFPEF patients is lacking.1  
 
4.3 Outcome after discharge 
 
Rather few HF hospital registries have collected data on post discharge mortality and readmissions 
for HF (see table 4). In general, they noticed a high mortality and morbidity rate early after 
hospitalization of acute HF. We also report a comparable all-cause mortality of 7.6% and a combined 
all-cause mortality or heart failure rehospitalization of 18.3%. To the best of our knowledge these are 
the first reported outcome data for Belgian patients. The ESC-HF Pilot survey reported a 1-year all-
cause mortality of 17.4% and all-cause mortality of rehospitalization for heart failure of 35.8%. Of 
note, only 218 of the 1892 patients came from Western Europe (Austria, France, Germany and The 
Netherlands) with similar event rates (respectively 18.4% and 33.9% at 1 year).14 
 
The short-term outcome in our registry was mainly driven by the absence of the use of β blockers at 
discharge and the presence of different comorbidities. Comorbidities are prevalent in patients with 
HF and contribute to an increased morbidity and mortality and an impairment of quality of life.17-19 
The prevalence of different comorbidities in the present registry are generally similar to the data 
reported by other registries on acute HF (see table 4). They are also in line with data in patients with 
chronic HF, for example for diabetes (27% in the present survey vs. 29% in the European Heart 
Failure Pilot Survey for chronic HF), hypertension (62% vs. 58%), COPD (19% vs. 15%) and stroke (11% 
vs. 11%).20 Especially impaired renal function and COPD emerged as important independent 
prognostic parameters for both short-term all-cause mortality and the combined endpoint of all-
cause mortality and hospitalization for HF. The prognostic value of renal dysfunction is in line with 
several other registries10, 13, 14, 21 although our patients showed in general more advanced kidney 
impairment with a mean creatinine of 1.4 mg/dl and a GFR<60 ml/min/1.73m² in 64% of patients. 
Our present data regarding COPD are in agreement with previous reports showing that COPD is an 
independent predictor of all-cause mortality in HF patients.22-26 COPD in HF patients has not only 
been associated with a low-grade systemic inflammation,23 increased myocardial damage and arterial 
stiffness25, 26 but also with increased other comorbidities and less use of evidence-based heart failure 
medications.27 Importantly, the use of β blockers had a positive effect on the short-term outcome, 
independent of the presence of COPD. This finding further supports the notion that selective beta-1 
blockade or combined nonselective beta- and alpha-adrenergic blockade should not be denied to HF 
patients with concomitant stable COPD who do not have reversible airway obstruction.1, 27 Although 
diabetes was highly prevalent in our study, its prevalence was lower than in other registries and it 
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was not associated with outcome measurements in multivariate analysis. Most studies have shown 
that diabetes is associated with a poorer prognosis in acute HF, although this relationship is less clear 
in patients with chronic HF.20, 28, 29 Our findings regarding diabetes can probably be explained by the 
short-term follow-up, the older age of the patients and the fact that systematic screening for 
diabetes was not performed. 
 
4.4 Limitations 
 
This study has some limitations. First, this is not a nationwide register but a register limited to 2 
hospitals. However, because of the large sample size, the consecutive inclusion during a longer time 
period and the fact that the general results are comparable to other large American or European 
registries, we believe that our data reflect the real-life situation in Belgium. Secondly, as it is the case 
for most hospital based heart failure registries, medical comorbidities such as hypertension, COPD 
and diabetes were self-recorded or extracted from chart review and lacked formal diagnostic criteria. 
Other potential important comorbidities such as body mass index, anemia, sleep disorders or 
depression were not recorded in all patients and were therefore not used for further analysis. Also, 
NT-proBNP levels on admission were only available in 54% of the patients and were therefore not 
included for further statistical analysis. Thirdly we only recorded all-cause and not cause-specific 
mortality during a short term (3 months) follow-up. Finally, we did not record reasons why certain 
evidence based medications were not given. These last 2 limitations are however part of an ongoing 
heart failure quality improvement project within the BIO-HF framework. 
 
5 Conclusion 
 
In this contemporary registry of mainly elderly patients admitted with acute HF, a relatively 
preserved LVEF and a reduced kidney function are present in the majority of patients. In-hospital and 
short-term mortality and rehospitalization after discharge remain high and are mainly related to the 
presence of comorbidities such as renal failure and COPD. Comorbidities should be the focus for 
future efforts to improve the dire outcome of these patients. 
  
 
Table 4. Comparison of the BIO-HF clinical characteristics and outcome results to other registries that reported outcome after hospital discharge for acute 
decompensated heart failure 
 BIO-HF  IN-HF (14) ESC-HF Pilot (10) KorAHF (12) OPTIMIZE-HF (13) 
Region Belgium Italy Europe Korea USA 
Time period 2008-2012 2007-2009 2009-2010 2011-2012 2003-2004 
Sample Size 904 1855 1892 2066 4402 
Age (years) 77±11 72±12 69±13 69±14 72±14 
Women (%) 44 40 37 45 49 
History of CAD/IHD (%) 45 42 51 38 50 
LVEF (%)  42±17 38±11 38±14 40±18 37±17 
LVEF <40  (%) 42 58 65 (LVEF <45%) 56 49 
NT-proBNP (pg/ml) on admission 6500 (3216,11800) 5168 (2518,11583) 4007 (2043,9487) NA NA 
Hypertension (%) 62 58 62 59 72 
Diabetes (%) 27 40 35 36 42 
COPD (%) 19 30 15 11 31 
Creatinine (mg/dl) 1.4±0.9 1.2 (1, 1.6) NA 1.5±1.6 1.3 (1.0, 1.8) 
eGFR <60 ml/min/1.73m² (%) 64 55 49 NA NA 
eGFR<30 ml/min/1.73m² (%) 15 13 10 NA NA 
Discharge medication (%)      
ACE-I/ARB 66 78 78 65 68 
β blockers  77 61 81 44 67 
MRA 33 55 37 40 NA 
Median length of stay (days) 9 10 8 8 4 
In-hospital mortality  (%) 7.1 6.4 3.8 6.1 1.6 
All-cause mortality after discharge (%) 7.6 (3 months) 12.3 (3 months)  9.2 (6 months) 8.6 (60-90 days) 
  24 (1 year) 17 (1 year)   
All-cause mortality or rehospitalization 
for heart failure after discharge (%) 
18.3 (3 months) NA 36 (1 year) 28 (6 months) 36.2 (60-90 days) 
Data are presented as mean ± SD, median (IQR range) or %. CAD, coronary artery disease; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ACE-I, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NA not available. 
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Supplement 1. Univariate predictors of all-cause mortality at 3 months after discharge 
 Alive 
N=734 
Deceased 
N=60 
p-value 
Age (years) 76±11 79±10 0.048 
Women (%) 44 43 0.985 
LVEF (%) 43±17 43±16 0.995 
LVEF ≥ 50 (%) 42 43 0.804 
Ischemic heart disease (%) 43 49 0.383 
ACS on admission (%) 16 16 0.948 
LBBB (%) 16 10 0.180 
AF at discharge (%) 22 34 0.037 
Creatinine (mg/dl) 1.3±0.9 1.6±0.8 0.008 
eGFR (ml/min/1.73m²) 56±20 43±20 <0.001 
Hypertension (%) 62 63 0.837 
Diabetes (%) 27 25 0.706 
COPD (%) 18 33 0.005 
Smoking (%) 12 17 0.258 
Stroke (%) 11 18 0.069 
Malignancy (%) 12 14 0.665 
β Blocker at discharge (%) 79 63 0.007 
ACE-I/ARB at discharge (%) 67 43 <0.001 
MRA at discharge (%) 33 28 0.461 
Data are presented as mean±SD or %. LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome; 
LBBB, left bundle branch block; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; ACE-I, 
angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; MRA, mineralocorticoid 
receptor antagonist. 
 
Supplement 2. Univariate predictors of the combined endpoint of all-cause mortality and hospitalization for 
heart failure at 3 months after discharge 
 Alive 
N=649 
Deceased 
N=145 
p-value 
Age (years) 76±11 78±10 0.060 
Women (%) 43 46 0.459 
LVEF (%) 43±17 43±16 0.762 
LVEF ≥ 50 (%) 42 41 0.804 
Ischemic heart disease (%) 42 50 0.115 
ACS on admission (%) 15 19 0.211 
LBBB (%) 16 16 0.925 
AF at discharge (%) 21 28 0.101 
Creatinine (mg/dl) 1.3±0.9 1.5±0.7 0.043 
eGFR (ml/min/1.73m²) 57±20 48±20 <0.001 
Hypertension (%) 61 66 0.258 
Diabetes (%) 27 30 0.440 
COPD (%) 17 28 0.004 
Smoking (%) 13 10 0.476 
Stroke (%) 10 17 0.024 
Malignancy (%) 13 10 0.426 
β Blocker at discharge (%) 79 70 0.026 
ACE-I/ARB at discharge (%) 67 58 0.031 
MRA at discharge (%) 35 24 0.016 
Data are presented as mean±SD or %. LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome; 
LBBB, left bundle branch block; AF, atrial fibrillation; eGFR, estimated glomerular filtration rate; COPD, chronic 
obstructive pulmonary disease; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; MRA, mineralocorticoid receptor antagonist. 
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Supplement 3. Multivariate Cox regression analysis of the combined endpoint of all-cause 
mortality and hospitalization for heart failure at 3 months after discharge 
 OR 95% CI p-value 
eGFR 0.98 0.97-0.99 <0.001 
COPD 1.66 1.12-2.44 0.011 
β Blocker at discharge 0.75 0.51-1.11 0.152 
ACE-I/ARB at discharge 0.99 0.69-1.45 0.990 
MRA at discharge 0.65 0.42-1.00 0.051 
Stroke 1.58 1.01-2.50 0.045 
OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; COPD, 
chronic obstructive pulmonary disease; ACE-I, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist. 
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Abstract 
 
Purpose: The relation between exercise capacity and neurohormonal activation is unclear in coronary 
artery disease (CAD) patients. Therefore, we evaluated whether exercise capacity was related to 
neurohormonal activation in CAD patients with a wide range of left ventricular ejection fraction 
(LVEF) and NT-proBNP as well as whether the functional improvement after exercise training 
depends on LVEF or NT-proBNP.  
Methods: 581 patients who were referred for cardiac rehabilitation after a coronary event, were 
stratified according to LVEF (<50%, n=94 and ≥50%, n=487) and to tertiles of NT-proBNP (≤279, >279 
and ≤656, >656pg/ml). Six-minute walking distance (6MWD) before and after cardiac rehabilitation 
was available in all patients, spiro-ergometry was performed in 285 patients. Baseline exercise 
capacity and the benefit from exercise training were compared between the groups.  
Results: Patients with reduced and preserved LVEF showed a similar decrease in baseline exercise 
capacity with increasing NT-proBNP, as expressed by a lower load (all p<0.05), peakVO2, 6MWD, and 
a higher VE/VCO2 slope (all p<0.001 in preserved LVEF). In the upper tertile of NT-proBNP, exercise 
intolerance was comparable in patients with reduced and preserved LVEF. Exercise training resulted 
for each level of NT-proBNP in an overall improvement in exercise capacity and this gain was 
comparable for all levels of NT-proBNP, both for patients with reduced and preserved LVEF.  
Conclusions: Exercise capacity shows a similar decrease with increasing NT-proBNP, irrespective of 
left ventricular function in CAD. Exercise training improves exercise capacity regardless of left 
ventricular function or neurohormonal activation.  
 
 
 
Keywords: exercise capacity, exercise training, natriuretic peptide, left ventricular function, coronary 
artery disease 
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1 Introduction 
 
Biomarkers such as natriuretic peptides, brain natriuretic peptide or N-terminal pro brain natriuretic 
peptide (NT-proBNP), have become increasingly important for the diagnosis and prognosis of heart 
failure patients, both with reduced and preserved ejection fraction.1, 2 In addition to their role in 
heart failure, natriuretic peptides have also been demonstrated to be predictive for cardiac events 
and mortality in other clinical settings such as acute coronary syndrome, coronary artery bypass 
graft, valvular heart disease and even in patients without coronary artery disease (CAD) at baseline.1, 
3-7  
 
Previous research has already shown that neurohormonal activation, as assessed by NT-proBNP, is 
associated with an impaired exercise capacity and ventilatory inefficiency in heart failure with 
reduced 8-11 and preserved ejection fraction.12 Nevertheless, studies investigating this relation in CAD 
patients with a wide range of left ventricular ejection fraction (LVEF) and neurohormonal activation 
are lacking. Exercise training has been demonstrated to improve both exercise intolerance13-17 and 
neurohormonal activation,18-20 but whether the functional improvement after exercise training is 
related to the baseline level of neurohormonal activation is currently unknown.  
 
In this study, we wanted to evaluate whether exercise capacity was related to neurohormonal 
activation in CAD patients with a wide range of LVEF and NT-proBNP as well as whether the 
functional improvement after exercise training depends on left ventricular function or 
neurohormonal activation. 
 
2 Patients and methods 
 
2.1 Study population 
 
A total of 581 patients who were referred for cardiac rehabilitation after a coronary event (acute 
coronary syndrome n=283 or coronary artery bypass graft n=298) were prospectively included in the 
study. According to tertiles of NT-proBNP, 3 groups were defined with 194 patients having NT-
proBNP ≤279 pg/ml (T1), 194 patients with a value >279 and ≤656 pg/ml (T2) and 193 patients with 
NT-proBNP >656 pg/ml (T3). The study population was further classified according to their LVEF, 94 
patients had a LVEF<50% and 487 patients had a LVEF≥50%. CAD and LVEF were assessed with 
coronary angiography. This study protocol was approved by the local ethical committee of AZ Maria 
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Middelares Ghent and all patients gave informed consent. The clinical investigations were conducted 
according to the principles of the declaration of Helsinki. 
 
2.2 Exercise testing 
 
Prior to the rehabilitation program, cardiopulmonary exercise testing was performed on a cyclo-
ergometer using a ramp protocol adapted at the patients’ physical status approximately 3 weeks 
after discharge from the hospital (median 20 days [7, 28] for the total patient group, 7 days [4,10] 
after acute coronary syndrome and 27 days [22,31] after coronary artery bypass graft). Ventilatory 
and respiratory gas measurements were obtained on a breath-by-breath basis using an Oxycon Pro 
spirometer (Jaeger – Viasys Healthcare, Germany). Heart rate was continuously registered by a 12-
lead electrocardiogram and blood pressure was non-invasively measured, using a manual 
sphygmanometer every 2 minutes during the exercise test. Patients exercised to the limits of their 
functional capacities established by a respiratory exchange ratio >1.15 or until the physician stopped 
the test because of adverse signs and/or symptoms, such as chest pain, dizziness, potentially life-
threatening arrhythmias, ST segment deviations (≥1mm), and marked systolic hypotension or 
hypertension. The maximal achieved load during incremental exercise was recorded. Peak oxygen 
consumption (peak VO2) was defined as the mean of the last 30 seconds of peak exercise and was 
expressed as ml.min-1.kg-1. The slope of the linear relation between VE (y-axis) and VCO2 (x-axis), the 
VE/VCO2 slope, was calculated by including all data points to the end of exercise. The anaerobic 
threshold was defined as the exercise level at which ventilation starts to increase exponentially, 
relative to the increase in VO2 
21.  
 
At the beginning of the exercise training program, a six-minute walk test was also performed in a 
30m hallway. The distance a patient could quickly walk on a flat hard surface in a period of 6 
minutes, was measured (6MWD).  
 
This protocol, both the cardiopulmonary exercise testing and six-minute walk test, were repeated at 
the end of the rehabilitation program. The six-minute walk test before and after cardiac 
rehabilitation was available in all patients (n=581), spiroergometry was performed in 285 patients. 
The gain in exercise capacity was expressed as a percentage of improvement and calculated as 
follows for the aforementioned exercise parameters: (exercise parameterend – exercise 
parameterstart)/ (exercise parameterstart) *100.  
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2.3 Exercise training 
 
Rehabilitation was initiated at the first day after hospital admission and focused on respiration in 
combination with low-intensity aerobic exercises. After discharge, patients were encouraged to 
continue low-intensity aerobic exercises at home until they were referred for outpatient cardiac 
rehabilitation approximately 4 weeks after discharge from the hospital (median 29 days [interquartile 
range 20, 41] for the total patient group, 23 days [14, 31] after acute coronary syndrome and 38 days 
[28, 50] after coronary artery bypass graft). Patients trained 2 or 3 times weekly during 60 minutes 
for a period of 3 to 5 months with a maximum of 45 sessions. The exercise training program 
consisted of a combination of aerobic and strengthening exercises. Aerobic training mainly included 
cycling, treadmill walking and stepping and was performed at an intensity of the heart rate at the 
anaerobic threshold with an evaluation of the rating of perceived exertion. Strengthening exercises 
targeted both lower and upper body muscles at 60%1RM for 2 sets of 15 to 20 repetitions. Upper 
body strength training was started in a later phase in coronary artery bypass graft patients after the 
sternum was healed. Every training session was initiated and terminated with 5 minutes warm-up 
and cool-down period. 
 
2.4 Statistical analysis 
 
Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New 
York, USA: IBM Corp). Clinical characteristics and exercise capacity were assessed according to LVEF, 
thereafter the same parameters were analyzed according to the NT-proBNP level within each group 
of LVEF separately. Chi², Fisher exact and Kruskal Wallis test were used to evaluate these parameters. 
A Wilcoxon matched – pairs signed – ranks test was used to evaluate the improvement after exercise 
training within each group separately. Differences in training effects were then compared between 
the tertiles of NT-proBNP within each class of LVEF, using the Kruskal Wallis test. Within the patient 
group with the highest level of NT-proBNP, clinical characteristics and training effects were also 
compared between patients with preserved and reduced LVEF, using the aforementioned statistical 
tests. For all analyses, the level of significance was set at p < 0.05. 
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3 Results 
 
3.1 Patient characteristics 
 
Clinical characteristics according to LVEF are given in supplement 1. Table 1 summarizes the clinical 
characteristics according to NT-proBNP, stratified by LVEF. 82% of the total patient population 
(n=581) were men and this ratio was similar between patients with reduced and preserved LVEF. The 
highest percentage of women was found in the upper tertile of NT-proBNP. Patients, both with 
reduced and preserved LVEF, had a mean age of 63 years. Within the group with a preserved LVEF 
separately, patients were older with increasing NT-proBNP (p<0.001). In both groups of left 
ventricular function, a worse clinical status was seen with increasing NT-proBNP, as reflected by a 
decrease in LVEF, worse renal function and more patients in NYHA class II or III (all p<0.001 in 
preserved LVEF). Hypertension was significantly more present in the upper tertile of NT-proBNP, but 
only in patients with preserved LVEF (p<0.05). B-blockers, diuretics and spironolacton were more 
frequently used in the highest NT-proBNP level (all p<0.05 in preserved LVEF). 
 
3.2 Baseline exercise capacity and training effects according to LVEF and  tertiles of NT-proBNP 
 
Exercise capacity and functional improvement after attending cardiac rehabilitation was assessed 
according to LVEF and neurohormonal activation (figure 1, 2 and 3). In general, patients with a 
reduced LVEF had a worse exercise capacity after their event as compared with patients with 
preserved LVEF. Both patients with reduced and preserved LVEF showed a similar decrease in 
baseline exercise capacity with increasing NT-proBNP, as expressed by a progressively lower maximal 
achieved load (all p<0.05), peak VO2, 6MWD and a higher VE/VCO2 slope (p<0.001 in preserved 
LVEF). Patients attended 38 training sessions on average and this number was comparable for both 
groups of left ventricular function and each level of neurohormonal activation. Exercise training 
resulted for each level of NT-proBNP in an overall improvement in load (all p<0.05), 6MWD (all 
p<0.01) and peak VO2 (all p<0.05 except for tertile 1 in LVEF<50%). This gain in exercise capacity was 
comparable for the three levels of NT-proBNP, both for patients with reduced and preserved LVEF. 
Only in patients with preserved ejection fraction and the highest level of NT-proBNP, a small but 
significant effect on the VE/VCO2 slope was found (p<0.001).  
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3.3 Patient characteristics and training effects in patients with an increased NT-proBNP  
 
In patients with an increased neurohormonal activation (>656pg/ml), patients with preserved LVEF 
were approximately 5 years older than those with reduced LVEF (p<0.01). Although patients with 
reduced LVEF had a higher NT-proBNP and more frequently a history of diabetes than patients with 
preserved LVEF (all p<0.05), no other signs for a worse clinical status were found. The percentage of 
patients in NYHA class II/III was similar as well as renal function and other comorbidities. Heart 
failure related medication such as ACE-inhibitors/angiotensin receptor blockers and diuretics was 
more frequently prescribed in patients with reduced LVEF (all p<0.05) (table 1). Patients with 
preserved LVEF showed a similar level of exercise intolerance as patients with reduced LVEF, with a 
decreased maximal achieved load, 6MWD, peak VO2 and an increased VE/VCO2 slope. Exercise 
training resulted in a comparable improvement in the aforementioned parameters, both in patients 
with reduced and preserved LVEF (figure 1, 2 and 3).  
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Table 1. Clinical characteristics according to LVEF and tertiles of NT-proBNP 
 LVEF<50% LVEF≥50% 
Tertiles of NT-proBNP  T1 T2 T3 P T1 T2 T3 P 
 N=12 N=24 N=58  N=182 N=170 N=135  
Age (years) 61±9 62±9 63±10 0.510 58±10 63±10 68±8
** 
<0.001 
Men (%) 75 88 74 0.419 89 87 72 <0.001 
BMI (kg/m²) 28±3 25±3 27±4 0.092 28±4 27±4 27±4 0.053 
LVEF (%) 41±5 42±5 37±10 0.123 69±8 68±9 64±9
*** 
<0.001 
NT-proBNP (pg/ml) 192 (126-242) 453 (389-561) 1854 (1141-2757) <0.001 144 (64-221) 434 (363-516) 1070 (872-1623)
*** 
<0.001 
GFR (ml/min/1.73m²) 75±11 78±15 69±22 0.344 79±12 77±13 67±18 <0.001 
NYHA (%)                                       I 73 62 41 0.214 78 65 48 <0.001 
II-III 27 38 59  22 35 52  
Risk factors & comorbidities (%)         
Hypertension 50 25 52 0.080 42 53 58 0.012 
Diabetes 8 17 28 0.318 13 19 15
* 
0.331 
Smoking 17 4 10 0.454 4 6 7 0.664 
COPD 0 0 10 0.512 5 3 5 0.835 
AF at start cardiac rehabilitation 8 0 7 0.398 0 2 9 <0.001 
Medication (%)         
Antiplatelets 100 96 98 0.622 100 99 99 1 
Lipid lowering drugs 83 100 93 0.105 97 98 90 0.003 
β blockers 92 96 97 0.757 86 95 94 0.003 
ACE inhibitors/ ARB 92 79 83 0.726 39 30 42
*** 
0.085 
Diuretics 8 17 36 0.070 7 8 22
* 
<0.001 
Spironolacton 8 21 14 0.691 2 1 5 0.029 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as mean ± standard deviation, non normally continuous 
variables are presented as median (interquartile range).  
LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; BMI, body mass index; GFR, glomerular filtration rate; NYHA, New York Heart 
Association; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; ACE inhibitors, Angiotensin Converting Enzym inhibitor; ARB, Angiotensin Receptor 
Blocker. 
Difference between LVEF<50 and ≥50% within the highest NT-proBNP level (T3): 
 
*p<0.05 
 
**p<0.01 
 
***p<0.001 
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Figure 1, 2 & 3. Six-minute walking distance, peak oxygen consumption and VE/VCO2 slope according to NT-
proBNP, stratified by left ventricular function 
Six-minute walking distance, peak oxygen consumption and the VE/VCO2 slope are shown at the start and end 
of the cardiac rehabilitation program, according to the level of NT-proBNP. Variables are presented as the 
mean ± standard deviation in the table under the figure. The improvement in exercise capacity is presented as 
a percentage (%) above the bars in each group separately, significance levels are indicated with an asterisk (*p 
<0.05, **p <0.01, and ***p <0.001). Differences in training benefits between the tertiles of NT-proBNP are 
shown on top of the figure.  
CR, cardiac rehabilitation; 6MWD, six-minute walking distance; peak VO2, peak oxygen consumption. 
. 
4 Discussion 
 
The primary finding of this study was that both in CAD patients with reduced and preserved LVEF a 
similar decrease in exercise capacity was observed as neurohormonal activation increased. 
Furthermore, exercise training resulted in an improvement in exercise tolerance, irrespective of the 
left ventricular function or the level of neurohormonal activation.  
 
As already previously mentioned in literature, a worse clinical status is seen in patients with 
increased plasma concentrations of NT-proBNP. Apart from this clinical status, we have 
demonstrated a progressive decline in exercise capacity as neurohormonal activation increased. In 
the past, the link between exercise capacity and NT-proBNP has been mainly investigated in heart 
failure.8-12 Our study provides a broader perspective by analysing CAD patients with a wide range of 
neurohormonal activation both with reduced and preserved LVEF. In general, exercise capacity is 
slightly more impaired in patients with reduced LVEF as compared with patients with preserved LVEF, 
which supports previous findings in heart failure.22 Nevertheless, there is a similar decrease in 
exercise capacity, as expressed by the 6MWD, for elevating levels of NT-proBNP in both groups of left 
ventricular function. The maximal achieved load and the peakVO2 describe a similar course as the 
6MWD whereas the VE/VCO2 slope tends to increase with elevating neurohormonal activation. Our 
findings are in agreement with Guazzi et al. 12 who recently demonstrated comparable correlations 
between NT-proBNP and peak VO2 and VE/VCO2 slope in a matched heart failure population with 
reduced and preserved LVEF of 68 patients. However, the relation in CAD has not been investigated 
so far and neither the link between training benefits and baseline neurohormonal activation.  
 
This study has shown an overall improvement in exercise capacity after exercise training, regardless 
of left ventricular function or level of neurohormonal activation. Numerous studies have already 
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demonstrated the beneficial effect of exercise training on peak VO2.
13, 18, 19, 23, 24 The average 
progression in peak VO2 in this study, ranging from 10 to 23%, is consistent with previous 
investigations both focusing on heart failure and other cardiac pathologies.24, 25 In contrast to the 
aforementioned variables, we only saw a modest decrease in the VE/VCO2 slope, which was only 
significant in the upper tertile of NT-proBNP in patients with preserved LVEF. Currently, there is no 
consensus on the effect of exercise training on ventilatory inefficiency.14, 19, 23, 24 A relatively healthy 
patient population in the lower tertiles of NT-proBNP with a baseline VE/VCO2 slope below 34, may 
be a plausible explanation for this finding. However, also the intensity and type of exercise training 
may have been insufficient to influence ventilatory inefficiency. Addition of inspiratory muscle 
therapy may result in an additional improvement in cardiorespiratory responses to exercise.26  
 
Patients with CAD in the highest level of NT-proBNP had a poor clinical status, both in patients with 
preserved and reduced LVEF. Also their level of exercise intolerance was generally comparable, 
which may  indicate they have a comparable disease severity and associated prognosis. Van 
Veldhuisen et al. 2 has provided evidence for this presumption in a HF population by demonstrating a 
similar risk of all cause mortality and heart failure related hospitalisation in patients with a reduced 
and preserved LVEF for a given BNP level. Therefore, neurohormonal activation may be the primary 
driver of outcome, whereas adding LVEF has limited value in prognostication.2  In addition, our study 
shows equal training benefits, irrespective of the left ventricular function. Consequently, more 
attention is needed for exercise intolerance and the beneficial role of exercise training, particularly in 
those patients with an increased neurohormonal activation.  
 
This study has several limitations. A small number of patients in some subgroups may have led to 
underpowered results, in particular in the lower tertiles of NT-proBNP for patients with a reduced 
LVEF. Therefore, these results should be interpreted with caution. NT-proBNP was not measured at 
the end of cardiac rehabilitation, hence potential improvements in neurohormonal activation after 
exercise training and the relation to changes in exercise tolerance could not be assessed. However, 
literature has already shown that neurohormonal activation may also improve after exercise training 
and that this change may be related to the progression in exercise capacity and ventilatory 
efficiency.18, 19  
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5 Conclusions 
 
In CAD patients, exercise capacity shows a similar decrease with increasing neurohormonal 
activation, irrespective of left ventricular function. Exercise training improves exercise capacity 
regardless of  left ventricular function or the level of neurohormonal activation. 
 
Acknowledgment: We would like to thank the cardiac rehabilitation team of AZ Maria Middelares 
Ghent for their contribution to data collection.  
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Supplement 1. Clinical characteristics according to LVEF 
 LVEF<50% LVEF≥50% P 
 N=94 N=487  
Age (years) 63±10 63±10 0.887 
Men (%) 78 83 0.201 
BMI (kg/m²) 27±4 27±4 0.108 
LVEF (%) 39±8 67±9 <0.001 
NT-proBNP (pg/ml) 1056 (440-2125) 393 (188-744) <0.001 
GFR (ml/min/1.73m²) 72±20 75±15 0.506 
NYHA (%)                                               I 50 65 0.019 
II-III 50 35  
Risk factors and comorbidities (%)    
Hypertension 45 50 0.336 
Diabetes 22 16 0.109 
Smoking 10 6 0.138 
COPD 7 4 0.410 
AF at start cardiac rehabilitation 5 3 0.361 
Medication (%)    
Antiplatelets 98 99 0.186 
Lipid lowering drugs 94 95 0.609 
β blockers 96 91 0.151 
ACE inhibitors/ ARB 83 36 <0.001 
Diuretics 28 12 <0.001 
Spironolacton 15 2 <0.001 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as 
mean ± standard deviation, non normally continuous variables are presented as median (interquartile range). 
LVEF, left ventricular ejection fraction; BMI, body mass index; NT-proBNP, N-terminal pro Brain Natriuretic 
Peptide; GFR, glomerular filtration rate; NYHA, New York Heart Association; COPD, chronic obstructive 
pulmonary disease; AF, atrial fibrillation; ACE inhibitors, Angiotensin Converting Enzym inhibitor; ARB, 
Angiotensin Receptor Blocker. 
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Abstract 
 
Objective: Participation in cardiac rehabilitation (CR) after hospitalisation for heart failure (HF) is 
estimated to be low, but specific data for Belgium are lacking. Therefore, we wanted to evaluate 
attendance after HF hospitalisation compared to patients after cardiac surgery or acute coronary 
syndrome (ACS). Moreover, the improvement in exercise capacity was compared with the other 
patient groups. 
Methods and results: Patients who were hospitalized for HF (n=428), cardiac surgery (n=358) or ACS 
(n=467) in a single hospital, were prospectively included between January 2010 and May 2012. After 
hospitalisation for HF only 9% participated, compared to 29% after ACS and 56% after cardiac 
surgery. Non-participants in HF were older, more frequently women (p<0.01) and had a better left 
ventricular ejection fraction (p<0.05). In addition, they had more frequently atrial fibrillation and 
problems to walk independently (p<0.01). At start of CR, HF patients had a worse clinical status and 
exercise capacity than patients after cardiac surgery or ACS (all p<0.001). However, exercise training 
resulted in a significant improvement in each group separately (all p<0.001) and the relative 
improvement in exercise capacity in HF was comparable with the other groups.  
Conclusions: Only 9% of HF patients participates in CR after hospitalisation. Age, female gender, a 
relatively well preserved ventricular function and atrial fibrillation seem to impede attendance to CR. 
However, HF patients can have as much improvement in exercise capacity as other patient 
populations, suggesting that more effort is needed to increase participation in CR among HF patients.  
 
Keywords: cardiac rehabilitation, participation, heart failure, exercise capacity   
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1 Introduction 
 
Cardiac rehabilitation (CR) has been recommended as an effective tool in the prevention and 
treatment of cardiovascular diseases.1 Nevertheless, figures on participation in CR are disappointing 
with less than 50% attendance of the eligible patients. In addition, mainly coronary heart disease 
patients are referred, whereas only a minority of heart failure (HF) patients is estimated to 
participate in CR.2  
 
In Belgium, general figures regarding participation in CR are varying 2, 3 and specific data among the 
different patient groups and in HF in particular, are lacking. Therefore, we wanted to evaluate 
attendance in CR after hospitalisation for HF in comparison with patients after hospitalisation for 
cardiac surgery or acute coronary syndrome (ACS). Potential differences in clinical characteristics at 
discharge from the hospital between HF patients who participated and those who did not participate, 
were assessed. Moreover, the benefit of exercise training in HF patients was compared with the 
results in the other patient groups. 
 
2 Methods 
 
2.1 Study population 
 
This study was performed in a single hospital (AZ Maria Middelares Ghent) providing on-site 
interventional cardiology, cardiac surgery and outpatient CR. Patients who were hospitalized for HF 
(n=428), cardiac surgery (n=358) or ACS (n=467) between January 2010 and May 2012 were 
prospectively included. Data on HF patients were based on the ongoing BIO-HF registry.4 During the 
same time period, attendance to CR in the different patient groups was also registered. This study 
protocol was approved by the ethical committee of AZ Maria Middelares Ghent and all patients gave 
informed consent. The clinical investigations were conducted according to the principles of the 
Declaration of Helsinki.  
 
2.2 Exercise testing 
 
Cardiopulmonary exercise testing (CPET) was performed 21 days [interquartile range 7-29] after 
hospitalisation on a cyclo-ergometer using a ramp protocol adapted to the patient’s physical status. 
Ventilatory and respiratory gas measurements were obtained on a breath-by-breath basis using an 
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Oxycon Pro spirometer (Jaeger – Viasys Healthcare, Germany). Heart rate was continuously 
registered by a 12-lead electrocardiogram and blood pressure was non-invasively measured, using a 
manual sphygmanometer every 2 minutes during the exercise test. Patients exercised to the limits of 
their functional capacities established by a respiratory exchange ratio >1.15 or until the physician 
stopped the test because of adverse signs and/or symptoms, such as chest pain, dizziness, potentially 
life-threatening arrhythmias, ST segment deviations (≥1mm), and marked systolic hypotension or 
hypertension. The maximal achieved load during incremental exercise was recorded. Peak oxygen 
consumption (peak VO2) was defined as the mean of the last 30 seconds of peak exercise and was 
expressed as ml.min-1.kg-1. The slope of the linear relation between VE (y-axis) and VCO2 (x-axis), the 
VE/VCO2 slope, was calculated by including all data points to the end of exercise. The anaerobic 
threshold (AT) was defined as the exercise level at which ventilation starts to increase exponentially, 
relative to the increase in VO2.
5
 The distance a patient could quickly walk on a flat hard surface in a 
period of 6 minutes, was also measured (6MWD). This protocol, both CPET and 6MWT, was repeated 
at the end of the rehabilitation program. The gain in exercise capacity was expressed as a percentage 
of improvement and calculated as follows for the aforementioned exercise parameters: (exercise 
parameterend – exercise parameterstart)/ (exercise parameterstart) *100.  
 
2.3 Exercise training 
 
Patients trained 2 or 3 times weekly during 60 minutes for a period of 3 to 5 months with a maximum 
of 45 sessions. The exercise training program consisted of a combination of aerobic and 
strengthening exercises. Aerobic training mainly included cycling, treadmill walking and stepping and 
was performed at an intensity of the heart rate at the anaerobic threshold. Strengthening exercises 
targeted both lower and upper body muscles at 60%1RM for 2 sets of 15 to 20 repetitions. Upper 
body strength training was started in a later phase in cardiac surgery patients after the sternum was 
healed. Every training session was initiated and terminated with 5 minutes warm-up and cool-down 
period. 
 
2.4 Statistical analysis 
 
Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New 
York, USA: IBM Corp). Clinical characteristics were assessed in patients hospitalized for HF according 
to their participation in CR using the Chi2, Fisher exact, Independent Samples T test and Mann 
Whitney U test as appropriate. Same statistical tests were used to evaluate the difference in clinical 
characteristics and baseline exercise capacity between patients who started CR after hospitalisation 
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for HF, cardiac surgery or ACS and to assess the difference in functional improvement after exercise 
training. A Wilcoxon matched – pairs signed – ranks test was used to evaluate the improvement after 
exercise training within each group separately. For all analyses, the level of significance was set at 
p<0.05.  
 
3 Results 
 
3.1 Participation in CR 
 
After hospitalisation for HF only 9% participated in CR, compared to 56% in patients hospitalized for 
cardiac surgery and 29% after ACS with a remarkable difference between patients who had a 
myocardial infarction with ST elevation (STEMI, 40%) and those without ST elevation (NSTEMI, 16%) 
(Figure 1). 
 
 
 
Figure 1. Participation in CR among the different patient groups. 
  
Table 1. Clinical characteristics of the hospitalized heart failure population  
 Total population Participation CR Non participation CR P 
 N=428 N=37 N=391  
Age (years) 78±10 65±10 79±10 <0.001 
Men (%) 54 76 52 0.005 
BMI at discharge (kg/m²) 26±4 27±5 26±4 0.419 
LVEF (%) 43±17 36±15 44±17 0.011 
LVEF≥50 (%) 40 23 42 0.030 
NT-proBNP (pg/ml) on admission   5728 (2985-11441) 5569 (2014-8474) 5744 (3008-11663) 0.266 
Creatinin (mg/dl) on admission 1.1 (0.9-1.5) 1.2 (1.0-1.5) 1.1 (0.9-1.5) 0.416 
Creatinin (mg/dl) at discharge 1.2 (0.9-1.6) 1 (0.8-1.3) 1.2 (0.9-1.6) 0.077 
GFR on admission 53 (41-73) 62 (44-78) 53 (41-73) 0.363 
NYHA at discharge  n=354                                I 20 19 20 0.808 
II 69 75 68  
III 11 6 11  
IV 1 0 2  
Ischemic heart disease (%) 45 57 44 0.128 
Risk factors & comorbidities (%)    Hypertension 63 49 65 0.053 
Hyperlipidemia (n=376) 52  72 50 0.012 
Diabetes 29 27 29 0.810 
Smoking 12 35 10 <0.001 
COPD 17 14 18 0.525 
CVA 12 5 13 0.292 
PAD 18 11 19 0.222 
AF  44 19 46 0.001 
Sinus rhythm at discharge 52 92 49 <0.001 
Able to walk independently at discharge 76 100 73 0.002 
Medication (%)                                   Antiplatelets 52 65 51 0.110 
β blockers 79 95 78 0.015 
ACE inhibitors/ ARB 60 73 59 0.093 
Diuretics 82 81 82 0.909 
Spironolacton 36 38 36 0.781 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as mean ± standard deviation, non normally continuous 
variables are presented as median (interquartile range). BMI, body mass index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; 
GFR, glomerular filtration rate; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PAD, peripheral arterial 
disease; AF, atrial fibrillation; ACE inhibitors, Angiotensin Converting Enzym inhibitor, ARB, Angiotensin Receptor Blocker. 
  
Table 2. Clinical characteristics of patients at start of cardiac rehabilitation 
 Cardiac Surgery Acute Coronary Syndrome Heart failure P 
 N=201 N=133 N=37  
Age (years) 65±10 58±11 64±10 <0.001 
Men (%) 79 79 76 0.909 
BMI (kg/m²) 27±4 29±5 26±5 0.001 
LVEF (%) 65±12 59±13 37±16 <0.001 
NT-proBNP (pg/ml)  487 (274-940) 321 (141-767) 1651 (843-2336) <0.001 
Creatinin (mg/dl)  0.9 (0.8-1.1) 1 (0.8-1.1) 1 (0.9-1.5) 0.073 
GFR  77 (62-90) 78 (65-90) 68 (42-83) 0.011 
NYHA                                                              I 63 76 38 <0.001 
II 32 22 30  
III 5 2 32  
Risk factors & comorbidities (%)     
Hypertension 53 39 41 0.029 
Hyperlipidemia 43 47 57 0.311 
Diabetes 20 13 22 0.166 
Smoking 2 13 16 <0.001 
COPD 4 3 6 0.700 
CVA 6 2 3 0.313 
PAD 7 4 11 0.233 
AF  9 2 11 0.017 
Medication (%)     
Antiplatelets 98 100 73 <0.001 
β blockers 93 90 92 0.755 
ACE inhibitors/ ARB 23 68 70 <0.001 
Diuretics 16 9 70 <0.001 
Spironolacton 3 4 35 <0.001 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as mean ± standard deviation, non normally continuous 
variables are presented as median (interquartile range).  
BMI, body mass index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; GFR, glomerular filtration rate; NYHA, New York 
Heart Association; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PAD, peripheral arterial disease; AF, atrial fibrillation; ACE inhibitors, 
Angiotensin Converting Enzym inhibitor, ARB, Angiotensin Receptor Blocker. 
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3.2 Clinical characteristics of the hospitalized HF patients  
 
Patients not attending CR after hospitalisation for HF, were significantly older and more female (both 
p<0.01), and they had a higher left ventricular function than HF patients who participated in CR 
(p<0.05). In addition, almost half of them had atrial fibrillation during hospitalisation and 27% 
reported problems to walk independently at discharge from the hospital (p<0.01). Clinical risk factors 
for CAD (hyperlipidemia and smoking) were less frequent in non-participants (both p<0.05). The 
medication use was comparable between the groups, except for β blockers which were less used in 
those not attending CR (p<0.05) (Table 1). 
 
3.3 Clinical characteristics of patients participating in cardiac rehabilitation 
 
In total, 371 patients attended CR of whom HF patients were the smallest group (10%). Patients 
participating after ACS were on average younger and had a higher BMI than patients after cardiac 
surgery or HF (p<0.001). HF patients had a lower left ventricular ejection fraction, a higher NT-
proBNP level, a higher NYHA class (p<0.001) and a worse renal function (p<0.05). Almost none of the 
patients who had cardiac surgery were smoking at the start of CR, whereas 13 to 16% did after ACS 
or HF respectively (p<0.001). Atrial fibrillation was present in 9% of patients after cardiac surgery and 
11% of HF patients which is significantly more than in ACS (p<0.05). HF related medications such as 
ACE inhibitors or ARB, diuretics and spironolacton, were significantly more prescribed in HF patients 
(p<0.001), whereas antiplatelets were prescribed in almost all patients after ACS or cardiac surgery 
(p<0.001) (Table 2).  
 
3.4 Exercise capacity and exercise training among the different patient groups 
 
At the start of CR, HF patients had the worst exercise capacity with a significantly lower maximal 
achieved load, peak VO2, 6MWD and a higher VE/VCO2 slope (all p<0.001). Exercise training resulted 
in a significant improvement in these exercise parameters in each patient group separately (all 
p<0.001), except for the VE/VCO2 slope which only decreased slightly in patients after cardiac surgery 
and HF (both p<0.05). Furthermore, the percentage of improvement after exercise training seen in 
HF, was comparable with patients after cardiac surgery or ACS (Figure 2).  
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Figure 2. Exercise capacity and improvement after exercise training among the different patient groups. 
Exercise capacity – expressed as the load, peakVO2, VE/VCO2 slope, and 6MWD – is shown at the start and end 
of the cardiac rehabilitation program. Variables are presented as the mean ±SD in the table. The improvement 
in exercise capacity is presented in percentage (%) above the bars in each group separately. Significance levels 
are indicated with an asterisk (*p <0.05, **p <0.001). Differences in training benefits between the patient 
groups are shown on top of the figure.  
CR, cardiac rehabilitation; ACS, acute coronary syndrome; HF, heart failure; peak VO2, peak oxygen 
consumption; 6MWD, six-minute walking distance. 
 
4 Discussion 
 
Overall, one third of eligible patients attended CR after discharge from the hospital, but large 
differences were found between patient groups. Only 9% of hospitalized HF patients participated in 
CR, which is far below the achieved rates in ACS and cardiac surgery. Higher participation rates were 
already previously demonstrated in CABG patients and may be due to a greater perceived need for 
CR.2, 6, 7 In addition, ACS patients have a shorter stay in hospital making it difficult to adequately refer 
to outpatient CR.6 Although not assessed in our study, literature has shown that NSTEMI patients are 
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older and have more frequently comorbidities8,9 which may result in a lower participation rate than 
in STEMI patients.   
 
Despite the increasing number of patients with HF and the efficacy of exercise training to reduce 
mortality and hospitalisation in HF,10, 11 barely one out of ten HF patients took part in CR. 
Neurohormonal activation, renal function and NYHA class were equal in both groups of HF, 
suggesting that disease severity did not have a major impact on participation in CR. Non-participants 
had a better left ventricular function, indicating the presence of heart failure with preserved ejection 
fraction (HFPEF). Also the higher age, the larger number of women and the presence of atrial 
fibrillation, which were all more frequently seen in non-participants, may be related to HFPEF.12 This 
high rate of non-attendance to CR among HFPEF is likely due to the national government guidelines 
restricting reimbursement for CR to HF patients with reduced ejection fraction (HFREF). The gap 
between men and women may also be related to differences in social status, but this could not be 
assessed in our study.6 Comorbidities, whether they are related to a higher age or not,6 may also 
underlie the lower participation rate. One quarter of non-participants reported problems to walk 
independently at discharge from the hospital, which is a major barrier in daily life. Individual-tailored  
exercise programs should be offered to these patients at discharge from the hospital. The presence 
of cardiovascular risk factors for coronary artery disease, such as hyperlipidemia and smoking, 
resulted in a higher participation rate in CR. In this case, both physicians and patients may be aware 
of the importance of lifestyle modification thereby encouraging attendance to CR. Although our 
findings regarding hyperlipidemia were in agreement with the study of Worcester et al.,6  this author 
reported that smoking appeared to reduce participation in CR. Other studies indicated that risk factor 
status did have little influence on CR participation.13  
 
In comparison with patients participating after cardiac surgery or ACS, HF patients had obviously a 
worse clinical status which may explain their lower baseline exercise capacity at the start of CR. 
However, their benefit of exercise training was equal with substantial improvements in exercise 
capacity and to a lesser extent in ventilatory efficiency, which may have important prognostic 
implications. In addition to the high-tech therapies that have emerged in recent years, clinicians and 
patients should also be aware of the potential of cardiac rehabilitation in the treatment of this 
vulnerable population. Future studies and guidelines should adequately address potential barriers to 
CR in order to increase the participation in cardiac rehabilitation among heart failure patients. 
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4.1 Limitations 
 
Our study was performed in a single-hospital making generalisation of our data difficult. However, to 
our knowledge these are the first data on attendance to CR in HF for Belgium. Due to the differences 
in reimbursement guidelines, these data are not applicable to other countries. In addition to clinical 
characteristics, psychosocial factors and exercise capacity at discharge from the hospital may have 
influenced the decision for (non-)participation in HF patients and this should be subject of further 
investigation.  
 
5 Conclusion 
 
Only 9% of HF patients participates in CR after hospitalisation. Age, female gender, a relatively well 
preserved ventricular function and atrial fibrillation seem to impede attendance to CR. However, HF 
patients can have as much improvement in exercise capacity as other patient populations, suggesting 
that more effort is needed to increase participation in CR among HF patients. 
 
Acknowledgement: We thank the cardiac rehabilitation team of AZ Maria Middelares Ghent for their 
contribution to data collection.  
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Abstract 
 
Background: Despite the clear benefits of cardiac rehabilitation (CR), a considerable number of 
patients drop out early.  
Objective: Therefore, we wanted to evaluate drop-out in CR in Belgium with a special focus on 
comorbidities and psychosocial background. 
Methods: Patients who attended CR after acute coronary syndrome, cardiac surgery or heart failure 
(n=489) were prospectively included. Drop-out was defined as attending ≤50% of the training 
sessions (n=96, 20%). Demographic and clinical characteristics, exercise parameters and psychosocial 
factors were analysed according to drop-out and those with a trend towards a significant difference 
(p<0.10) were entered in a multivariate logistic model.  
Results: The presence of chronic obstructive pulmonary disease (2.55[0.99-6.54]) or cerebrovascular 
accident (4.18[1.39-12.52]) involved a higher risk for drop-out as well as attending the training 
program only twice per week (3.76[2.23-6.35]). In contrast, patients on β blockers were less likely to 
withdraw prematurely (0.47[0.22-0.98]). Singles were more likely to drop out (2.89[1.56-5.35] ) as 
well as those patients who were dependent on others to get to CR (2.01[1.16-3.47]). Finally, the 
reporting of severe problems on the anxiety/depression subscale of the EuroQOL-5D questionnaire 
involved a higher odds for drop-out (7.17[1.46-35.29]).  
Conclusion: Demographic characteristics nor clinical status or exercise capacity could independently 
identify patients who were at risk for drop-out. The presence of comorbidities and a vulnerable 
psychosocial background rather seem to play a key role in drop-out. 
 
Keywords: cardiac rehabilitation, drop-out, comorbidities, exercise capacity, psychosocial 
characteristics  
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1 Introduction 
 
Cardiac rehabilitation (CR) has been shown to reduce the risk for mortality and hospitalisation, 
particularly in coronary artery disease. 1-6 Despite these clear benefits, more than half of eligible 
patients do not attend CR, 7, 8 mainly because of personal or logistic reasons. 8-10 In addition, a 
considerable number of those patients who actually attend CR, drop out prematurely varying from 
22 to 65%. 11, 12 This may be partly due to personal (perception of self control of the problem, illness 
cognition, socioeconomic status) or financial reasons 9, 11, 13, 14 but also physical and psychological 
health problems may play a key role. 9, 12 
 
The majority of these studies have often focused on a particular subgroup of cardiac patients which 
may not always be representative for the total CR population. Therefore, the aim of our study was to 
evaluate drop-out in CR among a Belgian cardiac population consisting of patients after acute 
coronary syndrome, cardiac surgery and heart failure, with a focus on potential predisposing 
demographic and clinical characteristics, exercise parameters and psychosocial factors which could 
lead to drop-out. 
 
2 Methods 
 
2.1 Study population  
 
489 patients who attended CR after hospitalisation for acute coronary syndrome (n=204), cardiac 
surgery (n=245) or heart failure (n=40) in two Belgian hospitals (AZ Maria Middelares Ghent and 
Onze-Lieve-Vrouw Hospital Aalst) between April 2011 and March 2013 were prospectively included. 
In both hospitals, a similar multidisciplinary outpatient CR program was offered to each patient with 
a maximum of 45 reimbursed sessions, which is further explained in this section. Since the length of 
phase II rehabilitation programs varies across countries, drop-out was defined as attending ≤50% of 
the rehabilitation program which is consistent with previous studies. 11 
 
2.2 Ethics  
 
This study protocol was approved by the ethical committee of the two participating hospitals (AZ 
Maria Middelares Ghent and Onze-Lieve-Vrouw Hospital Aalst) and all patients gave informed 
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consent. The clinical investigations conform with the principles outlined in the Declaration of 
Helsinki. 
 
2.3 Clinical characteristics  
 
Demographic characteristics, medication use, risk factors and comorbidities were collected at start of 
CR, based on chart review. A standard blood sample was taken to measure hematological 
parameters, glucose metabolism, lipids, renal function and N-Terminal pro brain natriuretic peptide. 
Echocardiography was performed on admission to the hospital in 456 patients with a measurement 
of left ventricular ejection fraction (Simpson’s method).  
 
2.4 Exercise testing  
 
Cardiopulmonary exercise testing was performed in 411 patients, 24 days after hospitalisation 
(median 24 interquartile range [10,34]) on a cyclo-ergometer using a ramp protocol adapted to the 
patient’s physical status. Ventilatory and respiratory gas measurements were obtained on a breath-
by-breath basis using an Oxycon Pro spirometer (Jaeger – Viasys Healthcare, Germany). Heart rate 
was continuously registered by a 12-lead electrocardiogram and blood pressure was non-invasively 
measured, using a manual sphygmanometer every 2 minutes during the exercise test. Patients 
exercised to the limits of their functional capacities established by a respiratory exchange ratio >1.15 
or until the physician stopped the test because of adverse signs and/or symptoms, such as chest 
pain, dizziness, potentially life-threatening arrhythmias, significant ST segment displacement 
(≥1mm), and marked systolic hypotension or hypertension. The maximal achieved load during 
incremental exercise was recorded. Peak oxygen consumption (peak VO2) was defined as the mean 
of the last 30 seconds of peak exercise and was expressed as ml.min-1.kg-1. The slope of the linear 
relation between VE (y-axis) and VCO2 (x-axis), the VE/VCO2 slope, was calculated by including all 
data points to the end of exercise. The anaerobic threshold (AT) was defined as the exercise level at 
which ventilation starts to increase exponentially, relative to the increase in VO2. 
15 At the beginning 
of the exercise training program, a six-minute walk test (6MWT) was also performed in a 30m 
hallway. The distance a patient could quickly walk on a flat hard surface in a period of 6 minutes, was 
measured (six-minute walking distance). 
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2.5 Psychosocial and logistic factors  
 
Educational background, social and occupational status were recorded as well as the dependency for 
transport and the distance to the CR centre. Health-related quality of life (HRQoL) was evaluated 
using the EuroQoL-5D-3L (EQ-5D-3L) which consists of two parts: the EQ-5D descriptive system and 
the EQ-5D visual analogue scale (EQ-5D VAS). The EQ-5D-3L descriptive system includes 5 dimensions 
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with 3 levels of severity 
of problems for each dimension (no problems, some problems, severe problems). An index value is 
calculated from the answers on the aforementioned dimensions with 1 representing perfect health, 0 
representing death and <0 representing a health state perceived worse than death. The EQ-5D VAS is 
a visual analogue scale used to record the patients self-perceived health with 0 as the worst 
imaginable health state and 100 as the best imaginable health state. 16, 17 The Hospital Anxiety and 
Depression Scale (HADS) was applied for identifying those patients with symptoms of anxiety or 
depression. The HADS comprises 14 items, of which 7 are related to anxiety (HADS-A) and 7 to 
depression (HADS-D). Each item is scored on a four-point response scale (0-3) and the total score on 
each subscale ranges between 0 and 21. A score <8 could be regarded as being in the normal range 
whereas a score of 11 or higher indicates the probable presence of a mood disorder. A score 
between 8 and 10 is just suggestive of the presence of the respective state. 18  
 
2.6 Cardiac rehabilitation program  
 
A multidisciplinary rehabilitation program was offered to each patient 29 [19-40] days after discharge 
from the hospital, including exercise training, dietary counseling, smoking cessation and 
psychological support. Patients had the choice to train 2 or 3 times weekly for 60 minutes during a 
period of 3 to 5 months with a maximum of 45 reimbursed sessions. Patients who withdrew 
prematurely attended 17 [10,20] training sessions, compared with 44 [38-45] training sessions in the 
group who continued the training program. The exercise training program consisted of a combination 
of aerobic and strengthening exercises. Body weight and waist were measured at start and end of 
the rehabilitation program and dietary counselling was offered to the patient as needed. Patients 
with an increased risk for anxiety or depression according to the HADS were invited for further 
psychological support. 
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2.7 Statistical methods  
 
Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New 
York, USA: IBM Corp). Clinical characteristics, baseline exercise capacity and psychosocial factors 
were assessed according to drop-out using the Chi square, Fisher exact, Independent Samples T test 
and Mann Whitney U test as appropriate. For all analyses, the level of significance was set at p<0.05. 
Variables with an overall significance value p<0.10 were entered in a multivariable backward logistic 
regression model to identify the strongest predictors for drop-out. Nagelkerke R² was reported to 
assess the percentage of variation that was explained by the model. Since the frequency of the 
training program was significantly different according to drop-out, differences in clinical and 
psychosocial characteristics between patients who trained 2 or 3 times per week were investigated in 
a supplementary analysis. 
 
3 Results 
 
3.1 Clinical characteristics according to drop-out 
 
Clinical characteristics are summarized in table 1. In total, 96 of the 489 patients (20%) who attended 
CR, dropped out in the first half of the training program. Age and BMI were comparable, but women 
tended to drop out earlier than men during the course of CR (p<0.05). A quite similar clinical status 
was seen in both groups with a comparable left ventricular function, renal function and level of 
neurohormonal activation. Patients who were referred after coronary artery bypass graft were less 
likely to drop out than patients after acute coronary syndrome or heart failure (p<0.05). 
Comorbidities such as chronic obstructive pulmonary disease (COPD) and cerebrovascular accident 
(CVA) were significantly more present in those patients who ceased in the first half of the training 
program and β blockers were less prescribed in the latter group (all p<0.05). No differences were 
found in exercise capacity, except for a trend towards a slightly lower maximal achieved load 
(p=0.051). Patients who chose to attend the training program 3 times weekly were clearly less likely 
to drop-out in the first half of CR (p<0.001). 
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Table 1. Clinical characteristics according to drop out in cardiac rehabilitation 
 Total population ≤23 sessions >23 sessions P 
 N=489 N=96 N=393  
Age (years) 60±11 60±13 60±11 0.824 
Men (%) 80 72 81 0.038 
BMI (kg/m²) 27±4 27±5 27±4 0.548 
LVEF (%) 59±16 58±16 59±16 0.785 
NT-proBNP (pg/ml)  475 
 (211-1073) 
430  
(246-1611) 
482  
(191-999) 
0.588 
Creatinin (mg/dl)  1 (0.8-1.1) 1 (0.8-1.1) 1 (0.8-1.1) 0.922 
GFR (ml/min/1.73m²) 76 (65-91) 75 (63-91) 76 (65-89) 0.953 
Exercise training after (%)                      ACS 42 48 41 0.020 
Cardiac surgery 50 39 52  
Heart failure 8 13 7  
Risk factors & comorbidities (%)     
Hypertension 50 52 49 0.571 
Hyperlipidemia 71 69 72 0.594 
Diabetes 18 17 18 0.792 
Smoking 7 10 6 0.087 
COPD 5 10 4 0.048 
CVA 3 7 2 0.022 
PAD 5 8 4 0.109 
AF at start CR  1 1 2 1 
Medication (%)     
Antiplatelets 89 91 88 0.517 
Lipid lowering drugs 80 78 81 0.576 
β blockers 88 81 90 0.016 
ACE inhibitors/ ARB 51 53 50 0.598 
Diuretics 20 22 20 0.699 
Spironolacton 15 18 14 0.357 
Exercise capacity     
Load (Watt) 114±38 107±43 116±37 0.051 
HR at anaerobic threshold (/min) 100±17 99±16 100±17 0.696 
Peak VO2 (ml.min
-1
.kg
-1
) 19±6 18±6 19±6 0.102 
VE/VCO2 slope 32±6 32±7 32±5 0.995 
6MWD (m) 432±93 420±104 436±89 0.178 
Frequency training program (%)   2x/week 38 62 32 <0.001 
3x/week 62 38 68  
Categorical variables are presented as percentages, normally distributed continuous variables are presented 
as mean ± standard deviation, non normally continuous variables are presented as median (interquartile 
range).  
BMI, body mass index; ACS, acute coronary syndrome; LVEF, left ventricular ejection fraction; NT-proBNP, N-
terminal pro Brain Natriuretic Peptide; GFR, glomerular filtration rate; CR, cardiac rehabilitation; COPD, 
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PAD, peripheral arterial disease; AF, 
atrial fibrillation; ACE inhibitors, Angiotensin Converting Enzym inhibitor, ARB, Angiotensin Receptor Blocker; 
HR, heart rate; peak VO2, peak oxygen consumption; VE/VCO2 slope, ventilatory slope; 6WMD, six-minute 
walking distance. 
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Table 2. Psychosocial and logistic factors according to drop out in cardiac rehabilitation 
 Total population ≤23 sessions >23 sessions P 
 N=489 N=96 N=393  
Education level (%)            Primary education 32 39 30 0.153 
Secondary education  36 36 36  
High education 32 25 34  
Partner (%) 83 71 86 <0.001 
Occupational status (%)                   Employed 39 37 39 0.160 
Retired 47 43 48  
Others  14 20 13  
Dependency for transport to CR (%) 27 39 24 0.004 
Distance to CR (%)                                  ≤10km 32 32 31 0.930 
>10 and ≤20km 48 47 49  
>20km 20 21 20  
EQ-5D Mobility (%)                      No problems 81 75 82 0.109 
Some problems 19 25 18  
Severe problems 0 0 0  
EQ-5D Self-care (%)                     No problems 95 90 96  0.017 
Some problems 5 10 4  
Severe problems 0 0 0  
EQ-5D Usual activities (%)          No problems 66 62 67 0.299 
Some problems 28 34 27  
Severe problems 6 4 6  
EQ-5D Pain/ discomfort (% )      No problems 51 53 50 0.440 
Some problems 47 44 48  
Severe problems 2 3 2  
EQ-5D Anxiety/ depression (%) No problems 76 76 76 0.003 
Some problems 23 18 23  
Severe problems 1 6 1  
EQ-5Dindex  0.76 (0.66-1) 0.76 (0.66-1) 0.76 (0.66-1) 0.680 
EQ-5D VAS 70 (60-75) 70 (60-80) 70 (60-75) 0.667 
HADS – Anxiety                                                                             5 (3-8) 6 (2-9) 5 (3-8) 0.677 
score between (%)     0-7 69 62 71 0.129 
8-10 19 21 19  
≥11 11 17 10 0.058 
HADS – Depression                                                                       4 (2-7) 5 (2-8) 4 (2-7) 0.300 
score between (%)     0-7 77 73 78 0.085 
8-10 16 15 16  
≥11 7 12 6 0.027 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as 
mean ± standard deviation, non normally continuous variables are presented as median (interquartile range).  
CR, cardiac rehabilitation; EQ-5D, EuroQOL-5D; VAS, visual analogue scale; HADS, hospital anxiety and depression 
scale.  
 
3.2 Psychosocial and logistic factors according to drop-out 
 
Table 2 shows the psychosocial and logistic factors according to drop-out. Educational and 
occupational status were comparable but patients without a partner were significantly more present 
in the group which has withdrawn prematurely (p<0.05). Evaluation of logistic factors revealed that 
patients who were dependent on others for getting to CR  were more likely to drop out than those 
who came on their own to the centre (p<0.01). Patients who dropped out prematurely, reported 
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more problems regarding HRQoL on the dimensions of self-care and anxiety/depression of the EQ-
5D-3L (all p<0.05). Nevertheless, their perception of health (EQ-5D VAS) was not significantly 
different. Also a higher percentage of patients with an increased risk for depression (HADS-D ≥11) 
was seen in the group which dropped out early from CR (p<0.05) and a similar trend was seen for 
patients with an increased risk for anxiety (HADS-A ≥11) (p=0.058).  
 
3.3 Logistic regression model for drop-out 
 
Logistic backward regression was performed to identify the strongest predictors for drop-out and the 
remaining significant variables are shown in table 3. The presence of comorbidities involved a higher 
risk for early withdrawal with patients suffering from COPD being nearly three times as likely (2.55 
[0.99-6.54]) to drop out and patients with CVA having four times (4.18 [1.39-12.52]) higher odds for 
drop out. Also attending the training program only two times per week involved a higher odds for 
early withdrawal (3.76 [2.23-6.35]). Patients on β blocker therapy on the other hand, were less likely 
to cease in the first half of the training program than patients who did not have β blocker therapy  
(0.47 [0.22-0.98]). Also several psychosocial characteristics remained in the final logistic regression 
model. Singles had a three times higher risk for drop-out ( 2.89 [1.56-5.35]) and being dependent on 
others to get to CR involved twice as much risk for drop-out (2.01 [1.16-3.47]). The reporting of 
severe problems on the anxiety/depression subscale of the EQ-5D was a final significant predictor for 
early withdrawal (7.17 [1.46-35.29]). Together, these  variables explained approximately one fifth of 
the total variation in drop-out (Nagelkerke R²=0.215). 
 
Table 3. Logistic regression model for drop out in cardiac rehabilitation 
 Odds ratio 95% CI  P 
COPD 2.55 0.99-6.54 0.050 
CVA 4.18 1.39-12.52 0.011 
β blockers 0.47 0.22-0.98 0.043 
Training program twice per week 3.76 2.23-6.35 <0.001 
No partner 2.89 1.56-5.35 0.001 
Dependency for transport to CR 2.01 1.16-3.47 0.013 
EQ-5D anxiety/depression   0.009 
Some problems 0.57 0.30-1.09 0.087 
Severe problems 7.17 1.46-35.29 0.015 
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CR, 
cardiac rehabilitation; EQ-5D, EuroQOL-5D. 
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3.4 Clinical, psychosocial and logistic factors according to the frequency of training program 
 
Supplementary analyses according to the frequency of the training program are described in 
supplement 1 and 2. Patients who attended CR only twice per week, were slightly older and more 
frequently women (all p<0.001). They also had signs of a worse clinical status with a trend towards a 
decreased left ventricular function (p=0.052) and an increased neurohormonal activation (p<0.01). 
Renal function was equal in both groups. No differences in risk factors, comorbidities or medication 
were found, except for diuretics which were more frequently prescribed in patients who trained 
twice per week (p<0.05). An impaired exercise capacity was seen in patients who attended CR twice 
per week with a decrease in load, peak VO2 and six-minute walking distance (all p<0.001).  
A lower education level was seen in the group which trained twice per week as well as more singles 
(both p<0.05). Patients attending CR only twice per week were also more frequently professionally 
inactive (p<0.01). In addition, they reported more problems regarding mobility and self-care 
influencing HRQoL (both p<0.01).  
 
4 Discussion 
 
In this prospective analysis of potential determinants of drop-out, one fifth of our patient population 
quit in the first half of the CR program with a higher risk in patients presenting with comorbidities 
and a vulnerable psychosocial background. 
 
Although demographic factors, age and gender, were predictive of drop-out in the report of 
Yohannes et al., 12 these were not crucial in our study. Women were slightly more represented in the 
group which dropped out early but this may be explained by the fact that women were more 
frequently single (26% vs. 15%) and dependent on others to get to CR (39% vs. 24%). Multivariate 
analysis revealed that being single or being dependent for transport were main drivers of drop-out 
rather than gender which is in line with previous findings. 11, 19 Similarly, clinical status as expressed 
by ventricular function, neurohormonal activation and renal function, was equal in both groups, 
suggesting that disease severity did not influence drop-out. On the other hand, the majority of 
patients participating in CR in our hospitals, were referred after cardiac surgery and they were also 
more likely to continue the training program than others, although this could not be confirmed in 
multivariate analysis. Their greater participation rate is rather due to the lack of perceived need for 
CR in other patient groups 11, 20 than to differences in clinical status. Surprisingly, baseline exercise 
capacity did neither have any influence on withdrawal, suggesting that physically impaired patients 
may as well successfully complete their program as patients who are fitter at the start of CR. 
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Traditional cardiovascular risk factors such as smoking and diabetes have been related to drop-out in 
the past, 11 but this was not supported by our results. Interestingly, the presence of comorbidities, in 
particular a history of CVA and COPD, turned out to play a key role. COPD has generally been 
recognized as an independent predictor of all-cause mortality in heart failure 21-24 and likewise, the 
presence of CVA after acute myocardial infarction has been related to a higher risk for mortality. 25 In 
addition, the presence of COPD may implicate a lower use of B-blockers, 26 which in turn also involves 
a higher risk for drop-out.  
 
Dependency for transport was a major predictor of drop-out, but not the distance to the CR center 
which was previously mentioned as an important barrier to attend CR. 9, 20 In contrast to countries 
with rural areas, 20, 27 the majority of our patients was living within a radius of 20km of the CR centre 
making it unlikely that distance itself was a major issue. Since being dependent for transport and 
having no partner were key drivers in drop-out, this suggests that a vulnerable social situation is 
more important than logistic barriers.  
 
Furthermore, HRQoL was a major determinant in our study. Patients who dropped out early, 
reported significantly more problems at the start of CR regarding self-care and symptoms of anxiety 
and depression. In coronary artery disease patients, an impaired HRQoL has been reported with 
problems on several dimensions of the EQ-5D except for self-care. 28 This discrepancy regarding self-
care may be due to a difference in time after the event. Since our patients were in the acute phase 
after their event (<6months), problems regarding self-care were more likely than at a later stage as in 
the previous study. 28 Perhaps more important than self-care, were the reported problems on anxiety 
and depression. Strikingly, only the severe problems did have an impact on drop-out. HRQoL is 
known to be related to lifestyle risk factors and may, together with psychological distress, be 
improved by modifying these risk factors. 29-32 However, symptoms of depression and anxiety are 
associated with a less frequent modification of lifestyle 33 which is in line with our findings on drop-
out. Consequently, those patients who are most likely to benefit from CR, are unfortunately just the 
ones who are at high risk of drop-out. 
 
Another strong predictor of early withdrawal seemed to rely on the choice whether patients 
preferred to attend CR 2 or 3 times weekly. Supplementary analyses revealed differences in the 
patient profile. Patients who attended CR only twice per week were slightly older and more 
frequently women. Moreover, they had a worse clinical status and a lower exercise capacity at the 
start of CR and they also differed in their psychosocial profile. Taken together, these demographic, 
clinical and psychosocial characteristics which did not influence withdrawal independently, actually 
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may have an impact on drop-out by influencing the choice of the training program. However, this 
should be subject of further investigations. 
 
4.1 Strengths and limitations 
 
This study has several strengths but also limitations. First, all patients were prospectively included at 
the beginning of the CR program, regardless of the recruiting diagnosis. Therefore, our study 
population is a fairly good representation of the ‘real life’ CR population. Another strength may be 
that we did not rely on the reasons for drop-out given by the patients, but we have prospectively 
collected potential predictors at the beginning of CR to see what their impact was on the course of 
the program. In spite of the broad spectrum of included variables, some interesting variables are 
lacking such as information on illness cognition and perception and the influence of the income 
which have been demonstrated to be important in literature. 9, 12, 14, 20 Only 21% of the variation was 
explained, suggesting that other unknown factors are involved in this complex issue.  
 
5 Conclusions 
 
This study aimed to evaluate potential predisposing factors for drop-out in CR. Demographic 
characteristics nor clinical status or exercise capacity could independently identify patients who were 
at risk for drop-out. The presence of comorbidities and a vulnerable psychosocial background rather 
seem to play a key role in drop-out. 
 
Acknowledgements: We thank the cardiac rehabilitation team of AZ Maria Middelares Ghent and 
Onze-Lieve-Vrouw Hospital Aalst for their contribution to data collection. 
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Supplement 1. Clinical characteristics according to frequency of the training program 
 Total population 2x/week 3x/week P 
 N=489 N=183 N=304  
Age (years) 60±11 62±12 59±10 <0.001 
Men (%) 80 71 85 <0.001 
BMI (kg/m²) 27±4 27±4 27±4 0.061 
LVEF (%) 59±16 57±16 60±15 0.052 
NT-proBNP (pg/ml)  475 (211-1073) 606 (246-1582) 413 (188-872) 0.006 
Creatinin (mg/dl)  1 (0.8-1.1) 1 (0.8-1.1) 1 (0.8-1.1) 0.528 
GFR (ml/min/1.73m²) 76 (65-91) 74 (62-89) 77 (67-91) 0.165 
Exercise training after (%)           ACS 42 39 43 0.609 
Cardiac surgery 50 51 49  
Heart failure 8 10 8  
Risk factors & comorbidities (%)     
Hypertension 50 54 47 0.186 
Hyperlipidemia 71 72 71 0.839 
Diabetes 18 18 18 0.938 
Smoking 7 5 7 0.310 
COPD 5 6 5 0.572 
CVA 3 4 3 0.604 
PAD 5 6 4 0.392 
AF at start CR  1 2 1 0.771 
Medication (%)     
Antiplatelets 89 88 90 0.611 
Lipid lowering drugs 80 80 81 0.828 
β blockers 88 89 88 0.903 
ACE inhibitors/ ARB 51 53 49 0.393 
Diuretics 20 25 17 0.041 
Spironolacton 15 16 14 0.379 
Exercise capacity     
Load (Watt) 114±38 103±36 121±38 <0.001 
HR at anaerobic threshold (/min) 100±17 98±17 101±17 0.092 
Peak VO2 (ml.min
-1
.kg
-1
) 19±6 18±5 20±6 <0.001 
VE/VCO2 slope 32±6 33±6 32±6 0.050 
6MWD (m) 432±93 399±102 452±80 <0.001 
Training sessions 42 (29-45) 33 (20-42) 44 (38-45) <0.001 
Drop-out (%) 20 32 12 <0.001 
Categorical variables are presented as percentages, normally distributed continuous variables are presented 
as mean ± standard deviation, non normally continuous variables are presented as median (interquartile 
range).  
BMI, body mass index; ACS, acute coronary syndrome; LVEF, left ventricular ejection fraction; NT-proBNP, N-
terminal pro Brain Natriuretic Peptide; GFR, glomerular filtration rate; CR, cardiac rehabilitation; COPD, 
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PAD, peripheral arterial disease; AF, 
atrial fibrillation; ACE inhibitors, Angiotensin Converting Enzym inhibitor, ARB, Angiotensin Receptor Blocker; 
HR, heart rate; peak VO2, peak oxygen consumption; VE/VCO2 slope, ventilatory slope; 6WMD, six-minute 
walking distance. 
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Supplement 2. Psychosocial and logistic factors according to frequency of the training program 
 Total population 2x/week 3x/week P 
 N=489 N=183 N=304  
Education level (%)               Primary education 32 38 28 0.042 
Secondary education  36 36 36  
High education 32 27 36  
Partner (%) 83 78 86 0.033 
Occupational status (%)                     Employed 39 26 47 0.001 
Retired 47 57 41  
Others  14 17 12  
Dependency for transport to CR (%) 27 32 24 0.060 
Distance to CR (%)                                     ≤10km 32 36 28 0.176 
>10 and ≤20km 48 45 51  
>20km 20 19 21  
EQ-5D Mobility (%)                        No problems 81 73 86 0.001 
Some problems 19 27 14  
Severe problems 0 0 0  
EQ-5D Self-care (%)                        No problems 95 90 98 <0.001 
Some problems 5 10 2  
Severe problems 0 0 0  
EQ-5D Usual activities (%)            No problems 66 63 68 0.120 
Some problems 28 29 28  
Severe problems 6 8 4  
EQ-5D Pain/ discomfort (% )        No problems 51 50 51 0.190 
Some problems 47 47 48  
Severe problems 2 3 1  
EQ-5D Anxiety/ depression (%)   No problems 76 71 78 0.153 
Some problems 23 26 21  
Severe problems 1 3 1  
EQ-5Dindex  0.76 (0.66-1) 0.75 (0.66-1) 0.76 (0.71-1) 0.042 
EQ-5D VAS 70 (60-75) 69 (60-75) 70 (60-77) 0.057 
HADS – Anxiety                                                                             5 (3-8) 5 (3-8) 5 (2-8) 0.359 
score between (%)     0-7 69 67 70 0.366 
8-10 19 19 20  
≥11 11 14 10 0.156 
HADS – Depression                                                                       4 (2-7) 4 (2-7) 4 (2-7) 0.538 
score between (%)     0-7 77 77 77 0.226 
8-10 16 13 17  
≥11 7 9 6 0.165 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as 
mean ± standard deviation, non normally continuous variables are presented as median (interquartile range).  
CR, cardiac rehabilitation; EQ-5D, EuroQOL-5D; VAS, visual analogue scale; HADS, hospital anxiety and depression 
scale.  
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Abstract 
 
Information on exercise capacity and training in patients who underwent valvular surgery is scarce. 
The aim of this study is to evaluate postoperative exercise capacity and functional improvement after 
exercise training according to the preoperative risk and type of surgery. In this prospective study, 145 
patients who underwent aortic valve surgery (AVS) or mitral valve surgery (MVS) and who were 
referred for cardiac rehabilitation, were stratified according to the preoperative risk (European 
System for Cardiac Operative Risk Evaluation [EuroSCORE] ) and type of surgery (sternotomy vs 
ministernotomy or port access). Exercise capacity was evaluated at the start and end of cardiac 
rehabilitation. Postoperative exercise capacity and the benefit from exercise training were compared 
between the groups. Patients with a higher preoperative risk, had a worse postoperative exercise 
capacity, with a lower load, peak VO2, anaerobic threshold and 6-minute walking distance (all 
p<0.001) and a higher VE/VCO2 slope (p=0.01). In MVS, port access patients performed significantly 
better at baseline (all p<0.05) but in AVS, ministernotomy patients performed better than 
sternotomy patients with a concomitant coronary artery bypass graft (p<0.05). Training resulted in 
an improvement in exercise capacity in each risk group and each type of surgery (all p<0.05). This 
gain in exercise capacity was comparable for the EuroSCORE risk groups and for the types of surgery, 
for patients after AVS or MVS. In conclusion, exercise capacity after cardiac surgery is related to the 
preoperative risk and the type of surgery. Despite these differences in postoperative exercise 
capacity, a similar benefit from exercise training is obtained, regardless of their preoperative risk or 
type of surgery. 
 
 
Key words: valvular heart disease, minimal invasive surgery, exercise capacity, EuroSCORE 
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1 Introduction 
 
Information on exercise capacity and exercise training in patients who underwent valvular surgery is 
scarce. Current literature suggests that exercise capacity does not recover spontaneously after aortic 
valve surgery (AVS) or mitral valve surgery (MVS).1-3 This argues in favor of the need for cardiac 
rehabilitation. The primary aim of this study was to evaluate the difference in exercise capacity early 
after valvular surgery between patients with a low or high preoperative risk profile, assessed using 
the European System for Cardiac Operative Risk Evaluation (EuroSCORE). Similarly, the difference in 
postoperative exercise capacity was evaluated between patients after invasive versus minimal 
invasive surgery. The secondary aim was to assess whether the functional improvement after 
exercise training was affected by this preoperative risk profile or type of surgery. 
 
2 Methods 
 
One hundred and forty-five patients who underwent AVS (n=72) or MVS ( n=73) for valvular 
regurgitation or stenosis and who were referred for cardiac rehabilitation between October 2007 and 
March 2012 were prospectively included. Patients with multivalvular disease were not eligible for 
inclusion and neither were patients with transcatheter aortic valve implantation or mitraclip because 
of the fewer number of these procedures. Only patients with classic sternotomy, ministernotomy or 
port access were considered for analysis. Combined coronary artery bypass graft (CABG) and valvular 
surgery was performed in 52 patients (36%). This study protocol was approved by the ethical 
committee of the two participating hospitals (AZ Maria Middelares Ghent and Onze-Lieve-Vrouw 
Hospital Aalst) and all patients gave informed consent. The clinical investigations were conducted 
according to the principles of the declaration of Helsinki. 
 
The EuroSCORE was used to assess the mortality risk in cardiac surgery. EuroSCORE I calculation 
consists of patient, cardiac and operation-related factors and results in an additive and a logistic risk 
score.4 According to the additive EuroSCORE, patients were divided into 3 risk groups.5 A score 
ranging from 0 to 2 was classified as a low risk (n= 20), 3 to 5 as a medium risk (n=64) and > 5 as a 
high risk profile (n=60). EuroSCORE was not calculated for 1 patient because of missing data on left 
ventricular function. The decision regarding the type of surgery (classic sternotomy vs 
ministernotomy or port access) was made by the cardiac surgeon on the basis of preoperative clinical 
data and anatomic status. 
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Cardiopulmonary exercise testing was performed 1 month (31±16 days) after surgery on a cyclo-
ergometer using a ramp protocol adapted to the patient’s physical status. Ventilatory and respiratory 
gas measurements were obtained on a breath-by-breath basis using an Oxycon Pro spirometer 
(Jaeger – Viasys Healthcare, Germany). Heart rate was continuously registered by a 12-lead 
electrocardiogram and blood pressure was non-invasively measured, using a manual 
sphygmanometer every 2 minutes during the exercise test. Patients exercised to the limits of their 
functional capacities established by a respiratory exchange ratio >1.15 or until the physician stopped 
the test because of adverse signs and/or symptoms, such as chest pain, dizziness, potentially life-
threatening arrhythmias, significant ST segment displacement (≥1mm), and marked systolic 
hypotension or hypertension. The maximal achieved load during incremental exercise was recorded. 
Peak oxygen consumption (peak VO2) was defined as the mean of the last 30 seconds of peak 
exercise and was expressed as millilitre per minute per kilogram. The slope of the linear relation 
between VE (y axis) and VCO2 (x axis), the VE/VCO2 slope, was calculated by including all data points 
to the end of the exercise. The anaerobic threshold (AT) was defined as the exercise level at which 
ventilation starts to increase exponentially, relative to the increase in VO2.
6
 At the beginning of the 
exercise training program, a 6-minute walk test was performed in a 30-m hallway. The distance a 
patient could quickly walk in a period of 6 minutes (i.e. 6-minute walking distance [6MWD]) was 
measured. This protocol was repeated at the end of the rehabilitation program. The gain in exercise 
capacity was expressed as a percentage of improvement and calculated for the previously mentioned 
exercise parameters: (exercise parameterend – exercise parameterstart)/ (exercise parameterstart) *100.  
 
Rehabilitation was initiated at the hospital on the first day after surgery and focused on respiration in 
combination with low-intensity aerobic exercises. After discharge, patients were encouraged to 
continue low-intensity aerobic exercises at home until they were referred for outpatient cardiac 
rehabilitation (43 ± 22 days after surgery). Outpatient rehabilitation was started not earlier than 4 
weeks after surgery to ensure optimal healing. Patients trained 2 or 3 times a week for 60 minutes 
during a period of 3 to 5 months with a maximum of 45 sessions. The exercise training program 
consisted of a combination of aerobic and strengthening exercises. Aerobic training mainly included 
cycling (15 minutes), treadmill walking (15 minutes) and stepping (5 minutes) and was performed at 
an intensity of the heart rate at AT combined with an evaluation of the rating of perceived exertion. 
Strengthening exercises (15 minutes) primarily targeted lower body muscles with leg press and leg 
curl exercises at 60% of 1 repetition maximum for 2 sets of 15 to 20 repetitions. In a later phase, 
after the sternum had healed, upper body strength training for biceps, triceps and trunk was added. 
Every training session was initiated and terminated with 5 minutes warm-up and cool-down period. 
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Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 21.0 (Armonk, New 
York, USA: IBM Corp). Differences in clinical characteristics between patients who had AVS or MVS 
were assessed with chi square and Independent Samples t test or Mann Whitney U test, as 
appropriate. Because of an unequal number of patients and an unequal spread in variances, 
nonparametric tests were chosen for analyzing exercise capacity according to the preoperative risk 
profile. Differences in baseline exercise capacity and differences in functional improvement after the 
exercise training program were evaluated with Kruskal Wallis-test or Mann-Whitney U test, 
depending on the number of groups. A Wilcoxon matched- pairs signed-ranks test was used to 
evaluate the improvement after the exercise training program within each group separately. Same 
statistical tests were used to evaluate the differences between invasive versus minimal invasive 
surgery. A p value <0.05 was considered to be statistically significant. 
 
3 Results 
 
Clinical characteristics of the 145 study patients are listed in Table 1. Age, gender and body mass 
index were comparable between AVS and MVS. MVS patients had a slightly lower preoperative left 
ventricular function as compared with AVS patients (60% vs 67%, p<0.01). MVS was mainly 
performed for mitral regurgitation (97%) whereas AVS patients were mainly referred for aortic 
stenosis (75%). Mitral valve repair was performed in 85% of those who were referred for MVS. The 
large majority of patients who were referred for AVS underwent aortic valve replacement. In mitral 
valve disease, sternotomy was performed in 40 patients (55%), of whom 28 patients underwent also 
CABG and 33 patients (45%) underwent minimal invasive surgery through port access. Sternotomy 
was performed in 45 patients with aortic valve disease (63%) of whom 23 patients had a concomitant 
CABG and 27 patients (37%) underwent a ministernotomy. Patients attended 38 training sessions on 
an average; this number was comparable for AVS and MVS. At the end of the exercise training 
program, an overall increase in exercise capacity was seen in the total patient group with an increase 
of 31% in load, 23% in peak VO2, 10% in AT and 26% in 6MWD. A decrease of 5% was recorded for 
the VE/VCO2 slope. 
 
Exercise capacity early after surgery and functional improvement after attending cardiac 
rehabilitation, was assessed for all patients according to the EuroSCORE risk profile (Figure 1). 
Patients with a higher preoperative risk, had a worse postoperative exercise capacity as expressed by 
a lower load, peak VO2, AT and 6MWD (all p<0.001) and a higher VE/VCO2 slope (p=0.01). Load, peak 
VO2, and 6MWD at baseline were significantly different between the 3 risk groups (all p<0.01). AT 
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Table 1. Clinical characteristcs of the total patient group and patients who underwent AVS or MVS 
Variable  Total group 
n=145 
Mitral valve surgery 
n=73 
Aortic valve surgery 
n=72 
P value 
Age (years) 64 ± 10 64 ± 9 65 ± 12 0.696 
Men 74% 71% 76% 0.480 
BMI (kg/m²) 26±4 25±3 26±4 0.128 
LVEF (%) 64 ± 13 60 ± 15 67 ± 11 0.004 
EuroSCORE risk profile    0.296 
low risk 14% 18% 10%  
medium risk 44% 45% 43%  
high risk 42% 37% 47%  
Aetiology valve disease    <0.001 
regurgitation 61% 97% 25%  
stenosis 39% 3% 75%  
AVS/MVS    <0.001 
mechanical prosthetic valve 17% 4% 30%  
bioprosthetic valve 40% 11% 69%  
repair 43% 85% 1%  
CABG 36% 38% 33% 0.528 
Type of surgery    <0.001 
sternotomy 58% 55% 63%  
ministernotomy 19% - 37%  
port access 23% 45% -  
NYHA classification    0.990 
I 69% 70% 68%  
II 26% 25% 27%  
III 5% 5% 5%  
NT-proBNP (pg/ml) 565 (309-1149) 686 (357-1508) 476 (297-919) 0.225 
Hypertension 50% 45% 54% 0.281 
Hyperlipidemia 40% 44% 36% 0.342 
Diabetes 12% 4% 19% 0.004 
Smoking 9% 6% 12% 0.271 
COPD 1% 2% 0% 0.489 
PAD 3% 3% 4% 0.681 
AF at start cardiac rehabilitation 13% 12% 14% 0.781 
Pacemaker  6% 4% 7% 0.494 
Medication     
B-blocker 88% 82% 94% 0.022 
ACE-I/ARB 37% 34% 39% 0.562 
diuretics 26% 29% 22% 0.366 
statins 49% 44% 54% 0.213 
Categorical variables are presented as percentages, normally distributed continuous variables are presented as 
mean ± SD, non normally continuous variables are presented as median (interquartile range).  
ACE-I, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body 
mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NT-proBNP, N-
Terminal pro brain natriuretic peptide; NYHA, New York Heart Association; PAD, peripheral arterial disease. 
 
was significantly decreased, and VE/VCO2 slope was significantly increased in the high-risk group as 
compared with the low- and medium-risk group (all p<0.05). Exercise training resulted in a significant 
improvement in load, peak VO2, AT and 6MWD in each risk group separately (all p<0.01). A small but 
significant decrease in the VE/VCO2 slope was only present in the medium- and high-risk patient 
groups (p<0.05). The percentage of improvement in exercise capacity was comparable in low-, 
medium- and high-risk groups. Table 2 lists the training effects according to the preoperative risk 
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profile, stratified by aortic and mitral valve disease. In patients with MVS, postoperative exercise 
capacity was significantly worse in high-risk as compared with low-/medium-risk patients (all p<0.01). 
In contrast, load, peak VO2, AT and 6MWD were lower but not significantly different in high-risk as 
compared with low-/medium-risk AVS patients. Only in AVS, VE/VCO2 slope was significantly higher 
in high-risk patients (p<0.05). After exercise training, distinct improvements in load, peak VO2 and 
6MWD were seen in all groups (all p<0.01). An increase in the AT was present in MVS (all p<0.05). 
The VE/VCO2 slope was significantly decreased in the high-risk group of AVS (p<0.05). The functional 
improvement in exercise capacity was generally comparable in low-/medium-risk and high-risk 
patients, for AVS and MVS.  
 
 
Figure 1. Exercise capacity and training benefits according to the preoperative risk profile 
Exercise capacity after valvular surgery - expressed as the load, peak VO2, VE/VCO2 slope and 6MWD- is shown 
at the start and end of the cardiac rehabilitation program, according to the EuroSCORE risk profile. Variables 
are presented as the mean ± SD in the table. The improvement in exercise capacity is presented in percentage 
(%) above the bars in each group separately, significance levels are indicated with an asterisk (*p<0.05 
**p<0.01 and ***p<0.001). Differences in training benefits between the EuroSCORE risk groups are shown on 
top of the figure. CR, cardiac rehabilitation. 
  
  
Table 2. Training effect according to the preoperative risk profile, stratified by valve disease 
Variable MVS (n=73) AVS (n=71) 
 low/medium risk 
(n=46) 
high risk 
(n=27) 
diff in training 
effects between 
risk groups 
low/medium risk 
(n=38) 
high risk 
(n=33) 
diff in training 
effects between 
risk groups 
 mean ± SD p value mean ± SD p value p value mean ± SD p value mean ± SD p value p value 
Load (Watt)           
start CR 122 ± 36 
] <0.001 
78 ± 22*** 
] 0.001 
 102 ± 39 
] <0.001 
80 ± 26 
] 0.004 
 
end CR 157 ± 49 98 ± 30  136 ± 60 108 ± 35  
Δ Load (%) 29 ± 16  26 ± 22  0.452 33 ± 20  39 ± 36  0.918 
Peak VO2 (ml.min
-1
.kg
-1
)           
start CR 21 ± 6 
] <0.001 
15 ± 4*** 
] 0.006 
 19 ± 6 
] 0.001 
17 ± 3 
] 0.003 
 
end CR 26 ± 8 17 ± 5  25 ± 6 21 ± 5  
Δ Peak VO2 (%) 23 ± 18  15 ± 17  0.135 29 ± 27  23 ± 21  0.603 
HR at AT (/min)           
start CR 99 ± 17 
] 0.004 
86 ± 12** 
] 0.028 
 102±12 
] 0.134 
99±24 
] 0.209 
 
end CR 110 ± 18 92 ± 11  109±17 107±21  
Δ HR at AT (%) 12 ± 20  8 ± 11  0.577 8±17  9±20  0.930 
VE/VCO2 slope           
start CR 31 ± 5 
] 0.092 
35 ± 7 
] 0.422 
 30 ± 7 
] 0.101 
36 ± 5* 
] 0.012 
 
end CR 30 ± 6 35 ± 8  28 ± 5 32 ± 4  
Δ VE/VCO2 slope (%) -4 ± 12  -2 ± 12  0.553 -5 ± 13  -9 ± 8  0.186 
6MWD (m)           
start CR 472 ± 62 
] <0.001 
359 ± 76*** 
] <0.001 
 430 ± 69 
] <0.001 
394 ± 92 
] <0.001 
 
end CR 582 ± 73 460 ± 93  551 ± 90 478 ± 108  
Δ 6MWD (%) 24 ± 13  30 ± 24  0.501 29 ± 13  22 ± 13  0.021 
Data are presented as mean ± SD. Differences in baseline exercise capacity between low-/medium-risk and high-risk groups are presented with an asterisk *p<0.05**p<0.01 ***p<0.001. 
CR, cardiac rehabilitation; Diff, difference; HR at AT, heart rate at the anaerobic threshold; Δ HR at AT (%), percentage of improvement in the HR at AT after exercise training; Δ load (%), 
percentage of improvement in load after exercise training; Δ peak VO2 (%), percentage of improvement in peak VO2 after exercise training; Δ VE/VCO2 slope (%), percentage of 
improvement in VE/VCO2 slope after exercise training.Δ6MWD (%), percentage of improvement in 6MWD after exercise training. 
  
Research Part 3 – Chapter 8 
173 
 
 
 
 
Figure 2. Exercise capacity and training benefits according to the type of surgery 
Exercise capacity after valvular surgery - expressed as the peak VO2 and VE/VCO2 slope- is shown at the start 
and end of the cardiac rehabilitation program, according to the type of surgery. Variables are presented as the 
mean ± SD in the table. The improvement in exercise capacity is presented in percentage (%) above the bars in 
each group separately, significance levels are indicated with an asterisk (*p<0.05 **p<0.01 and ***p<0.001). 
Differences in training benefits between the types of surgery are shown on top of the figure.  
CR, cardiac rehabilitation. 
 
Differences in exercise capacity early after surgery and in functional improvement after cardiac 
rehabilitation according to the type of surgery are shown in Figure 2. As the results for load, AT and 
6MWD were comparable with peak VO2, only the results of peak VO2 and VE/VCO2 slope are shown 
in Figure 2. In MVS, patients who had port access performed significantly better at baseline regarding 
peak VO2 and VE/VCO2 slope (overall p <0.05) as compared with patients who had sternotomy with 
or without CABG (p<0.05). In AVS, baseline exercise capacity was also different (overall p<0.05) but 
only between ministernotomy patients and patients who had a sternotomy with CABG (p<0.05). No 
significant difference in baseline exercise capacity was found between the groups who had a 
ministernotomy or a sternotomy for valve surgery, except for the VE/VCO2 slope (p<0.01). Exercise 
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training resulted in an improvement in load, peak VO2, AT and 6MWD for each type of surgery, in 
AVS or MVS (all p<0.05). However, only in patients who had sternotomy for AVS in combination with 
CABG, a small but significant decrease in the VE/VCO2 slope was seen (p<0.05). The gain in exercise 
capacity was comparable for the 3 types of surgery, both for patients after AVS or MVS.  
 
4 Discussion 
 
The main novel finding of this study is that exercise capacity after valvular surgery is related to the 
preoperative risk and to the type of surgery. However, a similar benefit from exercise training can be 
obtained, independent of the preoperative risk class or the type of surgery. Therefore, exercise 
training should be offered to all patients after valvular surgery, regardless their EuroSCORE risk (low 
or high risk) or type of surgery (classic sternotomy or minimal invasive surgery). 
 
Our study results revealed that patients who had a high preoperative risk, had also the worst 
exercise capacity early after surgery. As exercise performance does not recover spontaneously after 
valvular surgery,1-3 exercise training is recommended, in particular in this high-risk group. In this 
study, all patients were included in a cardiac rehabilitation program irrespective of their risk profile. 
Although exercise capacity at the end of the training program remained the lowest in patients at high 
risk, their benefit from exercise training was similar to that obtained in other risk groups. In 
literature, peak VO2 is the most frequently used parameter to evaluate functional improvements 
after an intervention. In this study, the improvement in peak VO2 ranged from 18% to 28% according 
to their preoperative risk profile, respectively, which is in accordance with previous studies in heart 
valve patients and other cardiac patient groups.7-10 Besides peak VO2, also other exercise variables 
were evaluated, more specifically the load, AT, 6MWD and VE/VCO2 slope. In contrast to the other 4 
variables, modest changes were observed in the VE/VCO2 slope. This may be due to the different 
physiologic properties of this parameter as compared with the peak VO2,
11
 but also to the applied 
exercise training program. Studies regarding the influence of the intensity and the type of exercise 
training on the VE/VCO2 slope after heart valve surgery are currently lacking. An alternative 
explanation may be the intrinsic characteristics of this study population. In this study, no patients 
with severe signs of decompensation were included, as expressed by the relatively low levels of N-
Terminal pro-brain natriuretic peptide, and the VE/VCO2 slope has been shown to be increased 
specifically in heart failure patients. Previous research has indicated that patients after AVS have a 
better exercise performance as compared with patients after MVS, even 6 months after surgery.12 To 
exclude potential differences due to the type of valve disease, the effects of the preoperative risk on 
exercise performance were also assessed for aortic and mitral valve disease separately. Although in 
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both types of valve disease the high-risk group appeared to have a lower level of baseline exercise 
performance, there was only a distinct difference between the risk groups in mitral valve disease. 
Training benefits however, were similar between the risk groups in both types of valve disease.  
 
This study shows that patients after minimal invasive surgery have a better exercise performance 
early after surgery than patients who had a sternotomy, but these findings should be interpreted 
with caution. In mitral valve patients, a better exercise capacity is seen in patients who had a port 
access as compared with a sternotomy, despite whether it was combined with CABG or not. In aortic 
valve patients, patients after ministernotomy performed better than those who had sternotomy with 
a concomitant CABG. This could implicate that a ministernotomy, in contrast to a port access, is not 
always a less invasive procedure than a sternotomy.  However, age could be an additional factor to 
explain these results. In the mitral valve group, patients who had a port access were considerably 
younger than their counterparts. In the aortic valve group, patients who underwent a 
ministernotomy differed in age from those who had a sternotomy with concomitant CABG. As 
patients who had minimal invasive surgery performed relatively well early after surgery with a peak 
VO2 of 21 ml.min
-1.kg-1 on average, one could suggest there is no need for exercise training in this 
particular group. In contrast, this is not an excellent result for a young, otherwise healthy population 
with a preserved systolic function and may thus indicate an impaired exercise capacity. In addition, 
these patients also had a benefit of exercise training that was comparable with the training effects in 
patients after invasive surgery. These findings indicate that all patients should be advised to attend 
cardiac rehabilitation, regardless of their type of surgery.   
 
This study has several limitations. No data on the preoperative exercise capacity were available. 
However, maximal exercise testing is often contraindicated in high-risk patients before surgery (e.g. 
patients with severe aortic valve stenosis). The inclusion of patients with valvular regurgitation and 
stenosis may have affected postoperative remodeling and exercise capacity. The lack of a comparison 
with a control group to evaluate spontaneous recovery after surgery is another shortcoming. 
Nevertheless, other studies have already demonstrated that there is no or little spontaneous 
improvement in exercise capacity after valvular surgery.1-3 Since the study was performed between 
2007 and 2012, EuroSCORE I instead of EuroSCORE II has been used with a potential overestimation 
of the risk as a result.13 As fewer than 1/2 of eligible cardiovascular patients actually benefit from 
cardiac rehabilitation in most European countries,14 a potential selection bias toward healthier 
patients could not be excluded. Frequency and length of the training period were varying between 
patients, which may be a barrier for standardisation of the training protocol. Despite this variation 
between patients, no significant difference was found between the patient groups, thereby excluding 
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a potential confounding effect on the results. A small number of patients in some subgroups may 
have led to underpowered results, in particular in the risk analyses, stratified by valve disease. 
Therefore, these results should be interpreted with caution. This study was only focused on the 
ventilatory gains after exercise training, future research should also evaluate the potential benefits 
on body weight, lipid profile and quality of life. 
 
Acknowledgment: We would like to thank the cardiac rehabilitation team of AZ Maria Middelares 
Ghent en Onze-Lieve-Vrouw Hospital Aalst for their contribution to data collection. 
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1 Introduction  
 
Exercise intolerance, characterized by fatigue and dyspnoea, is a key phenomenon in HF but is also 
present in other cardiac diseases. It is an ominous sign for a poor prognosis, whose mechanisms are 
not completely understood thus far. Cardiac rehabilitation has been proven to affect exercise 
intolerance by acting on its determinants, however, it is not clear whether its effectiveness is 
determined by left ventricular function or neurohormonal activation. Despite the clear benefits of 
CR, figures on participation and drop-out in CR are disappointing. Although exercise intolerance is 
seen also in VHD patients, exercise training has received little attention in this patient group at 
present.  
 
This work is composed of three parts, each focusing on a different aspect of exercise intolerance and 
its treatment. The first part aims to gain insight in the pathophysiological mechanisms underlying 
exercise intolerance, in particular in the reflex mechanism arising from the muscle, i.e. the 
ergoreflex. The second part describes the clinical characteristics and short-term outcome of 
hospitalized HF patients together with the effects of an exercise training program in patients with a 
wide range of left ventricular function and neurohormonal activation. Barriers in the implementation 
of CR including attendance and adherence to CR are discussed in the last part, together with a 
chapter focused on exercise capacity and the value of exercise training in VHD.  
 
2 Exercise intolerance in heart failure: mechanisms and relevance of the ergoreflex 
 
2.1  Main findings 
 
The primary aim of this study was to evaluate the presence of ergoreflex activity and its current 
relationship to exercise intolerance and subsequent prognosis in a broad spectrum of subjects. We 
evaluated healthy subjects (n=29), patients with CAD (n=25) and HF patients (n=51). Ergoreflex 
activity turned out to contribute to hyperventilation only in those HF patients with persistent 
symptoms despite optimal medical treatment. In addition, ergoreflex activity was closely associated 
with the MAGGIC mortality risk score, thereby emphasizing the link with the severity of HF. In 
contrast, ergoreflex activity was not present in healthy subjects and neither in patients with CAD or 
stable HF.  
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2.2 Clinical implications 
 
The introduction of ACE-inhibitors and β blockers as a standard of care in HF may have influenced the 
results presented in this work. Both drugs are known to influence neurohormonal activation and a 
decrease in the ventilatory slope has already been described in literature.1-4 It may therefore be 
possible that ergoreflex activation in HF patients was lower in this study compared with earlier 
studies owing to the prescribed medication. Nevertheless, a substantial part of HF patients did have 
ergoreflex activation in spite of the use of aforementioned medication, suggesting that this 
mechanism becomes upregulated late in the disease process. This late presentation is also related to 
a poor prognosis, with ergoreflex activation being present in those patients who have an 
intermediate or high mortality risk according to the MAGGIC score and in those patients  who have a 
peak VO2 < 14 ml.min
-1.kg-1 and a VE/VCO2 slope > 45.
5 The presence of ergoreflex activity may be a 
signal to reconsider the patient’s condition and his treatment.  
 
Despite its link with prognosis in patients with increasing disease severity, this parameter is not 
appropriate to evaluate outcome in the early onset of this disease and for this reason cannot be used 
among a broad spectrum of cardiac patients. The presence of a slightly increased VE/VCO2 slope in 
patients who did not present with ergoreceptor activation, i.e. patients with CAD and a subgroup of 
stable HF patients, may suggest that other mechanisms are responsible for the early onset of this 
increased ventilatory drive.  
 
2.3 Strengths and limitations 
 
The main strength of our study was that we did not focus on a particular subgroup of cardiac 
patients, but tried to evaluate the ergoreflex activation among a broad spectrum of subjects. This 
approach has led us to suggest that under current medical treatment, the activation of the 
ergoceptors becomes present only late in the disease process. Nevertheless, longitudinal studies 
should investigate the precise onset of ergoreflex activation during the disease process.   
 
As already previously mentioned, it is possible that the use of some pharmacological agents has 
influenced our results. In our opinion, however, it was more clinically relevant to assess patients who 
were treated according to the current medical guidelines than to interrupt their treatment. In clinical 
practice, a patient’s state is also interpreted taking into account his treatment, e.g. in the 
interpretation of cardiopulmonary exercise testing.  
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Due to the relatively small sample size, it was not possible to assess outcome. Therefore, the 
MAGGIC mortality risk score was used, but this cannot replace outcome analyses regarding short or 
long-term prognosis, which should be subject of further studies.  
 
2.4 Future prospects 
 
Because ergoreflex activity represents a poor prognosis, longitudinal studies in patients with 
asymptomatic left ventricular dysfunction are necessary to investigate the precise onset of ergoreflex 
activation during the course of the disease. This onset may also indicate when the current treatment 
is failing and perhaps more intensive treatment is warranted. Given the changes in pharmacological 
treatment, larger longitudinal studies are also needed  to evaluate its influence on outcome properly.  
 
In addition, since research has focused solely on HFREF patients thus far, a thorough investigation on 
the underlying mechanisms of exercise intolerance including ergoreflex activation is necessary in 
HFPEF patients. Since ergoreflex activity also contributes to the blood pressure response, a second 
point of interest may be to explore the role of ergoreflex activation in hypertensive patients and 
moreover, how renal denervation may have an influence on this mechanism.  
 
Furthermore, the current pharmacological agents that are thought to influence ergoreflex activity, 
such as β blocker therapy, need to be further analyzed on how they could possibly affect this 
mechanism.  In addition, the effects of more advanced therapeutic modalities such as CRT, should be 
considered. The improvement in exercise capacity which is seen after CRT implantation is thought to 
be partially driven by peripheral changes6 and a small non-randomized study revealed already a 
decrease in ergoreflex activation after CRT implantation.7 Similar results were obtained in a subgroup 
of our patient population who received CRT implantation (n=8), with a decrease in ergoreflex activity 
six months after implantation. However, further studies are necessary to entirely investigate the 
underlying mechanisms in both responders and non-responders to CRT.  
 
Another interesting topic remains which mechanisms are responsible for the increased ventilatory 
response in patients not having an increased ergoreflex activation. These may include 
chemoreceptor activation,8 but also disturbances occurring at the lung level.3, 9, 10 and should be the 
focus of further research. 
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3 Outcome and the key role of exercise training in heart failure 
 
3.1 Main findings 
 
In order to investigate the characteristics and outcome of patients admitted with HF in Belgium, the 
BIO-HF registry was used (n=904). Our registry consisted mainly of elderly patients, of whom 60% 
presented with a preserved LVEF or only a moderately reduced LVEF. LVEF did not predict outcome 
with a similar event rate for mortality and rehospitalisation in both patients with reduced and 
preserved LVEF. Short-term outcome was rather driven by the absence of β blocker prescription at 
discharge and the presence of different comorbidities.  
 
In the second chapter of this part, the role of left ventricular function and neurohormonal activation 
in exercise intolerance and the effect of an exercise training program among a broad spectrum of 
CAD patients were analyzed, based on data from the Cardiac Rehabilitation Database (n=581). 
Exercise capacity was slightly worse in patients with a reduced ejection fraction compared with those 
with a preserved ejection fraction which is in line with previous observations.11 More importantly, a 
similar decrease in exercise capacity was seen in both groups with increasing neurohormonal 
activation. Exercise training improved exercise capacity regardless of this initial left ventricular 
function or neurohormonal activation . 
 
3.2 Clinical implications 
 
The BIO-HF registry is the first registry to report on clinical characteristics and outcome in 
hospitalized HF patients for Belgium. Our findings indicate a comparable trend as in larger 
international registries with a growing number of elderly patients with HFPEF, a population for who 
scientific evidence regarding optimal treatment is limited at present. A similar unfavorable outcome 
was seen in both groups of LVEF, which was mainly driven by the absence of β blocker prescription 
and the presence of different comorbidities. Therefore, more attention is needed for a systematic 
screening of comorbidities such as COPD when evaluating a patient’s clinical state. In addition, since 
β blockers had a positive effect on outcome irrespective of the presence of COPD, this should not be 
a reason for not giving β blocker therapy. 
 
The observation concerning the increasing prevalence of HFPEF with a similar detrimental outcome 
as HFREF, led us to the second chapter of this part. The predominant role of neurohormonal 
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activation in exercise capacity, may further confirm the findings of Van Veldhuisen et al.,12 who 
stated that neurohormonal activation may be the primary driver of outcome instead of LVEF. As a 
result, patients in the highest level of neurohormonal activation, which may suggest the presence of 
HF, had a similar level of exercise intolerance regardless of their left ventricular function. Thus, 
patients with HFPEF may have a similar impaired exercise capacity as those with HFREF. However, 
they are currently not included in the Belgian reimbursement guidelines for cardiac rehabilitation. 
Our results have shown that an improvement in exercise capacity is possible after following an 
exercise training program, irrespective of left ventricular function or neurohormonal activation. 
Therefore, exercise training may be an effective treatment modality also in HF patients with 
preserved ejection fraction.  
 
3.3 Strengths and limitations 
 
The lack of nationwide registers makes it difficult to generalize our results, but we think that our data 
reflect the real-life situation in Belgium due to the fairly large sample size in both datasets and the 
consecutive inclusion over a longer time period.  
 
Since patients with HFPEF are not eligible for inclusion in cardiac rehabilitation, it is difficult to 
evaluate the effect of exercise training in this group. Our work tries to provide an alternative by 
evaluating both patients with reduced and preserved LVEF according to the level of neurohormonal 
activation. This approach is similar to Van Veldhuisen et al.12, who studied prognosis in HF according 
to natriuretic peptides across a wide range of LVEF. They stated that the use of natriuretic peptides 
to define HF may be an alternative to the strict echocardiographic criteria which are often difficult to 
measure and therefore not always useful for daily practice. However, these echocardiographic 
criteria remain the golden standard and should be included in further studies regarding exercise 
training in HFPEF. Another weakness is that  our study population was restricted to CAD patients and 
is thus not representative for all HF patients.  
 
3.4 Future prospects 
 
Our findings regarding outcome should be interpreted with caution since only short-term outcome 
was considered and therefore, future studies are planned within the BIO-HF framework to assess 
one-year outcome and to see whether different characteristics or comorbidities may play a role in 
the long term. In addition, the role of neurohormonal activation in outcome will be investigated in 
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the entire study population as well as among subgroups including HF patients with reduced and 
preserved ejection fraction, and patients with different etiologies of HF.  
 
Furthermore, since the objective of the BIO-HF registry is to collect data over a period of ten years, 
time trends will be assessed regarding in-hospital mortality, one-year outcome and treatment 
modalities (e.g. medication prescription) .   
 
Because of the prognostic importance, a systematic screening for comorbidities should be performed 
on admission to the hospital. Currently, knowledge on comorbidities is based on self-recorded 
information or extracted from chart review, which makes it difficult to evaluate adequately the 
prevalence of these comorbidities and their impact on prognosis. Future therapeutic guidelines 
should also pay attention on how to deal with these comorbidities in HF patients to improve 
outcome. A closer cooperation with other disciplines within medicine is essential to provide an 
optimal treatment of comorbidities such as COPD and diabetes among the HF population. A detailed 
registration of the reasons for non-prescription of evidence-based medication is also planned to 
further improve the quality of care in HF patients. 
 
The increasing prevalence and poor prognosis of HFPEF patients indicates the urgent need for novel 
treatment strategies. The results of our study indicate that exercise training may be a valuable part 
of this treatment,  however, this should be further confirmed in larger randomized controlled trials. A 
new approach in the government guidelines concerning the reimbursement criteria for cardiac 
rehabilitation is necessary, so that patients with HFPEF may have equal access to CR as patients with 
HFREF.  
 
4 Barriers in the implementation of cardiac rehabilitation 
 
4.1 Main findings 
 
Participation in CR is estimated to be low, in particular in HF patients but concrete figures are lacking 
for Belgium. Therefore, we evaluated participation in CR among HF patients, by evaluating both the 
BIO-HF registry and the Cardiac Rehabilitation Database for a similar period. Overall one third of 
eligible patients attended CR, but only 9% of patients admitted with HF did participate in a CR 
program. This is far below the achieved participation rates in patients with ACS (29%) or cardiac 
surgery (56%). HF patients not participating in CR, were mainly elderly and female patients and those 
with a preserved LVEF. HF patients who actually did participate in CR, had an equal training benefit as 
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patients participating after ACS or cardiac surgery, despite their worse clinical status and lower 
exercise capacity at the start of the program.  
 
A second barrier which is often mentioned together with the low participation rate, is drop-out in CR. 
We evaluated drop-out, defined as attending ≤50% of the training sessions, and tried to identify 
potential predisposing factors. Patients who attended CR after ACS, cardiac surgery or HF were 
prospectively included (n=489). One fifth of this population quit in the first half of the program. 
Demographic nor clinical characteristics could independently identify patients who were at risk for 
drop-out. The presence of comorbidities such as COPD and CVA involved a higher risk for drop-out as 
well as the absence of β blocker use. In addition, a vulnerable psychosocial background seemed to 
play a key role with singles, patients who were dependent for transport and those reporting 
problems regarding anxiety and depression being more likely to withdraw prematurely.  
 
A different type of barrier than participation and drop-out, is the low number of studies that have 
been performed regarding exercise intolerance and the importance of exercise training among VHD 
patients. Current literature suggests that exercise capacity does not recover spontaneously after 
aortic valve surgery or mitral valve surgery.13-15 Together with the expected increase in degenerative 
VHD, this argues in favour of the need for more research regarding exercise training in this 
population. For that reason, the final study assessed exercise intolerance and the effects of exercise 
training after valvular surgery (AVS n=72 and MVS n=73), according to the preoperative risk profile as 
assessed by the EuroSCORE and to the type of surgery. Patients with a higher preoperative risk and 
those who had invasive surgery, had a worse postoperative exercise capacity. Despite these 
differences in postoperative exercise capacity, training resulted in a similar improvement regardless 
of this preoperative risk or type of surgery.  
 
4.2 Clinical implications 
 
Participation in CR among HF patients is poor and may be partly due to the national government 
guidelines restricting reimbursement for HFPEF. However, we think that also in HFREF attendance is 
suboptimal and should gain more attention, given the clear training benefits which have been 
demonstrated. Increasing awareness of the benefit of exercise training may optimize referral to CR 
but also adaptation of training schemes and modalities to the patient’s condition and preferences 
may be necessary to improve this low participation rate.16  
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The poor participation rate among elderly patients and women may be related to HFPEF, but also to 
the presence of comorbidities and differences in social status respectively. This could not be verified 
from our results but has been described in earlier studies.17 Though, we have demonstrated the 
impact of comorbidities and psychosocial factors on drop-out, which emphasizes the importance of a 
multidisciplinary approach in CR, taking into account all different aspects of the physical and mental 
well-being of a patient.  
 
Our results regarding VHD patients seem to indicate that patients after minimal invasive surgery 
perform better early after surgery. These findings should, however, be interpreted with caution 
because patients who had minimal invasive surgery were generally younger and the difference in 
exercise capacity did not apply to all subgroups of patients i.e. after aortic valve surgery. Despite 
their relatively worse exercise capacity, patients after invasive surgery had a similar training effect as 
those after minimal invasive surgery. The aforementioned findings suggest to further investigate the 
advantages of minimal invasive surgery compared with invasive surgery regarding exercise 
intolerance.  
 
4.3 Strengths and limitations 
 
The use of two parallel datasets in a single hospital gives us a unique opportunity to evaluate the 
attendance of HF patients to outpatient CR. As a result, we have an accurate figure concerning the 
participation rate instead of raw estimates. Another strength of our study was that we did not rely on 
reasons for drop-out given by patients, but rather prospectively collected potential predisposing 
factors. This approach has made it possible to identify those patients who were most vulnerable for 
drop-out, with a key role for comorbidities and psychosocial characteristics. Unfortunately, we did 
not have similar parameters concerning psychosocial characteristics at discharge from the hospital 
and we were thus not able to investigate their impact on the decision to attend CR.  
 
In our study in VHD patients, we performed our analyses separately for AV and MV patients in order 
to exclude potential differences due to the type of valve disease. However, we did not consider the 
impact of the underlying aetiology i.e. stenosis or regurgitation, which may have influenced our 
results. In addition, not all types of surgery were included (e.g. transcatheter aortic valve 
implantation, mitraclip) because of the small number of these procedures but these should be 
subject of further investigation.   
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4.4 Future prospects 
 
The current patient population that is candidate for attending CR is changing, with a growing part of 
elderly patients with comorbidities, suffering from complex pathologies and surgery, which makes 
cardiac rehabilitation more challenging. To date, cardiac rehabilitation programs are mostly based on 
an outpatient structure with little personal input of the patient. Future rehabilitation programs will 
have to deal with these novel patient characteristics and try to convene the patient’s needs and his 
preferences. Therefore, a more individual approach in CR which is not only focused on the heart 
disease but also takes comorbidities into consideration, may be necessary. The possibilities and 
safety of home-based cardiac rehabilitation with the use of telemedicine should also be further 
investigated. 
 
Since comorbidities are not only predictors of drop-out but also of a poor outcome, drop-out may 
indirectly represent an ominous sign for prognosis. Development of a risk stratification model, based 
on predictors for drop-out, would be helpful to screen patients from the early onset of CR and to 
provide an individual-tailored approach for those who are at risk for drop-out. In addition, the impact 
of drop-out on  outcome parameters including recurrent events and mortality, may be another point 
of investigation. Psychosocial characteristics seem to influence drop-out similar to comorbidities, 
therefore, it would be interesting to register these characteristics already during the hospital stay to 
evaluate their influence on the decision to attend CR. 
 
Since the prevalence of VHD continues to increase with increasing life expectancy, more studies are 
needed to gain knowledge on the underlying mechanisms of exercise intolerance in VHD. 
Furthermore, the impact of surgical interventions with inclusion of  novel treatment modalities such 
as mitraclip and transcatheter aortic valve implantation has to be further explored as well as  the role 
of exercise training. Currently, most rehabilitation programs in VHD are routinely based on 
prescriptions which were originally intended for HF or CAD patients. Therefore, future guidelines for 
VHD should include recommendations on the role of CR, specifically adapted to the characteristics of 
VHD patients. 
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5 Conclusion 
 
The studies presented in this thesis have contributed to the knowledge on three different but related 
domains of exercise intolerance and its treatment. 
 
The work presented in the first part has provided new information on the underlying mechanisms of 
exercise intolerance. We have demonstrated that ergoreflex activity contributes to hyperventilation 
only in those HF patients with persistent symptoms. Despite its link with the MAGGIC mortality risk 
score in patients with increasing disease severity, this parameter is not appropriate to evaluate 
outcome among a broad spectrum of cardiac patients. Mechanisms other than ergoreflex activity 
may be responsible for the early onset of the increased ventilatory drive. 
 
Analysis of the BIO-HF registry has demonstrated an increasing prevalence of HFPEF patients with a 
similar outcome as patients with HFREF, indicating an urgent need for novel treatment strategies. 
Similar to outcome, a comparable trend towards a decrease in exercise capacity was seen in both 
groups of left ventricular function with increasing neurohormonal activation. Exercise training has 
been shown to improve exercise capacity regardless of this initial left ventricular function or 
neurohormonal activation and may therefore be an effective treatment modality also in HFPEF 
patients, a group which is currently not included for reimbursement in the Belgian legislation. Our 
study has also emphasized the link between comorbidities and outcome, which should be taken into 
consideration for future efforts to improve outcome. 
 
The studies regarding the implementation of cardiac rehabilitation in clinical practice, have revealed 
that participation is poor, in particular among HF patients. In addition, one fifth of those patients 
actually attending CR, quit in the first half of the program with a predisposing role for comorbidities 
and psychosocial factors. These findings emphasize the importance of a multidisciplinary approach in 
CR, but also that adaptations in the current training modalities may be necessary to improve this 
sobering numbers. Finally, our study in VHD patients has drawn attention to exercise intolerance and 
the benefit of exercise training in patients after valvular surgery, which is necessary given the 
increasing prevalence that is expected with increasing life expectancy.  
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Cardiovascular disease remains the leading cause of death worldwide, but a better prevention and 
treatment policy has led to a decrease in mortality in coronary artery disease (CAD). Together with 
the ageing of the population, this success in secondary prevention and prolonging survival in patients 
suffering from coronary events, may contribute to the increasing overall prevalence of heart failure 
(HF). CAD is by far the most common cause of HF, but also other diseases including valvular heart 
disease (VHD) may eventually lead to HF. VHD is usually less regarded as a major public-health 
problem, however a substantial burden of this disease exists and will probably further increase, due 
to increasing life expectancy.  
 
Exercise intolerance is a hallmark feature of HF and indicates a poor prognosis, but its origin is not 
completely understood thus far. Likewise, an impaired exercise capacity is also present in CAD and 
VHD patients with a similar prognostic value. Cardiac rehabilitation (CR) has been recommended in 
both CAD and HF but is currently not mentioned in the management guidelines on VHD. Despite its 
clear benefits, figures on participation in CR are disappointing.  
 
This thesis is composed of three parts, each focusing on a different aspect of exercise intolerance and 
its treatment. The general aim was to obtain knowledge on the underlying mechanisms of exercise 
intolerance, both in patients with and without HF and to evaluate the outcome in HF and the effects 
of an exercise training program in a broader cardiac patient population. In addition, barriers in the 
implementation of cardiac rehabilitation were further explored in this work.  
 
HF is marked by an interplay between the underlying myocardial dysfunction and the compensatory 
neurohormonal mechanisms, including the sympathetic nervous system. Neurohormonal activation, 
which is driven by peripheral reflex mechanisms, is thought to play a key role in exercise intolerance. 
It is remarkable that a reflex arising from the exercising muscle, i.e. the ergoreflex, may influence 
both fatigue and dyspnoea, being the major characteristics of exercise intolerance in HF. Therefore, 
the first part handles about exercise intolerance and its mechanisms with a focus on this muscle 
reflex. The role of the autonomic nervous system in the development of HF has been described in the 
first chapter of this work. The second chapter provides an overview on prognostically important 
cardiopulmonary exercise variables, such as the peak VO2 and the VE/VCO2 slope, and their 
determinants. The third chapter reports on the presence of ergoreflex activity and its current relation 
to exercise intolerance and subsequent prognosis in a broad spectrum of subjects, ranging from 
healthy subjects (n=29) and patients with CAD (n=25) to HF (n=51). Our findings have demonstrated 
that ergoreflex activation contributes to hyperventilation only in HF patients with persistent 
symptoms despite optimal medical treatment. In addition, the presence of ergoreflex activity was 
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closely associated with parameters of exercise intolerance and an increased mortality risk, thereby 
emphasizing the link with the severity of HF and prognosis.  In contrast, ergoreflex activity was not 
present in healthy subjects and neither in patients with CAD or stable HF. This may suggest that this 
mechanism may become upregulated with increasing disease severity but is not responsible for the 
early onset of an increased ventilatory drive.  
 
For the second and third part of this thesis, two datasets were used i.e. the Belgian BIO-HF registry, 
collecting data from hospitalized HF patients, and the Cardiac Rehabilitation database, a 
multidisciplinary registry collecting data from the diverse population that participates in CR.  
 
The second part focuses on outcome in HF and exercise training as an effective treatment modality. 
Despite improvements in the treatment of HF, mortality and readmission rates remain high but 
figures for Belgium are lacking. In the fourth chapter, clinical characteristics and short-term outcome 
of hospitalized HF patients in Belgium (n=904) were assessed. Patients admitted with HF were mainly 
elderly patients with a relatively preserved left ventricular ejection fraction (LVEF), indicating the 
increasing prevalence of heart failure with preserved ejection fraction (HFPEF). In-hospital and short-
term mortality after discharge were high, both 7% on an average, with short-term mortality being 
related to the absence of β blocker use and the presence of comorbidities rather than to LVEF. 
Comorbidities should therefore be the focus for further studies to improve outcome. The observation 
concerning the increasing prevalence of HFPEF with a similar outcome as HFREF, led us to the fifth 
chapter of this work which investigated the influence of LVEF and neurohormonal activation, as 
assessed by NT-proBNP, on exercise capacity and the effectiveness of exercise training among a 
broad spectrum of CAD patients (n=581). Our results have shown that exercise capacity shows a 
similar decrease with increasing neurohormonal activation, irrespective of left ventricular function. 
As a result, patients with the highest level of neurohormonal activation which may suggest the 
presence of HF, had a similar level of exercise intolerance in both groups of LVEF. Similar to outcome, 
this may indicate that neurohormonal activation is the primary driver of exercise capacity rather than 
LVEF. Moreover, exercise training resulted in an improvement in exercise capacity irrespective of 
neurohormonal activation or LVEF and may therefore be an effective treatment modality also in 
HFPEF, a group that is currently not included for reimbursement in the Belgian legislation. 
 
CR has been recommended to improve exercise intolerance, health-related quality of life and 
prognosis but encounters several barriers in the implementation in the ‘real life’ setting, which are 
the focus of the third part of this work. Participation is poor in particular in HF, but concrete figures 
are lacking for Belgium. Therefore, we evaluated participation among HF patients in the sixth 
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chapter. Barely one out of ten patients admitted with HF did participate in CR which is far below the 
participation rates after acute coronary syndrome or cardiac surgery. Non-attendance to CR among 
HF patients was primarily related to age, female gender and a preserved LVEF. Nevertheless, HF 
patients who did actually participate in CR had an equal training benefit as patients after acute 
coronary syndrome or cardiac surgery. This low participation rate may be partly due to the restriction 
of reimbursement regarding HFPEF but also in HFREF attendance may be suboptimal. These findings 
emphasize the urgent need to increase awareness regarding the benefits of CR but also that 
adaptation of the current training modalities may be necessary to improve attendance to CR. In the 
seventh chapter, early withdrawal from CR was assessed among a population consisting of HF 
patients, patients after acute coronary syndrome and cardiac surgery (n=489). One fifth of this 
population quit in the first half of the program with a predisposing role for comorbidities and a 
vulnerable psychosocial background. Therefore, a multidisciplinary approach in CR is indispensable, 
taking into account all different aspects of the physical and mental well-being of a patient. Because 
of the expected increase in degenerative valvular heart disease (VHD) with increasing life expectancy, 
more attention is warranted concerning exercise intolerance and the effects of exercise training in 
this patient population. Our final study has provided additional information on this topic by 
evaluating the postoperative exercise capacity and the benefits of exercise training after valvular 
surgery (n=145), according to the preoperative risk profile and the type of surgery. Patients with a 
higher preoperative risk and those who had invasive surgery, had a worse postoperative exercise 
capacity. However, this should be interpreted with caution since this advantage regarding minimal 
invasive surgery was not applicable to all types of patients and a potential confounding effect of age 
was possible. Moreover, exercise training resulted in an improvement in exercise capacity, regardless 
of this preoperative risk profile or type of surgery. Our findings suggest to further investigate exercise 
intolerance, the impact of surgical interventions and the role of exercise training in this patient 
population. 
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Cardiovasculaire aandoeningen blijven wereldwijd de belangrijkste doodsoorzaak, maar de 
vooruitgang in behandeling en het preventiebeleid voor coronair lijden hebben geleid tot een daling 
in sterfte. Samen met de vergrijzing van de bevolking, heeft dit succes in secundaire preventie en de 
verbeterde overlevingskansen voor patiënten die lijden aan coronaire aandoeningen er mede toe 
geleid dat er een toename is in de prevalentie van hartfalen (HF). Coronair lijden is veruit de 
belangrijkste oorzaak van HF, maar ook andere hartaandoeningen zoals kleplijden kunnen 
uiteindelijk leiden tot de ontwikkeling van HF. Kleplijden wordt doorgaans minder aanzien als een 
bedreiging voor de maatschappelijke gezondheid, hoewel er een aanzienlijk aantal patiënten lijdt aan 
deze aandoening en dit aantal naar de toekomst hoogstwaarschijnlijk nog verder zal toenemen door 
de stijgende levensverwachting.  
 
Inspanningsintolerantie is een hoofdkenmerk van HF en wijst op een slechte prognose, maar de 
onderliggende mechanismen zijn tot op heden nog niet volledig gekend. Bij patiënten met coronair 
lijden en kleplijden is er eveneens sprake van een beperkte inspanningscapaciteit met een 
gelijkaardige prognostische waarde. Cardiale revalidatie (CR) wordt aanbevolen bij zowel patiënten 
met coronair lijden als patiënten met HF, maar wordt niet vermeld in de therapeutische richtlijnen 
voor patiënten met kleplijden. Ondanks de bewezen voordelen van CR, zijn de cijfers rond 
participatie teleurstellend.  
 
Deze thesis is opgebouwd uit drie delen, die elk gericht zijn op een ander aspect van 
inspanningsintolerantie en de behandeling ervan. Het voornaamste doel was om kennis te verwerven 
over de onderliggende mechanismen van inspanningsintolerantie, zowel in patiënten met als zonder 
HF, alsook om de prognose bij HF patiënten te bestuderen en de effecten van een 
trainingsprogramma in een bredere cardiale patiëntenpopulatie. In het laatste deel van dit werk 
werden barrières bij de huidige toepassing van cardiale revalidatie besproken. 
 
HF wordt gekenmerkt door een samenspel van de onderliggende cardiale dysfunctie en de 
compensatoire neurohormonale mechanismen, waaronder het sympathisch zenuwstelsel. Er wordt 
aangenomen dat neurohormonale activatie dat gemedieerd wordt door perifere reflexen, een 
belangrijke rol speelt in het ontstaan van inspanningsintolerantie. Het is opvallend dat een reflex die 
zijn oorsprong vindt in de werkende spieren, namelijk de ergoreflex, zowel vermoeidheid als 
kortademigheid zou kunnen beïnvloeden, wat de twee voornaamste karakteristieken zijn van 
inspanningsintolerantie bij HF. Daarom handelt het eerste deel van deze thesis over 
inspanningsintolerantie en de onderliggende mechanismen met de nadruk op de ergoreflex. De rol 
van het autonoom zenuwstelsel in de ontwikkeling van HF wordt beschreven in het eerste hoofdstuk 
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van dit werk. Het tweede hoofdstuk geeft een overzicht van de belangrijkste prognostische 
inspanningsparameters, zoals de peak VO2 en de VE/VCO2 slope, en hun determinanten. Het derde 
hoofdstuk evalueert de aanwezigheid van ergoreflexactiviteit en de huidige relatie met 
inspanningsintolerantie en prognose in een breed spectrum van proefpersonen, gaande van gezonde 
personen (n=29) en patiënten met coronair lijden (n=25) tot patiënten met HF (n=51). Onze 
resultaten hebben aangetoond dat ergoreflex activatie bijdraagt tot hyperventilatie, maar enkel in HF 
patiënten die symptomen blijven vertonen ondanks een optimaal medicamenteus beleid. Daarnaast 
was de aanwezigheid van ergoreflexactiviteit gerelateerd aan inspanningsintolerantie en een 
toegenomen kans op sterfte, waardoor het verband met de ernst van HF en de prognose benadrukt 
werd. In gezonde proefpersonen, patiënten met coronair lijden en patiënten met stabiel HF was er 
echter geen teken van ergoreflex activatie. Deze bevindingen zouden erop kunnen wijzen dat dit 
mechanisme pas actief wordt bij toenemende ziekte ernst maar niet verantwoordelijk is voor het 
allereerste begin van een toegenomen ventilatie. 
 
Voor het tweede en derde deel van deze thesis werd gebruik gemaakt van 2 datasets, namelijk de 
BIO-HF registry die data verzamelt van gehospitaliseerde HF patiënten, en de Cardiac Rehabilitation 
Database, dat een multidisciplinair register is waarin data worden verzameld van de 
patiëntenpopulatie die deelneemt aan CR. 
 
Het tweede deel is gericht op de prognose van HF patiënten en training als een effectieve 
behandeling. Ondanks de verbeteringen in de behandeling van HF, blijven de sterfte – en 
hospitalisatiecijfers hoog, maar concrete gegevens voor België zijn momenteel niet beschikbaar. In 
het vierde hoofdstuk worden de klinische karakteristieken en korte termijn prognose geëvalueerd 
van gehospitaliseerde HF patiënten (n=904). Patiënten die opgenomen werden met HF, waren 
voornamelijk oudere patiënten met een relatief goed bewaarde linkerventrikel ejectiefractie (LVEF), 
wat wijst op een toename in hartfalen met bewaarde ejectiefractie (HFPEF). Zowel de sterfte tijdens 
hospitalisatie als op korte termijn na ontslag uit het ziekenhuis was hoog, beiden gemiddeld 7%, 
waarbij de korte termijn prognose gerelateerd was aan de afwezigheid van β blocker gebruik en de 
aanwezigheid van comorbiditeiten maar niet aan LVEF. De toename in prevalentie van HFPEF met 
een gelijkaardige prognose als patiënten met HFREF, heeft geleid tot het vijfde hoofdstuk waarin de 
invloed werd onderzocht van LVEF en neurohormonale activatie, gemeten d.m.v. NT-proBNP, op 
inspanningscapaciteit en de effectiviteit van training bij een brede patiëntenpopulatie met coronair 
lijden (n=581). Onze resultaten hebben aangetoond dat inspanningscapaciteit een daling kent met 
toenemende neurohormonale activatie, die gelijklopend is in zowel patiënten met gedaalde als 
bewaarde LVEF. Dit betekent dan ook dat bij patiënten met de grootste neurohormonale activatie, 
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wat kan wijzen op de aanwezigheid van HF, er een gelijkaardige mate van inspanningsintolerantie 
bestaat in beide groepen van LVEF. Dit zou er kunnen op wijzen dat inspanningscapaciteit net zoals 
prognose eerder bepaald wordt door neurohormonale activatie dan door LVEF. Daarenboven heeft 
het volgen van een trainingsprogramma geleid tot een verbetering in inspanningscapaciteit die 
losstaat van de initiële neurohormonale activatie of LVEF. Dit betekent dat training ook een 
effectieve behandeling kan zijn in HFPEF, een groep die momenteel nog niet in aanmerking komt 
voor terugbetaling volgens de Belgische wetgeving. 
 
CR wordt aanbevolen om de inspanningscapaciteit te verbeteren alsook de gezondheidsgerelateerde 
levenskwaliteit en de prognose, maar er zijn verschillende barrières bij de toepassing ervan in de 
klinische praktijk, die dan ook het onderwerp vormen van het derde deel van dit werk. De 
participatiegraad in CR is laag, in het bijzonder bij HF patiënten maar concrete cijfers ontbreken in 
België. Om deze reden hebben we participatie bij HF patiënten onderzocht in het zesde hoofdstuk. 
Amper 9%  van de patiënten die opgenomen werden met HF, participeerden in CR wat ver beneden 
de deelnamecijfers ligt bij patiënten met acuut coronair syndroom of cardiale chirurgie. Deze lage 
participatiegraad was voornamelijk gerelateerd aan een hoge leeftijd, het vrouwelijke geslacht en 
een bewaarde LVEF. Desalniettemin vertoonden de HF patiënten die toch deelnamen aan CR een 
gelijk trainingseffect als patiënten die deelnamen na acuut coronair syndroom of cardiale chirurgie. 
Deze lage participatiegraad kan deels te wijten zijn aan de beperking in terugbetaling voor patiënten 
met HFPEF maar ook de deelname bij HFREF is waarschijnlijk suboptimaal. Deze bevindingen 
benadrukken de nood aan een grotere bewustwording van de voordelen van CR maar ook dat een 
aanpassing van de huidige trainingsmodaliteiten misschien nodig is om de deelname in CR te 
verhogen. In het zevende hoofdstuk werd het vroegtijdig onderbreken van een 
revalidatieprogramma geëvalueerd in een patiëntenpopulatie bestaande uit HF patiënten, patiënten 
na acuut coronair syndroom en cardiale chirurgie (n=489). Een vijfde van deze populatie onderbrak 
het trainingsprogramma in de eerste helft, met een hoger risico voor patiënten met comorbiditeiten 
en een kwetsbare psychosociale achtergrond. Een multidisciplinaire aanpak in CR is dan ook 
noodzakelijk, waarbij rekening wordt gehouden met de verschillende aspecten van het fysieke en 
mentale welzijn van een patiënt. Omwille van de verwachte toename in degeneratief kleplijden met 
de stijgende levensverwachting, is er meer aandacht nodig voor inspanningsintolerantie en de 
effecten van training in deze patiëntenpopulatie. Onze laatste studie heeft hieromtrent nieuwe 
inzichten geleverd door  postoperatieve inspanningscapaciteit en de effecten van training na 
klepchirurgie (n=145) te bestuderen volgens het preoperatief risicoprofiel en het type van 
toegepaste chirurgie. Patiënten met een hoger preoperatief risico en diegene die invasieve chirurgie 
hadden gehad, bleken een slechtere postoperatieve inspanningscapaciteit te hebben. Toch moeten 
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deze resultaten met voorzichtigheid geïnterpreteerd worden, aangezien het voordeel dat patiënten 
met minimaal invasieve chirurgie leken te hebben niet van toepassing was op alle onderzochte 
patiënten en er mogelijks ook een beïnvloedend effect van de leeftijd heeft meegespeeld. Training 
resulteerde in een verbetering in inspanningscapaciteit, ongeacht het preoperatief risicoprofiel of het 
type van chirurgie. Verder onderzoek is dan ook nodig naar inspanningsintolerantie, de impact van 
chirurgische interventies en de rol van training in deze patiëntenpopulatie. 
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Tijdens de afgelopen jaren heb ik de kans gekregen om samen te werken met heel wat boeiende 
mensen, zonder wie dit proefschrift nooit tot stand zou zijn gekomen. Ik wil hen dan ook van harte 
bedanken. 
 
In de eerste plaats wil ik mij richten tot de patiënten die belangeloos hebben deelgenomen aan de 
studies of hun toestemming gaven voor dataregistratie. Het is dankzij hun inzet dat dit werk 
gerealiseerd kon worden.  
 
Een bijzonder woord van dank is voor mijn promotor, Prof. dr. Johan De Sutter. Bedankt om mij de 
kans te geven om dit doctoraat aan te vatten en mij kennis te laten maken met de wereld van 
cardiologie en cardiale revalidatie. Ook al heeft mijn doctoraat af en toe aan een zijden draadje 
gehangen, jij bent mij steeds blijven steunen. Jij bracht mij de essentie van wetenschappelijk 
onderzoek bij en dat ‘schrijven ook schrappen is’ . Het is dankzij jouw kennis en ervaring – zorg 
steeds dat er een ‘B-plan’ is weet je wel? – dat dit werk tot een goed einde werd gebracht. Daarnaast 
heb ik je ook mogen leren kennen als een warm persoon die begrip toonde als het op persoonlijk vlak 
wat minder ging, waardoor ik alleen nog maar meer respect voor jou heb gekregen. 
 
Ik wens ook mijn co-promotor, Prof. dr. Patrick Calders, te bedanken. Patrick, dankzij jouw 
enthousiaste manier van lesgeven, heb je als student mijn interesse gewekt in de fysiologie en de 
afstudeerrichting ‘inwendige aandoeningen’. Tijdens de afgelopen jaren heb je mij steeds bijgestaan 
waar nodig met jouw kennis maar ook met jouw empathie, bedankt voor de fijne gesprekken. Ik kijk 
ernaar uit om de komende maanden opnieuw met jou te mogen samenwerken.  
 
Ik dank de leden van de examencommissie, Prof. dr. Eric Derom, Prof. dr. Tine De Backer, Prof. dr. 
Mira Meeus, Prof. dr. Paul Dendale, Prof. dr. Emeline Van Craenenbroeck en Dr. Roselien Buys voor 
hun kritische bemerkingen die hebben bijgedragen tot de kwaliteit van dit proefschrift. Ik bedank ook 
Prof. dr. Johan Van de Voorde als voorzitter van de examencommissie. 
 
Ik wens Prof. dr. Jozef Bartunek, tevens lid van de begeleidingscommissie, en Dr. Marc Vanderheyden 
te bedanken om mij de ruimte en vrijheid te geven om dit onderzoeksproject mede in het Onze-
Lieve-Vrouwziekenhuis in Aalst te organiseren. Bedankt om steeds aanwezig te zijn op de cruciale 
overlegmomenten en jullie waardevolle suggesties om dit project vorm te geven. Dank ook aan de 
revalidatieartsen die meewerkten aan het project van de ‘Cardiale Revalidatiedatabase’.  
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Binnen het OLV ziekenhuis heb ik het grootste deel van de tijd doorgebracht op de dienst Cardiale 
Revalidatie onder leiding van Inge Du Bois. Inge, jij hebt er samen met jouw team voor gezorgd dat ik 
mij welkom voelde in jullie groep. De aangename werksfeer met soms hilarische momenten heeft 
ervoor gezorgd dat ik met plezier enkele dagen per week doorbracht op jullie dienst. Ik heb steeds op 
jullie medewerking kunnen rekenen wat betreft de revalidatiedatabase alsook op jullie hulp bij het 
rekruteren van patiënten voor deelname aan de ergoreflex testings. Tevens wil ik ook de 
medewerkers van de dienst Studies Cardiologie bedanken om de ‘follow-up’ van de patiënten van de 
revalidatie voor hun rekening te nemen.  
 
Een bijzonder iemand verdient het om hier nog even apart vermeld te worden en dat is Karin 
Lippevelde. Karin, ik heb het genoegen gehad om de afgelopen jaren een bureau op het secretariaat 
met jou te delen en op die manier de werking van de revalidatie met alle bijkomende regelgeving te 
leren kennen. Jouw praktische ondersteuning is van onschatbare waarde voor een vlotte werking van 
de revalidatie maar heeft ook mij vaak geholpen bij de (hectische) organisatie van testings en 
dataverzameling. Bedankt ook voor je oprechte interesse , de aanmoedigende woorden en luisterend 
oor wanneer ik er nood aan had. 
 
Ook vanuit AZ Maria Middelares Gent kon ik steeds op de nodige ondersteuning rekenen, daarom wil 
ik diensthoofd Dr. Frank Provenier bedanken om mij de mogelijkheid te bieden om binnen de dienst 
Cardiologie aan dit project te werken. In het bijzonder wil ik ook Prof. dr. Nico Van de Veire en Dr. 
Veronique Moerman bedanken voor hun medewerking aan dit project en hun feedback bij het 
nalezen van papers. Verder gaat mijn dank ook uit naar het hele team van verpleegkundigen en 
medewerkers van de dienst Cardiologie voor de fijne samenwerking.  
 
Net zoals in Aalst, was er ook in Gent een revalidatieteam dat met veel enthousiasme heeft 
bijgedragen aan dit project. Ondanks jullie drukke werkschema, kon ik steeds rekenen op jullie inzet 
voor het welslagen van het databaseproject en testings alsook op jullie ‘olifantengeheugen’ als ik nog 
met een vraag over een patiëntendossier van enkele maanden terug in de tijd kwam aandraven.  
 
De tijd die ik doorbracht in AZ Maria Middelares is onlosmakelijk verbonden met mijn ‘bureaugenoot’  
Dr. Anne-Marie Willems. Anne-Marie, jij werd al gauw mijn steun en toeverlaat tijdens de afgelopen 
jaren. Jij wist als geen ander de juiste woorden te kiezen op de momenten dat alles wel eens 
tegenzat en gaf mij tijdens onze ‘vrijdagmiddag lunch’ telkens een nieuwe portie moed om ertegen 
aan te gaan. Bedankt ook voor de niet- werkgerelateerde activiteiten die voor de nodige afleiding en 
ontspanning zorgden. Dankzij jouw kennis en expertise werd het concept ‘Cardiale 
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Revalidatiedatabase’ ook daadwerkelijk een operationele database in beide ziekenhuizen, een 
prestatie waar je terecht fier mag op zijn. 
 
Er zijn ook een aantal personen van de vakgroep Maatschappelijke Gezondheidskunde die ik hier wil 
vermelden. In de eerste plaats Prof. dr. Dirk De Bacquer, bedankt om mij de kans te bieden mee te 
werken aan EUROASPIRE IV, waardoor ik kon kennismaken met wetenschappelijk onderzoek op 
internationaal niveau alsook voor de hulp bij statistische vraagstukken. Dank ook aan Dr. Delphine De 
Smedt. Delphine, bedankt om jouw kennis omtrent ‘health-related quality of life’ met mij te delen 
alsook voor de praktische hulp bij het indienen van mijn doctoraat. En uiteraard een welgemeende 
dankjewel aan Christine Ghysbrecht. Christine, jij kan als geen ander het administratieve kluwen dat 
bij een doctoraat hoort doorgronden en jij weet steeds de juiste personen en achterpoortjes te 
vinden om al die administratieve regelgeving ook tijdig in orde te krijgen, respect. 
 
Naast al deze mensen op de werkvloer, zijn er ook nog een aantal personen die van op de zijlijn er 
mee hebben voor gezorgd dat dit project uiteindelijk dan toch tot een goed einde werd gebracht. 
 
 Aan mijn vrienden, bedankt voor de steun en begrip voor mijn afwezigheid bij bepaalde 
aangelegenheden,  maar vooral ook een dikke merci voor de nodige portie ontspanning tijdens onze 
momenten samen. Een bijzonder woordje van dank is voor Emina, jij hebt je uitzonderlijke talent 
bovengehaald om mijn vage omschrijving van ‘handen die een hart omsluiten’ om te zetten in een 
prachtige tekening die nu de kaft van dit boek siert.  
 
 Ann, als kind heb jij steeds als oudere zus over mij gewaakt en ook nu nog geeft jouw bekommernis 
om mij een warm gevoel. Ik ben blij om de sterke band die we delen. Mijn ouders wil ik bedanken 
voor hun onvoorwaardelijke steun en liefde. Jullie hebben ons alle kansen gegeven om onze dromen 
waar te maken, woorden van dank lijken hier tekort te schieten.  
 
En tot slot richt ik mij tot jou Joost, reeds twaalf jaar sta jij aan mijn zijde ook op de momenten dat 
het minder goed gaat. Jouw humor, relativeringsvermogen en bovenal jouw liefde hebben er mede 
voor gezorgd dat ik dit werk nu kan afsluiten en samen met jou kan vooruitkijken naar de toekomst.   
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